Health

Vyessence Cream | Official Store - Trial Offer! on Strikingly

vyessence-cream.mystrikingly.com
Submitted 1 hour(s) ago by vyessencecream

Many creams that are used are made with the help of chemicals, but there is a natural cream that is made with natural ingredients called Vyessence Cream. In the same way, to look beautiful, women prefer to use different types of creams to be able to look beautiful. Old age is a type of problem that afflicts women with an inferiority complex. This makes women feel insecure in society.

 

https://sites.google.com/site/vyessencecreamskincare/

https://vyessence-cream.mystrikingly.com/

http://vyessence-cream.moonfruit.com/

https://vyessence-cream-11.webself.net/


https://vyessencecream.wixsite.com/moisturizer


https://publons.com/researcher/3985174/vyessence-cream/


https://sites.google.com/site/vyessenceskincarecream/


https://works.bepress.com/vyessence-skin-cream/1/


https://muckrack.com/vyessenceskincarecream/bio


https://www.facebook.com/Vyessence-Cream-104012741508112/


https://teespring.com/en-GB/vyessence-cream-reviews


https://vyessence-skin-cream.over-blog.com/face-moisturizer-reviews.html


https://www.wattpad.com/971258280-vyessence-cream-shark-tank-reviews-and-side


https://www.toevolution.com/blog/view/970156/no1-vyessence-cream-anti-aging-skin-care


https://www.completefoods.co/diy/recipes/vyessence-cream-moisturizer-face-cream-reviews


https://kaalama.org/read-blog/3337


http://socialsea.com/blogs/1677/No-1-Vyessence-Cream-Anti-Aging-Skin-Care


http://dev.infotechnologist.biz/motor/blogs/1162/Vyessence-Cream-95-Off-Exclusive-Offer


https://talknchat.net/read-blog/1085_vyessence-cream-up-to-95-off-today.html


http://droidt99.com/read-blog/9852_vyessence-cream-buy-1-get-1-free-bottle.html


https://yarabook.com/read-blog/151539_vyessence-cream-get-100-free-bottle.html


https://envolvedfoundation.org/platform/blogs/1701/NO-1-Vyessence-Cream-99-Discount


https://gole.life/blogs/3206/Vyessence-Cream-Official-100-Natural


http://www.wassernet.com/blogs/4032/Vyessence-Cream-Up-to-95-Off-Today


https://www.sportjim.com/blogs/5939/Vyessence-Cream-95-Off-Exclusive-Offer


http://www.majalisa.com/blogs/4276/Vyessence-Cream-Get-100-Free-Bottle


https://wilkasocial.com/read-blog/3481_vyessence-cream-buy-1-get-1-free-bottle.html


https://social.smartzworld.com/read-blog/5186_vyessence-cream-get-100-free-bottle.html


https://wandasn.com/read-blog/999_vyessence-cream-95-off-exclusive-offer.html


https://zwatshitangani.co.za/read-blog/3588_vyessence-cream-up-to-95-off-today.html


https://lifesspace.com/read-blog/1728_vyessence-cream-buy-1-get-1-free-bottle.html


https://acrochat.com/read-blog/3581_vyessence-cream-official-100-natural.html

 

    Keto Burn Reviews

    apnews.com
    Submitted 20 hour(s) ago by mekyzohn

    Keto Burn is another and new weight reduction keto arrangement, a quick and characteristic recipe. The item is utilizing sheltered and tried fixings, that make this keto recipe hazard free.From the web that we have, we can say the item is perhaps the best answer for keto calorie counters.

    Buy Now ==>> https://apnews.com/press-release/ts-newswire/lil-dicky-830ddf786f94d616fd83e7126fbd66fb

    Keto Burning : Secret Solution To Lose Weight Fast!

    www.nutrislate.com
    Submitted 1 day(s) ago by davorahorton

    You'll be able to come up together with your own approach to do this if you wish. What precisely do not they perceive? It is surely essential that you simply comprehend Keto Burning Weight Loss inside and out thus that I imagine that this can be creating a mountain out of a molehill. It appearance like the buzzards are circling. You'll be able to do that while not Weight Loss. I expect Weight Loss may provide you with the identical breathtaking results that it has done on behalf of me. Obviously, you ought to grasp this, however did you see where I was going with this idea?. These are paramount secrets. I'm really annoyed. I discovered a ancient deal. It is easy to achieve success at Weight Loss.

    https://www.nutrislate.com/keto-burning/

    https://twitter.com/NutriSlate/status/1318776948059828224
    https://www.facebook.com/nutri.slate.9/posts/225916452197853
    https://www.linkedin.com/pulse/keto-burning-reduce-intake-junk-food-make-body-healthy-nutri-slate-/
    https://www.apsense.com/article/keto-burning-weight-loss-formula-with-efficient-outcomes.html
    https://www.youtube.com/watch?v=dK1v0GwZ9wc&feature=youtu.be

    http://supplementstore4u.com/ultra-thermo-keto/

    supplementstore4u.com
    Submitted 1 day(s) ago by Edmondarren


    Ultra Thermo Keto

    If you do notice some health issue occurring, make sure you stop taking the formula and speak with a doctor right away. The should be able to help you navigate any health problem you may eb experiencing. Feel free to speak with them before you begin taking the formula as well.As the keto diet rises in popularity, so do supplements for it. When demand goes up, it’s pretty common for price to do the same. To pay the lowest possible Ultra Thermo Keto cost, we strongly urge you to order today!

    http://supplementstore4u.com/ultra-thermo-keto/

    https://publons.com/researcher/3977324/ultra-thermo-keto-ultra-thermo-keto-uk/

    https://sites.google.com/site/ultrathermoketo4u/

    https://www.justgiving.com/crowdfunding/ultra-thermoketo

    https://k12.instructure.com/eportfolios/5619/Home/Ultra_Thermo_Keto_Reviews__UK_NZ_AU_Pills_2020_Benefits_Does_it_really_work

    https://www.quora.com/Does-it-Ultra-Thermo-Keto-really-work-Special-Offer-Get-50-Instant-Discount-Today/answer/Ultra-Thermo-Keto-7?prompt_topic_bio=1

    https://youtu.be/mJ-XWPL4QsM

    https://5f927e06b676b.site123.me/

     

    The “Gene Therapy Market (3rd Edition), 2019-2030” report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies and genome editing therapies.


    Submitted 1 day(s) ago by Harry sins

     

    To order this detailed 670+ page report, please visit this link

     

    Key Inclusions

    • A detailed review of the overall landscape of gene therapies and genome editing therapies, including information on various drug / therapy developer companies, phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, key therapeutic areas (cardiovascular disorders, muscular disorders, neurological disorders, ocular disorders, oncology and others) and target disease indication(s), information on gene type, type of vector used, type of therapy (ex vivo and in vivo), mechanism of action, type of gene modification (gene augmentation, oncolytic viral therapy and others) and special drug designation (if any).
    • A discussion on the various types of viral and non-viral vectors, along with information on design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vectors.
    • A world map representation, depicting the most active geographies, in terms of the presence of companies engaged in developing gene therapies, and a bull's eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy (ex vivo and in vivo).
    • A discussion on the regulatory landscape related to gene therapies across various geographies, namely North America (the US and Canada), Europe and Asia-Pacific (Australia, China, Japan and South Korea), providing details related to the various challenges associated with obtaining reimbursements for gene therapies.
    • Detailed profiles of marketed and phase II/III and gene therapies, including a brief history of development, information on current development status, mechanism of action, affiliated technology, strength of patent portfolio, dosage and manufacturing details, along with information on the developer company.
    • An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development, namely prior to drug launch, at / during drug launch and post-marketing.
    • A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies, featuring detailed profiles of technologies that were / are being used for the development of four or more products / product candidates.
    • An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016. The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC classification, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.
    • An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019. The analysis also provides information on the key value drivers and deal multiples related to the mergers and acquisitions that we came across.
    • An analysis of the investments made at various stages of development in companies that are focused in this area, between 2014-2019, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings.
    • An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of gene therapies under development, funding information, partnership activity and strength of patent portfolio.
    • A case study on the prevalent and emerging trends related to vector manufacturing, with information on companies offering contract services for manufacturing vectors. The study also includes a detailed discussion on the manufacturing processes associated with various types of vectors.
    • A discussion on the various operating models adopted by gene therapy developers for supply chain management, highlighting the stakeholders involved, factors affecting the supply of therapeutic products and challenges encountered by developers across the different stages of the gene therapy supply chain.
    • An analysis of the various factors that are likely to influence the pricing of gene-based therapies, featuring different models / approaches that may be adopted by manufacturers to decide the prices of these therapies.

     

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

    • Key therapeutic areas
    • Autoimmune disorders
    • Cardiovascular diseases
    • Genetic disorders
    • Hematological disorders
    • Metabolic disorders
    • Ophthalmic disorders
    • Oncological disorders
    • Others

     

    • Type of vector
    • Adeno associated virus
    • Adenovirus
    • Herpes simplex virus type 1
    • Lentivirus
    • Plasmid DNA
    • Retrovirus
    • Vaccinia Virus

     

    • Type of therapy
    • Ex vivo
    • In vivo

     

    • Type of gene modification
    • Gene augmentation
    • Immunotherapy
    • Oncolytic therapy
    • Others

     

    • Route of administration
    • Intraarticular
    • Intracerebellar
    • Intramuscular
    • Intradermal
    • Intravenous
    • Intravitreal
    • Intravesical
    • Subretinal
    • Others

     

    • Key geographical regions
    • North America
    • Europe
    • Asia-Pacific

     

    The report includes detailed transcripts of discussions held with the following experts:

    • Adam Rogers (CEO, Hemera Biosciences)
    • Al Hawkins (CEO, Milo Biotechnology)
    • Buel Dan Rodgers (Founder & CEO, AAVogen)
    • Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
    • Christopher Reinhard (CEO and Chairman, Cardium Therapeutics)
    • Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela)
    • Jeffrey Hung (CCO, Vigene Biosciences)
    • Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)
    • Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)
    • Robert Jan Lamers (CEO, Arthrogen)
    • Tom Wilton (Chief Business Officer, LogicBio Therapeutics)

     

    To request sample pages, please visit this link            

     

    Key Questions Answered

    • Who are the leading industry players in this market?
    • How big is the development pipeline and which new indications are coming in focus? Which vectors are being used for effective delivery of the therapeutic agents?
    • Who are the key investors in the gene therapy market?
    • How is the current and future market opportunity likely to be distributed across key market segments?
    • What kind of commercialization strategies are being adopted by gene therapy developers?
    • What are the different pricing models and reimbursement strategies used for gene therapies?
    • What are the prevalent R&D trends related to gene therapies?
    • What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?
    • Who are the key CMOs / CDMOs that claim to supply viral / plasmid vectors for gene therapy development?

     

    You may also be interested in the following titles:

    1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)
    2. CAR-T Therapies Market (2nd Edition), 2019-2030
    3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

     

    Contact Us

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

    Presently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated for the treatment of a variety of disease indications


    Submitted 1 day(s) ago by Harry sins

     

     

    Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.

     

    To order this 670+ page report, which features 190+ figures and 340+ tables, please visit this link

     

    The USD 11.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

    • Key therapeutic areas
    • Autoimmune disorders
    • Cardiovascular diseases
    • Genetic disorders
    • Hematological disorders
    • Metabolic disorders
    • Ophthalmic disorders
    • Oncological disorders
    • Others

     

    • Type of vector
    • Adeno associated virus
    • Adenovirus
    • Herpes simplex virus type 1
    • Lentivirus
    • Plasmid DNA
    • Retrovirus
    • Vaccinia Virus

     

    • Type of therapy
    • Ex vivo
    • In vivo

     

    • Type of gene modification
    • Gene augmentation
    • Immunotherapy
    • Oncolytic therapy
    • Others

     

    • Route of administration
    • Intraarticular
    • Intracerebellar
    • Intramuscular
    • Intradermal
    • Intravenous
    • Intravitreal
    • Intravesical
    • Subretinal
    • Others

     

    • Key geographical regions
    • North America
    • Europe
    • Asia-Pacific

     

    The Gene Therapy Market (3rd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:

    • Advantagene
    • Advaxis
    • BioMarin
    • bluebird bio
    • FKD Therapies
    • Freeline Therapeutics
    • GenSight Biologics
    • Gradalis
    • Inovio Pharmaceuticals
    • Marsala Biotech
    • Orchard Therapeutics
    • Pfizer
    • Sarepta Therapeutics
    • Spark Therapeutics
    • Tocagen
    • Transgene
    • uniQure Biopharma
    • VBL Therapeutics
    • ViroMed

     

    Table of Contents

     

    1. Preface

     

    1. Executive Summary

     

    1. Introduction

     

    1. Gene Delivery Vectors

     

    1. Regulatory Landscape and Reimbursement Scenario

     

    1. Competitive Landscape

     

    1. Marketed Gene Therapies

     

    1. Key Commercialization Strategies

     

    1. Late Stage (Phase II/III and Above) Gene Therapies

     

    1. Emerging Technologies

     

    1. Promising Therapeutics Areas

     

    1. Patent Analysis

     

    1. Mergers and Acquisitions

     

    1. Funding and Investment Analysis

     

    1. Cost Price Analysis

     

    1. Big Pharma Players: Analysis of Gene Therapy Related Initiatives

     

    1. Market Forecast and Opportunity Analysis

     

    1. Vector Manufacturing

     

    1. Case Study: Gene Therapy Supply Chain

     

    1. Conclusion

     

    1. Interview Transcripts

     

    1. Appendix 1: Tabulated Data

     

    1. Appendix 2: List of Companies and Organizations

     

    To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     

    The gene therapy market is projected to grow at an annualized rate of 45%, till 2030


    Submitted 1 day(s) ago by Harry sins

     

    Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

     

    To order this 670+ page report, which features 190+ figures and 340+ tables, please visit this link

     

    Key Market Insights

    • In the past four years, more than 31,000 patents related to gene therapies and gene editing have been filed / granted; this is indicative of the heightened pace of research in this domain
    • Presently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated for the treatment of a variety of disease indications
    • Most of the therapeutic leads are in the early stages of clinical development; a variety of viral and non-viral vectors are being used to introduce different types of gene modifications in such therapies
    • Although start-ups and mid-sized companies are spearheading the innovation, several big biopharmaceutical companies are also actively engaged
    • With multiple approved products and several under development, price is one of the major concerns in this market; the future is likely to witness the establishment of more affordable pricing and reimbursement strategies
    • As several candidates progress towards approval, developers are exploring diverse commercialization strategies to be implemented across different stages of a product’s launch cycle
    • CMOs offering vector manufacturing services have become an integral part of the gene therapy supply chain, owing to their ability to overcome the various associated challenges
    • Several investors, having realized the untapped opportunity within this emerging segment of genetic disorders, have invested over USD 16.5 billion across 280 instances, in the period between 2014 and 2019
    • Overall, prevalent trends indicate that the market for gene therapies is poised to grow significantly as multiple late stage molecules get commercialized in the near future for the treatment of different therapeutic areas
    • The projected future opportunity is expected to be distributed across different types of gene modifications, therapy delivery routes and key geographical regions

     

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

     

    Table of Contents

     

    1. PREFACE
      1.1. Scope of the Report
      1.2.      Research Methodology
      1.3.      Chapter Outlines

      2.         EXECUTIVE SUMMARY

     

    1. INTRODUCTION

    3.1.      Context and Background

    3.2.      Evolution of Gene Therapies

    3.3.      Classification of Gene Therapies

    3.3.1.    Somatic and Germline Gene Therapy

    3.3.2.    Ex Vivo and In Vivo Gene Therapy

    3.4.      Routes of Administration

    3.5.      Mechanism of Action of Gene Therapies

    3.6.      Concept of Gene Editing

    3.7.      Advantages and Disadvantages of Gene Therapies

    3.8.      Ethical and Social Concerns Related to Gene Therapies

     

    3.9.      Future Constraints and Challenges Related to Gene Therapies

    3.9.1.    Concerns Related to Therapy Development

    3.9.2.    Concerns Related to Manufacturing

    3.9.3.    Concerns Related to Commercial Viability

     

    1. GENE DELIVERY VECTORS

    4.1.      Chapter Overview

    4.2.      Viral Vectors

    4.2.1     Types of Viral Vectors

    4.2.1.1. Adeno-associated Viral Vectors

    4.2.1.1.1. Overview

    4.2.1.1.2. Design

    4.2.1.1.3. Advantages

    4.2.1.1.4. Limitations

     

    4.2.1.2. Adenoviral Vectors

    4.2.1.2.1. Overview

    4.2.1.2.2. Design

    4.2.1.2.3. Advantages

    4.2.1.2.4. Limitations

     

    4.2.1.3. Lentiviral Vectors

    4.2.1.3.1. Overview

    4.2.1.3.2. Design

    4.2.1.3.3. Advantages

    4.2.1.3.4. Limitations

     

    4.2.1.4. Retroviral Vectors

    4.2.1.4.1. Overview

    4.2.1.4.2. Design

    4.2.1.4.3. Advantages

    4.2.1.4.4. Limitations

     

    4.2.1.5. Other Viral Vectors

    4.2.1.5.1. Alphavirus

    4.2.1.5.2. Herpes Simplex Virus

    4.2.1.5.3. Simian Virus

    4.2.1.5.4. Vaccinia Virus

     

    4.3.      Non-Viral Vectors

    4.3.1.    Types of Non-Viral Vectors

    4.3.1.1. Plasmid DNA

    4.3.1.2. Liposomes, Lipoplexes and Polyplexes

    4.3.1.3. Oligonucleotides

     

    4.4.      Methods of Transfection

    4.4.1.    Biolistic Method

    4.4.2.    Electroporation

    4.4.3.    Receptor Mediated Gene Delivery

    4.4.4.    Gene Activated Matrix (GAM)

     

    1. REGULATORY LANDSCAPE AND REIMBURSEMENT SCENARIO

    5.1.      Chapter Overview

    5.2.      Regulatory Guidelines in North America

    5.2.1.    The US Scenario

    5.2.2.    The Canadian Scenario

    5.3.      Regulatory Guidelines in Europe

    5.4.      Regulatory Guidelines in Asia Pacific

    5.4.1.    Chinese Scenario

    5.4.2.    Japanese Scenario

    5.4.3.    South Korean Scenario

    5.4.4.    Australian Scenario

    5.5.      Reimbursement Scenario

    5.5.1.    Challenges Related to Reimbursement

    5.6.      Payment Models for Gene Therapies

     

    1. COMPETITIVE LANDSCAPE

    6.1.      Chapter Overview

    6.2.      Gene Therapy Market: Clinical and Commercial Pipeline

    6.2.1.    Analysis by Phase of Development

    6.2.2.    Analysis by Therapeutic Area

    6.2.3.    Analysis by Type of Vector Used

    6.2.4.    Analysis by Type of Gene

    6.2.5.    Analysis by Type of Modification

    6.2.6.    Analysis by Type of Gene Therapy

    6.2.7.    Analysis by Route of Administration

     

    6.3.      Gene Therapy Market: Early Stage Pipeline

    6.3.1.    Analysis by Stage of Development

    6.3.2.    Analysis by Therapeutic Area

    6.3.3.    Analysis by Type of Vector Used

    6.3.4.    Analysis by Type of Gene

    6.3.5.    Analysis by Type of Modification

    6.3.6.    Analysis by Type of Gene Therapy

     

    6.4.      Gene Therapy: Special Designation Awarded

    6.4.1.    Analysis by Special Designation Awarded

    6.5.      Key Players: Analysis by Number of Product Candidates

    6.6.      Developer Landscape

    6.6.1.    Distribution by Year of Establishment

    6.6.2.    Distribution by Size of Developer

    6.6.3.    Distribution by Geographical Location

    6.7.      Regional Landscape

     

    1. MARKETED GENE THERAPIES

    7.1.      Chapter Overview

    7.2.      Gendicine® (Shenzhen Sibiono GeneTech)

    7.2.1.    Company Overview

    7.2.2.    Development Timeline

    7.2.3.    Mechanism of Action and Vectors Used

    7.2.4.    Target Indication(s)

    7.2.5.    Current Status of Development

    7.2.6.    Manufacturing, Dosage and Sales

     

    7.3.      Oncorine® (Shanghai Sunway Biotech)

    7.3.1.    Company Overview

    7.3.2.    Development Timeline

    7.3.3.    Mechanism of Action and Vectors Used

    7.3.4.    Target Indication(s)

    7.3.5.    Current Status of Development

    7.3.6.    Manufacturing, Dosage and Sales

     

    7.4.      Rexin-G® (Epeius Biotechnologies)

    7.4.1.    Company Overview

    7.4.2.    Development Timeline

    7.4.3.    Mechanism of Action and Vector Used

    7.4.4.    Target Indication(s)

    7.4.5.    Current Status of Development

    7.4.6.    Manufacturing, Dosage and Sales

     

    7.5.      Neovasculgen® (Human Stem Cells Institute)

    7.5.1.    Company Overview

    7.5.2.    Development Timeline

    7.5.3.    Mechanism of Action and Vectors Used

    7.5.4.    Target Indication(s)

    7.5.5.    Current Status of Development

    7.5.6.    Manufacturing, Dosage and Sales

     

    7.6.      Imlygic® (Amgen)

    7.6.1.    Company Overview

    7.6.2.    Development Timeline

    7.6.3.    Mechanism of Action and Vectors Used

    7.6.4.    Target Indication(s)

    7.6.5.    Current Status of Development

    7.6.6.    Manufacturing, Dosage and Sales

     

    7.7.      Strimvelis® (Orchard Therapeutics)

    7.7.1.    Company Overview

    7.7.2.    Development Timeline

    7.7.3.    Mechanism of Action and Vectors Used

    7.7.4.    Target Indication(s)

    7.7.5.    Current Status of Development

    7.7.6.    Manufacturing, Dosage and Sales

     

    7.8.      Invossa™ (Kolon TissueGene)

    7.8.1.    Company Overview

    7.8.2.    Development Timeline

    7.8.3.    Mechanism of Action and Vectors Used

    7.8.4.    Target Indication(s)

    7.8.5.    Current Status of Development

    7.8.6.    Manufacturing, Dosage and Sales

     

    7.9.      Luxturna™ (Spark Therapeutics)

    7.9.1.    Company Overview

    7.9.2.    Development Timeline

    7.9.3.    Mechanism of Action and Vector Used

    7.9.4.    Target Indication(s)

    7.9.5.    Current Status of Development

    7.9.6.    Manufacturing, Dosage and Sales

     

    7.10.     Zolgensma™ (AveXis / Novartis)

    7.10.1.  Company Overview

    7.10.2.  Development Timeline

    7.10.3.  Mechanism of Action and Vector Used

    7.10.4.  Target Indication(s)

    7.10.5.  Current Status of Development

    7.10.6.  Manufacturing, Dosage and Sales

     

    7.11.     Collategene® / Beperminogene Perplasmid (AnGes)

    7.11.1.  Company Overview

    7.11.2.  Development Timeline

    7.11.3.  Mechanism of Action and Vector Used

    7.11.4.  Target Indication(s)

    7.11.5.  Current Status of Development

    7.11.6.  Manufacturing, Dosage and Sales

     

    7.12.     Zyntelgo™ (bluebird bio)

    7.12.1.  Company Overview

    7.12.2.  Development Timeline

    7.12.3.  Mechanism of Action and Vector Used

    7.12.4.  Target Indication(s)

    7.12.5.  Current Status of Development

    7.12.6.  Manufacturing, Dosage and Sales

     

    1. KEY COMMERCIALIZATION STRATEGIES

    8.1.      Chapter Overview

    8.2.      Successful Drug Launch Strategy: ROOTS Framework

    8.3.      Successful Drug Launch Strategy: Product Differentiation

    8.4.      Commonly Adopted Commercialization Strategies based on Development Stage of the Product

    8.5.      Approved Gene Therapies

    8.6.      Key Commercialization Strategies Adopted by Companies Focused on Gene Therapy

    8.6.1.    Strategies Adopted Before Therapy Approval

    8.6.2.    Strategies Adopted During / Post Therapy Approval

    8.7.      Concluding Remarks

     

    1. LATE STAGE (PHASE II/III AND ABOVE) GENE THERAPIES

    9.1.      Chapter Overview

    9.2.      AMT-061: Overview of Therapy, Current Development Status and Clinical Results

    9.3.      BIIB111 (NSR-REP1): Overview of Therapy, Current Development Status and Clinical Results

    9.4.      BIIB112 (NSR-RPGR): Overview of Therapy, Current Development Status and Clinical Results

    9.5.      BMN 270 (valoctocogene roxaparvovec): Overview of Therapy, Current Development Status and Clinical Results

    9.6.      E10A: Overview of Therapy, Current Development Status and Clinical Results

    9.7.      FLT180a: Overview of Therapy, Current Development Status and Clinical Results

    9.8.      GS010: Overview of Therapy, Current Development Status and Clinical Results

    9.9.      Instiladrin®: Overview of Therapy, Current Development Status and Clinical Results

    9.10.     Lenti-D™: Overview of Therapy, Current Development Status and Clinical Results

    9.11.     LYS-SAF302: Overview of Therapy, Current Development Status and Clinical Results

    9.12.     OTL-101: Overview of Therapy, Current Development Status and Clinical Results

    9.13.     OTL-103: Overview of Therapy, Current Development Status and Clinical Results

    9.14.     OTL-200: Overview of Therapy, Current Development Status and Clinical Results

    9.15.     Pexa-Vec (pexastimogene devacirepvec): Overview of Therapy, Current Development Status and Clinical Results

    9.16.     PF-06838435 (fidanacogene elaparvovec): Overview of Therapy, Current Development Status and Clinical Results

    9.17.     ProstAtak®: Overview of Therapy, Current Development Status and Clinical Results

    9.18.     SPK-8011: Overview of Therapy, Current Development Status and Clinical Results

    9.19.     Toca 511 (vocimagene amiretrorepvec): Overview of Therapy, Current Development Status and Clinical Results

    9.20.     VB-111 (ofranergene obadenovec): Overview of Therapy, Current Development Status and Clinical Results

    9.21.     VGX-3100: Overview of Therapy, Current Development Status and Clinical Results

    9.22.     Vigil®: Overview of Therapy, Current Development Status and Clinical Results

    9.23.     VM202 (donaperminogene seltoplasmid): Overview of Therapy, Current Development Status and Clinical Results

     

    1. EMERGING TECHNOLOGIES

    10.1.     Chapter Overview

    10.2.     Gene Editing Technologies

    10.2.1.  Overview

    10.2.2.  Applications

     

    10.3.     Emerging Gene Editing Platforms

    10.3.1.  CRISPR / Cas9 System

    10.3.2.  TALENs

    10.3.3.  megaTAL

    10.3.4.  Zinc Finger Nuclease

     

    10.4.     Gene Expression Regulation Technologies

    10.5.     Technology Platforms for Developing / Delivering Gene Therapies

     

    1. PROMISING THERAPEUTICS AREAS

    11.1.     Chapter Overview

    11.2      Analysis by Special Designations Awarded

     

    11.3.     Autoimmune Disorders

    11.3.1.  Analysis by Target Indication

    11.3.2.  Analysis by Type of Vector Used

     

    11.4.     Cardiovascular Diseases

    11.4.1.  Analysis by Target Indication

    11.4.2.  Analysis by Type of Vector Used

    11.5.     Dermatological Disorders

    11.5.1.  Analysis by Target Indication

    11.5.2.  Analysis by Type of Vector Used

     

    11.6.     Genetic Disorders

    11.6.1.  Analysis by Target Indication

    11.6.2.  Analysis by Type of Vector Used

     

    11.7.     Hematological Disorders

    11.7.1.  Analysis by Target Indication

    11.7.2.  Analysis by Type of Vector Used

     

    11.8.     Infectious Diseases

    11.8.1.  Analysis by Target Indication

    11.8.2.  Analysis by Type of Vector Used

     

    11.9.     Metabolic Disorders

    11.9.1.  Analysis by Target Indication

    11.9.2.  Analysis by Type of Vector Used

     

    11.10.   Muscle-related Diseases

    11.10.1. Analysis by Target Indication

    11.10.2. Analysis by Type of Vector Used

     

    11.11.   Nervous System Disorders

    11.11.1. Analysis by Target Indication

    11.11.2. Analysis by Type of Vector Used

     

    11.12.   Oncological Disorders

    11.12.1. Analysis by Target Indication

    11.12.2. Analysis by Type of Vector Used

     

    11.13.   Ophthalmic Diseases

    11.13.1. Analysis by Target Indication

    11.13.2. Analysis by Type of Vector Used

     

    1. PATENT ANALYSIS

    12.1.     Chapter Overview

    12.2.     Gene Therapy-related Patents

    12.2.1.  Scope and Methodology

    12.2.1.1. Analysis by Publication Year

    12.2.1.2. Analysis by Geographical Location

    12.2.1.3. Analysis by CPC Classification

    12.2.1.4. Emerging Focus Areas

    12.2.1.5. Leading Players: Analysis by Number of Patents

    12.2.1.6. Patent Benchmark Analysis

    12.2.1.7. Patent Valuation Analysis

     

    12.3.     Gene Editing-related Patents

    12.3.1.  Scope and Methodology

    12.3.1.1. Analysis by Publication Year

    12.3.1.2. Analysis by Geographical Location

     

    12.3.1.3. Analysis by CPC Classification

    12.3.1.4. Emerging Focus Areas

    12.3.1.5. Leading Players: Analysis by Number of Patents

    12.3.1.6. Patent Benchmark Analysis

    12.3.1.7. Patent Valuation Analysis

     

    12.4.     Overall Intellectual Property Portfolio: Analysis by Type of Organization

     

    1. MERGERS AND ACQUISITIONS

    13.1.     Chapter Overview

    13.2.     Merger and Acquisition Models

    13.3.     Gene Therapy: Mergers and Acquisitions

    13.3.1.  Analysis by Year of Mergers and Acquisitions

    13.3.2.  Analysis by Type of Mergers and Acquisitions

    13.3.3.  Regional Analysis

    13.3.3.1. Continent-wise Distribution

    13.3.3.2. Intercontinental and Intracontinental Deals

    13.3.3.3. Country-wise Distribution

    13.3.4.  Analysis by Key Value Drivers

    13.3.4.1. Analysis by Key Value Drivers and Year of Acquisition

    13.3.5.  Analysis by Phase of Development of the Acquired Company’s Product

    13.3.6.  Analysis by Therapeutic Area

     

    1. FUNDING AND INVESTMENT ANALYSIS

    14.1.     Chapter Overview

    14.2.     Types of Funding

    14.3.     Funding and Investment Analysis

    14.3.1.  Analysis by Number of Funding Instances

    14.3.2.  Analysis by Amount Invested

    14.3.3.  Analysis by Type of Funding

    14.3.4.  Analysis by Amount Invested across Different Types of Therapies

    14.3.5.  Regional Analysis by Amount Invested

    14.3.6.  Most Active Players

    14.3.7.  Key Investors

    14.3.8.  Analysis by Stage of Development

    14.4.     Concluding Remarks

     

    1. COST PRICE ANALYSIS

    15.1.     Chapter Overview

    15.2.     Gene Therapy Market: Factors Contributing to the Price of Gene Therapies

    15.3.     Gene Therapy Market: Pricing Models

    15.3.1.  On the Basis of Associated Product / Component Costs

    15.3.2.  On the Basis of Competition

    15.3.3.  On the Basis of Patient Segment

    15.3.4.  On the Basis of Opinions of Industry Experts

     

    1. BIG PHARMA PLAYERS: ANALYSIS OF GENE THERAPY RELATED INITIATIVES

    16.1.     Chapter Overview

    16.2.     Top Pharmaceutical Companies

    16.2.1.  Analysis by Therapeutic Area

    16.2.2.  Analysis by Type of Vector Used

    16.2.3.  Analysis by Type of Modification

    16.2.4.  Analysis by Type of Gene Therapy

    16.3.     Other Big Pharma Players

     

    1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

    17.1.     Chapter Overview

    17.2.     Scope and Limitations

    17.3.     Key Assumptions and Forecast Methodology

    17.4.     Overall Gene Therapy Market, 2019-2030

    17.4.1.  Gene Therapy Market: Analysis by Type of Gene Modification

    17.4.2.  Gene Therapy Market: Analysis by Type of Therapy

    17.4.3.  Gene Therapy Market: Analysis by Type of Vector Used

    17.4.4.  Gene Therapy Market: Analysis by Therapeutic Area

    17.4.5.  Gene Therapy Market: Analysis by Route of Administration

    17.4.6.  Gene Therapy Market: Analysis by Geography

     

    17.5.     Gene Therapy Market: Value Creation Analysis

     

    17.6.     Gene Therapy Market: Product-wise Sales Forecasts

    17.6.1.  Gendicine®

    17.6.1.1. Target Patient Population

    17.6.1.2. Sales Forecast

    17.6.1.3. Net Present Value

    17.6.1.4. Value Creation Analysis

     

    17.6.2.  Oncorine®

    17.6.2.1. Target Patient Population

    17.6.2.2. Sales Forecast

    17.6.2.3. Net Present Value

    17.6.2.4. Value Creation Analysis

     

    17.6.3.  Rexin-G®

    17.6.3.1. Target Patient Population

    17.6.3.2. Sales Forecast

    17.6.3.3. Net Present Value

    17.6.3.4. Value Creation Analysis

     

    17.6.4.  Neovasculgen®

    17.6.4.1. Target Patient Population

    17.6.4.2. Sales Forecast

    17.6.4.3. Net Present Value

    17.6.4.4. Value Creation Analysis

     

    17.6.5.  Strimvelis®

    17.6.5.1. Target Patient Population

    17.6.5.2. Sales Forecast

    17.6.5.3. Net Present Value

    17.6.5.4. Value Creation Analysis

     

    17.6.6.  Imlygic®

    17.6.6.1. Target Patient Population

    17.6.6.2. Sales Forecast

    17.6.6.3. Net Present Value

    17.6.6.4. Value Creation Analysis

     

    17.6.7.  Invossa™

    17.6.7.1. Target Patient Population

    17.6.7.2. Sales Forecast

    17.6.7.3. Net Present Value

    17.6.7.4. Value Creation Analysis

     

    17.6.8.  Luxturna™

    17.6.8.1. Target Patient Population

    17.6.8.2. Sales Forecast

    17.6.8.3. Net Present Value

    17.6.8.4. Value Creation Analysis

     

    17.6.9.  Zolgensma™

    17.6.9.1. Target Patient Population

    17.6.9.2. Sales Forecast

    17.6.9.3. Net Present Value

    17.6.9.4. Value Creation Analysis

     

    17.6.10. Collategene® / Beperminogene Perplasmid

    17.6.10.1. Target Patient Population

    14.6.10.2. Sales Forecast

    17.6.10.3. Net Present Value

    17.6.10.4. Value Creation Analysis

     

    17.6.11. Zyntelgo™

    17.6.11.1. Target Patient Population

    17.6.11.2. Sales Forecast

    17.6.11.3. Net Present Value

    17.6.11.4. Value Creation Analysis

     

    17.6.12. AMT-061

    17.6.12.1. Target Patient Population

    17.6.12.2. Sales Forecast

    17.6.12.3. Net Present Value

    17.6.12.4. Value Creation Analysis

     

    17.6.13. BIIB111

    17.6.13.1. Target Patient Population

    17.6.13.2. Sales Forecast

    17.6.13.3. Net Present Value

    17.6.13.4. Value Creation Analysis

     

    17.6.14. BIIB112

    17.6.14.1. Target Patient Population

    17.6.14.2. Sales Forecast

    17.6.14.3. Net Present Value

    17.6.14.4. Value Creation Analysis

     

    17.6.15. BMN 270

    17.6.15.1. Target Patient Population

    17.6.15.2. Sales Forecast

    17.6.15.3. Net Present Value

    17.6.15.4. Value Creation Analysis

     

    17.6.16. E10A

    17.6.16.1. Target Patient Population

    17.6.16.2. Sales Forecast

    17.6.16.3. Net Present Value

    17.6.16.4. Value Creation Analysis

     

    17.6.17. FLT180a

    17.6.17.1. Target Patient Population

    17.6.17.2. Sales Forecast

    17.6.17.3. Net Present Value

    17.6.17.4. Value Creation Analysis

     

    17.6.18. GS010

    17.6.18.1. Target Patient Population

    17.6.18.2. Sales Forecast

    17.6.18.3. Net Present Value

    17.6.18.4. Value Creation Analysis

     

    17.6.19. Instiladrin®

    17.6.19.1. Target Patient Population

    17.6.19.2. Sales Forecast

    17.6.19.3. Net Present Value

    17.6.19.4. Value Creation Analysis

     

    17.6.20. Lenti-D™

    17.6.20.1. Target Patient Population

    17.6.20.2. Sales Forecast

    17.6.20.3. Net Present Value

    17.6.20.4. Value Creation Analysis

     

    17.6.21. LYS-SAF302

    17.6.21.1. Target Patient Population

    17.6.21.2. Sales Forecast

    17.6.21.3. Net Present Value

    17.6.21.4. Value Creation Analysis

     

    17.6.22. OTL-101

    17.6.22.1. Target Patient Population

    17.6.22.2. Sales Forecast

    17.6.22.3. Net Present Value

    17.6.22.4. Value Creation Analysis

     

    17.6.23. OTL-103

    17.6.23.1. Target Patient Population

    17.6.23.2. Sales Forecast

    17.6.23.3. Net Present Value

    17.6.23.4. Value Creation Analysis

     

    17.6.24. OTL-200

    17.6.24.1. Target Patient Population

    17.6.24.2. Sales Forecast

    17.6.24.3. Net Present Value

    17.6.24.4. Value Creation Analysis

     

    17.6.25. Pexa-Vec

    17.6.25.1. Target Patient Population

    17.6.25.2. Sales Forecast

    17.6.25.3. Net Present Value

    17.6.25.4. Value Creation Analysis

     

    17.6.26. PF-06838435

    17.6.26.1. Target Patient Population

    17.6.26.2. Sales Forecast

    17.6. 26.3. Net Present Value

    17.6.26.4. Value Creation Analysis

     

    17.6.27. ProstAtak®

    17.6.27.1. Target Patient Population

    17.6.27.2. Sales Forecast

    17.6.27.3. Net Present Value

    17.6.27.4. Value Creation Analysis

     

    17.6.28. SPK-8011

    17.6.28.1. Target Patient Population

    17.6.28.2. Sales Forecast

    17.6.28.3. Net Present Value

    17.6.28.4. Value Creation Analysis

     

    17.6.29. Toca 511

    17.6.29.1. Target Patient Population

    17.6.29.2. Sales Forecast

    17.6.29.3. Net Present Value

    17.6.29.4. Value Creation Analysis

     

    17.6.30. VB-111

    17.6.30.1. Target Patient Population

    17.6.30.2. Sales Forecast

    17.6.30.3. Net Present Value

    17.6.30.4. Value Creation Analysis

     

    17.6.31. VGX-3100

    17.6.31.1. Target Patient Population

    17.6.31.2. Sales Forecast

    17.6.31.3. Net Present Value

    17.6.31.4. Value Creation Analysis

     

    17.6.32. Vigil®

    17.6.32.1. Target Patient Population

    17.6.32.2. Sales Forecast

    17.6.32.3. Net Present Value

    17.6.32.4. Value Creation Analysis

     

    17.6.33. VM202

    17.6.33.1. Target Patient Population

    17.6.33.2. Sales Forecast

    17.6.33.3. Net Present Value

    17.6.33.4. Value Creation Analysis

     

    1. VECTOR MANUFACTURING

    18.1.     Chapter Overview

    18.2.     Overview of Viral Vector Manufacturing

    18.3.     Viral Vector Manufacturing Processes

    18.3.1.  Mode of Vector Production

    18.3.2.  Adherent and Suspension Cultures

    18.3.3.  Unit Processes and Multiple Parallel Processes

    18.3.4.  Cell Culture Systems for Production of Viral Vectors

    18.3.5.  Culture Media Specifications

     

    18.4.     Bioprocessing of Viral Vectors

    18.4.1.  AAV Vector Production

    18.4.2.  Adenoviral Vector Production

    18.4.3.  Lentiviral Vector Production

    18.4.4.  γ -Retroviral Vector Production

     

    18.5.     Challenges Associated with Vector Manufacturing

    18.6.     Companies Offering Contract Services for Viral and Plasmid Vectors

     

    1. CASE STUDY: GENE THERAPY SUPPLY CHAIN

    19.1.     Chapter Overview

    19.2.     Overview of the Gene Therapy Supply Chain

    19.3.     Implementation of Supply Chain Models

    19.4.     Logistics in Gene Therapy

    19.4.1.  Logistics Processes for Autologous and Allogeneic Therapies

    19.5.     Regulatory Supply Chain across the Globe

    19.6.     Challenges Associated with Gene Therapy Supply Chain

    19.7.     Optimizing Cell and Advanced Therapies Supply Chain Management

    19.8.     Recent Developments and Upcoming Trends

     

    1. CONCLUSION

    20.1.     Chapter Overview

    20.2.     Key Takeaways

     

    1. INTERVIEW TRANSCRIPTS

    21.1.     Chapter Overview

    21.2.     Adam Rogers, Chief Executive Officer, Hemera Biosciences

    21.3.     Al Hawkins, Chief Executive Officer, Milo Biotechnology

    21.4.     Buel Dan Rodgers, Founder & Chief Executive Officer, AAVogen

    21.5.     Cedric Szpirer, Executive & Scientific Director, Delphi Genetics

    21.6.     Christopher Reinhard, Chief Executive Officer and Chairman, Gene Therapeutics (previously known as Cardium Therapeutics)

    21.7.     Ryo Kubota, Chairman, President and Chief Executive Officer, Acucela

    21.8.     Jeffrey HunG, Chief Commercial Officer, Vigene Biosciences

    21.9.     Marco Schmeer, Project Manager and Tatjana Buchholz, Marketing Manager, PlasmidFactory

    21.10.   Michael Tripletti, Chief Executive Officer, Myonexus Therapeutics

    21.11.   Robert Jan Lamers, Chief Executive Officer, Arthrogen

    21.12.   Tom Wilton, Chief Business Officer, LogicBio Therapeutics

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     

    The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predicts Roots Analysis


    Submitted 1 day(s) ago by Harry sins

     

    With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades; innovator companies are gradually progressing their proprietary therapy candidates with cautious optimism

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”.

     

    The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies and genome editing therapies. The study also features an elaborate discussion on the future potential of this evolving market. In addition to other elements, the study includes:

    • A detailed review of the overall landscape of gene therapies and genome editing therapies.
    • A discussion on the various types of viral and non-viral vectors.
    • A world map representation, depicting the most active geographies, and a bull’s eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy.
    • A discussion on the regulatory landscape related to gene therapies across various geographies.
    • Detailed profiles of marketed and phase II/III and gene therapies.
    • An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development.
    • A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies.
    • An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016.
    • An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019.
    • An analysis of the investments made at various stages of development in companies that are focused in this area, between 2014-2019.
    • An analysis of the big biopharma players engaged in this domain.
    • A case study on the prevalent and emerging trends related to vector manufacturing, with information on companies offering contract services for manufacturing vectors.
    • A discussion on the various operating models adopted by gene therapy developers for supply chain management.
    • An analysis of the various factors that are likely to influence the pricing of gene-based therapies.
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
    • Key therapeutic areas
    • Autoimmune disorders
    • Cardiovascular diseases
    • Genetic disorders
    • Hematological disorders
    • Metabolic disorders
    • Ophthalmic disorders
    • Oncological disorders
    • Others
    • Type of vector
    • Adeno associated virus
    • Adenovirus
    • Herpes simplex virus type 1
    • Lentivirus
    • Plasmid DNA
    • Retrovirus
    • Vaccinia Virus
    • Type of therapy
    • Ex vivo
    • In vivo
    • Type of gene modification
    • Gene augmentation
    • Immunotherapy
    • Oncolytic therapy
    • Others
    • Route of administration
    • Intraarticular
    • Intracerebellar
    • Intramuscular
    • Intradermal
    • Intravenous
    • Intravitreal
    • Intravesical
    • Subretinal
    • Others
    • Key geographical regions
    • North America
    • Europe
    • Asia-Pacific
    • Transcripts of interviews held with the following senior level representatives of stakeholder companies
    • Adam Rogers (CEO, Hemera Biosciences)
    • Al Hawkins (CEO, Milo Biotechnology)
    • Buel Dan Rodgers (Founder & CEO, AAVogen)
    • Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
    • Christopher Reinhard (CEO and Chairman, Cardium Therapeutics)
    • Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela)
    • Jeffrey Hung (CCO, Vigene Biosciences)
    • Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)
    • Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)
    • Robert Jan Lamers (CEO, Arthrogen)
    • Tom Wilton (Chief Business Officer, LogicBio Therapeutics)

     

    Key companies covered in the report

    • Advantagene
    • Advaxis
    • BioMarin
    • bluebird bio
    • FKD Therapies
    • Freeline Therapeutics
    • GenSight Biologics
    • Gradalis
    • Inovio Pharmaceuticals
    • Marsala Biotech
    • Orchard Therapeutics
    • Pfizer
    • Sarepta Therapeutics
    • Spark Therapeutics
    • Tocagen
    • Transgene
    • uniQure Biopharma
    • VBL Therapeutics
    • ViroMed

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

     

    Other Recent Offerings

    1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)
    2. CAR-T Therapies Market (2nd Edition), 2019-2030
    3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

    The “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade.


    Submitted 1 day(s) ago by Harry sins

     

    To order this 170+ page report, please visit this link

     

    Key Inclusions

    • A detailed review of the overall landscape of fragment-based drug discovery library and service providers along with the information on type of product (library and technology), type of service offered (fragment screening and fragment optimization), type of technique used (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance, and other screening techniques), other services offered (target identification / validation, hit identification, hit-to-lead / lead generation, lead optimization), and end user (industry, academia, and contract research organizations).
    • Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered). Each profile features a brief overview of the company, its financial information (if available), fragment-based library and service portfolio, information on other drug discovery services, recent developments and an informed future outlook.
    • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, mergers and acquisitions, product development and commercialization agreements, commercialization agreements, distribution and supply agreements, product integration agreements, service agreements, and other relevant types of deals.
    • A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
    • An insightful competitiveness analysis of fragment-based drug discovery library and service providers, based on supplier power (based on the years of experience of service provider) and key specifications, such as number of fragment libraries and number of screening techniques.
    • An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.
    • Informed estimates of the existing market size and the future opportunity for fragment-based drug discovery library and services, over the next decade. Based on multiple parameters, such as annual number of drug discovery projects, outsourcing profile, and adoption of fragment-based drug discovery approach, we have provided informed estimates on the evolution of the market for the period 2020-2030.

     

    The report features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

    • Type of Screening Technique Used
    • X-ray Crystallography
    • Nuclear Magnetic Resonance
    • Surface Plasmon Resonance
    • Other Screening Techniques

     

    • Type of Service Offered
    • Library Screening
    • Fragment Screening
    • Fragment Optimization

     

    • End User
    • Industry Players
    • Non-Industry Players

     

    • Key geographical regions

    Press Release: Variation 4 (Format 5)

     

    • North America (US and Canada)
    • Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
    • Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)

     

    The report also features inputs from eminent industry stakeholders, according to whom the fragment-based approach significantly simplifies the drug discovery process. The report includes detailed transcripts of discussions held with the following experts:

     

    To request sample pages, please visit this link            

                                                                                                                   

    Key Questions Answered

    • Who are the leading players in the fragment-based drug discovery library and services market?
    • What are the key biophysical techniques used by service providers for screening fragment libraries and lead optimization?
    • Which types of partnership models are commonly adopted by stakeholders in this domain?
    • What is the likely cost-saving opportunity associated with the use of fragment-based drug discovery?
    • How is the current and future market opportunity likely to be distributed across key market segments?

     

    You may also be interested in the following titles:

    1. DNA-Encoded Libraries: Platforms and Services Market
    2. Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028
    3. In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)

     

    Contact Us:

    Gaurav Chaudhary

    +1 (415) 800 3415

    +44 (122) 391 1091

    Gaurav.Chaudhary@rootsanalysis.com

    Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologies


    Submitted 1 day(s) ago by Harry sins

     

    According to experts in this field, fragment-based drug discovery solutions have facilitated the identification of viable pharmacological leads against otherwise hard to target biomolecules. In fact, many service provider companies are offering fragment libraries and support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus.

     

    To order this 170+ page report, which features 55+ figures and 80+ tables, please visit this link

     

    The USD 1.6 billion (by 2030) financial opportunity within the fragment-based drug discovery market has been analyzed across the following segments:

    • Type of Screening Technique Used
    • X-ray Crystallography
    • Nuclear Magnetic Resonance
    • Surface Plasmon Resonance
    • Other Screening Techniques

     

    • Type of Service Offered
    • Library Screening
    • Fragment Screening
    • Fragment Optimization

     

    • End User
    • Industry Players
    • Non-Industry Players

     

    • Key geographical regions
    • North America (US and Canada)
    • Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
    • Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)

     

    The Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030 report features the following companies, which we identified to be key players in this domain:

    • 2bind
    • Charles River Laboratories
    • ChemAxon
    • ComInnex
    • Creative Biolabs
    • Creative Biostructure
    • CRELUX
    • Domainex
    • Evotec
    • Red Glead Discovery
    • SARomics Biostructures
    • Shanghai ChemPartner
    • Sygnature Discovery
    • Vernalis Research

     

    Table of Contents

     

     

     

    Press Release: Variation 3 (Format 4)

     

    1. Preface

      2. Executive Summary

    2. Introduction

    3. Current Market Landscape

    4. Company Profiles: Fragment-based Drug Discovery Library and Service Providers

    5. Partnerships and Collaborations

    6. Key Acquisition Targets

    7. Company Competitiveness Analysis

    8. Cost Saving Analysis

    9. Market Forecast and Opportunity Analysis

    10. Executive Insights

     

    1. Concluding Remarks

     

    1. Appendix 1: Tabulated Data

     

    1. Appendix 2: List of Companies and Organizations

     

    To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    Gaurav.Chaudhary@rootsanalysis.com

    The fragment-based drug discovery market is projected to grow at an annualized rate of ~10%, till 2030


    Submitted 1 day(s) ago by Harry sins

     

    Roots Analysis has done a detailed study on Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

     

    To order this 170+ page report, which features 55+ figures and 80+ tables, please visit this link

     

    Key Market Insights

    • Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologies
    • Industry stakeholders offer either customized fragment libraries or proprietary screening technologies, a select few claim to provide both; however, the expertise related to fragment optimization is still limited in this domain
    • Majority of stakeholders in the competitive market landscape are small / mid-sized firms, offering a variety of services to cater to the needs of a diverse clientele, featuring industry and non-industry players
    • Stakeholders are actively expanding their capabilities in order to enhance their respective fragment-based drug discovery service portfolios and thereby, maintain a competitive edge in this upcoming industry
    • The rising interest in this field is reflected in the number of partnerships inked in the recent past, involving both international and indigenous stakeholders, and focused on drug discovery for diverse range of indications
    • Considering the prevalent trend of drug discovery and approval, we are led to believe that the fragment-based approach has the potential to enable significant time and cost savings
    • The market is expected to witness growth at a CAGR of ~10%; the anticipated opportunity is likely to be distributed across various types of screening techniques, services and geographies

     

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

                                                                                                                   

    Table of Contents

     

    1. PREFACE

    1.1.       Scope of the Report

    1.2.       Research Methodology

    1.3.       Chapter Outlines

     

    1. EXECUTIVE SUMMARY

     

    1. INTRODUCTION

    3.1.      Chapter Overview

    3.2.      Overview of Drug Development

     

    3.3.      Drug Discovery Process

    3.3.1.    Target Identification

    3.3.2.    Target Validation

    3.3.3.    Hit Generation

    3.3.4.    Hit-to-Lead

    3.3.5.    Lead Optimization

     

    • High-Throughput Screening (HTS) and its Limitations

     

    3.5.      Fragment-based Drug Discovery (FBDD)

    Press Release: Variation 2 (Format 3)

     

    3.5.1.    FBDD Strategies

    3.5.2.    Screening Techniques Used in FBDD

    3.6.      Challenges Related to FBDD

    3.7.      Future Perspectives

     

    1. CURRENT MARKET LANDSCAPE

    4.1.      Chapter Overview

    4.2.      Fragment-based Drug Discovery: List of Library and Service Providers

    4.2.1.    Analysis by Year of Establishment of Company

    4.2.2.    Analysis by Company Size and Geographical Location

    4.2.3.    Leading Library and Service Providers: Analysis by Number of Products

    4.2.4.    Analysis by Geography

    4.2.5.    Analysis by Type of Service Offered

    4.2.6.    Analysis by Type of Technique Used

    4.2.7.    Analysis by Other Services Offered

    4.2.8.    Analysis by End User

     

    4.3.      Fragment-based Drug Discovery: List of Libraries and Technologies

    4.3.1.    Analysis by Type of Product

     

    1. COMPANY PROFILES: FRAGMENT-BASED DRUG DISCOVERY LIBRARY AND SERVICE    

     PROVIDERS

    5.1.      Chapter Overview

     

    5.2.      2bind

    5.2.1.    Recent Developments and Future Outlook

     

    5.3.      Charles River Laboratories

    5.3.1.    Recent Developments and Future Outlook

     

    5.4.      ChemAxon

    5.4.1.    Recent Developments and Future Outlook

     

    5.5.      ComInnex

    5.5.1.    Recent Developments and Future Outlook

     

    5.6.      Creative Biolabs

    5.6.1.    Recent Developments and Future Outlook

     

    5.7.      Creative Biostructure

     

    5.8.      CRELUX

    5.8.1.    Recent Developments and Future Outlook

     

    5.9.      Domainex

    5.9.1.    Recent Developments and Future Outlook

     

    5.10.     Evotec

    5.10.1.  Recent Developments and Future Outlook

     

    5.11.     Red Glead Discovery

     

    5.12.     SARomics Biostructures

     

    5.13.     Shanghai ChemPartner

    5.13.1.  Recent Developments and Future Outlook

    Press Release: Variation 2 (Format 3)

     

    5.14.     Sygnature Discovery

    5.14.1.  Recent Developments and Future Outlook

     

    5.15.     Vernalis Research

    5.15.1.  Recent Developments and Future Outlook

     

    1. PARTNERSHIPS AND COLLABORATIONS

    6.1.      Chapter Overview

    6.2.      Partnership Models

     

    6.3.      Fragment-based Drug Discovery Services Market: List of Partnerships and Collaborations

    6.3.1.    Analysis by Year of Partnership

    6.3.2.    Analysis by Type of Partnership

    6.3.3.    Analysis by Year of Partnership and Type of Partner

    6.3.4.    Most Active Players: Analysis by Number of Partnerships

    6.3.5.    Regional Analysis

    6.3.6.    Intercontinental and Intracontinental Agreements

     

    1. KEY ACQUISITION TARGETS

    7.1.       Chapter Overview

    7.2.       Scope and Methodology

    7.3.       Scoring Criteria and Key Assumptions

    7.4.      Potential Strategic Acquisition Targets in North America

    7.5.      Potential Strategic Acquisition Targets in Europe

    7.6.      Potential Strategic Acquisition Targets in Asia-Pacific

    7.7.      Concluding Remarks

     

    1. COMPANY COMPETITIVENESS ANALYSIS

    8.1.      Chapter Overview

    8.2.      Methodology

    8.3.      Key Parameters

    8.4.      Competitiveness Analysis: Fragment-based Drug Discovery Library and Service Providers

    8.4.1.    Fragment-based Drug Discovery Library and Service Providers based in North America

    8.4.2.    Fragment-based Drug Discovery Library and Service Providers based in Europe

    8.4.3.    Fragment-based Drug Discovery Library and Service Providers based in Asia-Pacific

     

    1. COST SAVING ANALYSIS

    9.1.       Chapter Overview

    9.2.       Key Assumptions and Parameters

    9.3.      Methodology

    9.4.      Overall Cost Saving Potential Associated with FBDD, 2020-2030

    9.5.      Concluding Remarks

     

    1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

    10.1.     Chapter Overview

    10.2.     Key Assumptions and Forecast Methodology

    10.3.     Global Fragment-based Drug Discovery Market, 2020-2030

    10.4.     Global Fragment-based Drug Discovery Market: Distribution by Type of Technique, 2020 and     

     2030

    10.4.1.  Fragment-based Drug Discovery Market for X-ray Crystallography, 2020-2030

    10.4.2.  Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-2030

    10.4.3.  Fragment-based Drug Discovery Market for Surface Plasmon Resonance, 2020-2030

    10.4.4.  Fragment-based Drug Discovery Market for Other Screening Techniques, 2020-2030

     

    10.5.     Global Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and 2030

    10.5.1.  Fragment-based Drug Discovery Market for Library Screening, 2020-2030

    Press Release: Variation 2 (Format 3)

     

    10.5.2.  Fragment-based Drug Discovery Market for Fragment Screening, 2020-2030

    10.5.3.  Fragment-based Drug Discovery Market for Fragment Optimization, 2020-2030

     

    10.6.     Global Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030

    10.6.1.  Fragment-based Drug Discovery Market for Industry Players, 2020-2030

    10.6.2.  Fragment-based Drug Discovery Market for Non-industry Players, 2020-2030

     

    10.7.     Global Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030

    10.7.1.  Fragment-based Drug Discovery Market in the US, 2020-2030

    10.7.2.  Fragment-based Drug Discovery Market in Canada, 2020-2030

    10.7.3.  Fragment-based Drug Discovery Market in the UK, 2020-2030

    10.7.4.  Fragment-based Drug Discovery Market in France, 2020-2030

    10.7.5.  Fragment-based Drug Discovery Market in Germany, 2020-2030

    10.7.6.  Fragment-based Drug Discovery Market in Spain, 2020-2030

    10.7.7.  Fragment-based Drug Discovery Market in Italy, 2020-2030

    10.7.8.  Fragment-based Drug Discovery Market in Rest of Europe, 2020-2030

    10.7.9.  Fragment-based Drug Discovery Market in China, 2020-2030

    10.7.10. Fragment-based Drug Discovery Market in Japan, 2020-2030

    10.7.11. Fragment-based Drug Discovery Market in India, 2020-2030

    10.7.12. Fragment-based Drug Discovery Market in Rest of Asia-Pacific and Rest of the World, 2020-

     2030

     

    1. EXECUTIVE INSIGHTS

    11.1.      Chapter Overview

     

    11.2.      Edelris

    11.2.1.  Company Snapshot

    11.2.2.  Interview Transcript: Jean-Yves Ortholand, Co-founder & Chief Executive Officer

     

    11.3.     SARomics Biostructures

    11.3.1.  Company Snapshot

    11.3.2.  Interview Transcript: Björn Walse, Chief Executive Officer

     

    1. CONCLUDING REMARKS

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    Gaurav.Chaudhary@rootsanalysis.com

    The fragment-based drug discovery market is estimated to be worth around USD 1.6 billion by 2030, predicts Roots Analysis


    Submitted 1 day(s) ago by Harry sins

     

    Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030.”

     

    The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

    • A detailed review of the overall landscape of fragment-based drug discovery library and service providers. 
    • Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered).
    • An analysis of the partnerships that have been established in the recent past.
    • A detailed analysis on acquisition targets.
    • An insightful competitiveness analysis of fragment-based drug discovery library and service providers.
    • An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
    • Type of Technique
    • X-ray Crystallography
    • Nuclear Magnetic Resonance
    • Surface Plasmon Resonance
    • Other Screening Techniques
    • Type of Service
    • Library Screening
    • Fragment Screening
    • Fragment Optimization
    • End User
    • Industry Players
    • Non-Industry Players
    • Key Geographical Region 
    • North America (US and Canada)
    • Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
    • Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)

     

    Key companies covered in the report:

    • 2bind
    • Charles River Laboratories
    • ChemAxon
    • ComInnex
    • Creative Biolabs
    • Creative Biostructure
    • CRELUX
    • Domainex
    • Evotec
    • Red Glead Discovery

    Press Release: Variation 1 (Format 2)

     

    • SARomics Biostructures
    • Shanghai ChemPartner
    • Sygnature Discovery
    • Vernalis Research

     

    For more information, please click on the following link: 

    https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

     

    Other recent offerings

    1. DNA-Encoded Libraries: Platforms and Services Market
    2. Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028
    3. In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    Gaurav.Chaudhary@rootsanalysis.com

    Vigor Smart Review

    apnews.com
    Submitted 1 day(s) ago by jociesile

    Vigor Smart is created by 100% pure compounds such as Hibiscus, Garlic, Hawthorn Berry, specified special vitamin – B vitamins, Juniper Berries, green tea extract and Vitamin C. Hibiscus is also the most important element of this item, that performs a exact significant part in quieting the nervous system of their human anatomy. Hawthorn Berries and specified b vitamins work with just one another to encourage the wellness of mental performance.

    Buy Now ==>> https://apnews.com/press-release/ts-newswire/health-nutrition-dietary-supplements-lil-dicky-d979f711f89ff9f7cf8f11e3449f198a

    The endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030, growing at an annualized rate of 30%, claims Roots Analysis


    Submitted 2 day(s) ago by Harry sins

     

    So far, more than 100 different types of cannabinoids have been identified and there is a growing body of evidence supporting the benefits of this class of compounds in offering symptomatic relief for a wide variety of chronic health conditions

     

    London

     

    Roots Analysis has announced the addition of “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report to its list of offerings.

     

    Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.

     

    To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this link

     

    Key Market Insights 

     

    Over 175 drugs targeting the endocannabinoid system are currently under development

    Most cannabinoid-based drug candidates are being developed to target the CB1 and CB2 receptors. Nearly 45% of such drugs are presently being investigated in clinical trials, while 50% are in the preclinical / discovery phase. Majority of these therapies (60%) are designed for oral administration.

     

    More than 60 companies claim to develop endocannabinoid system targeted therapeutics

    Post 2010, there has been a significant rise in the number of companies working in this domain; such companies represent 63% of the total number of players. Majority of the firms engaged in this domain (74%) are based in North America, followed by those headquartered in Asia-Pacific (16%), Europe (8%) and Latin America (2%).  

     

    Partnership activity has grown at an annualized rate of 35%, between 2017 and 2019  

    The maximum number of partnerships were observed in 2019 within this segment of the pharmaceutical industry. Majority of these agreements were reported to have been inked for research purposes (20%). In addition, more than 35 merger / acquisition deal were signed between 2016 and 2020; service / facility expansion emerged as the most prominent key value drivers for such agreements.

     

    Close to 600 grants were awarded for supporting research on endocannabinoid system targeted therapeutics, since 2016

    Almost 45% of the total amount awarded in the form of grants, was under the R01 (in support of health-related research and development based on the mission of the NIH) mechanism. Further, grants (394) worth USD 147 million were awarded to research projects related to endocannabinoid system.

     

    At present, therapies intended for the treatment of neurological disorders represent the majority share of the overall endocannabinoid system targeted therapeutics market

    Most of the therapies targeting neurological disorders are intended for the treatment of epilepsy. In addition to neurological disorders, therapies intended for autoimmune disorders, cancer and genetic disorders are likely to capture significant market opportunity in the foreseen future.

     

    To request a sample copy / brochure of this report, please visit this link   

     

    Key Questions Answered

    • Who are the leading industry players in this market?
    • What are the key clinical conditions addressed by endocannabinoid system targeted therapeutics?
    • What are the biological receptors targeted by cannabinoid-based therapies?
    • What are the factors that are likely to influence the evolution of this market?
    • What are the initiatives undertaken by start-ups and big pharma players engaged in this domain?
    • What kind of partnership models are commonly adopted by stakeholders in this industry?
    • How is the current and future market opportunity likely to be distributed across key market segments?

     

    The over USD 5 billion (by 2030) financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the following segments:

    • Target Disease Indication
    • Cancer
    • Genetic Disorders
    • Neurological Indications
    • Others

     

    • Route of Administration
    • Oral
    • Inhalation

     

    • Key Geographies
    • North America
    • Europe
    • Asia-Pacific and the Rest of the World

     

    The report features inputs from eminent industry stakeholders, according to whom, endocannabinoid system targeted therapeutics are considered as a promising alternative for the treatment of a diverse array of symptoms associated with a myriad of human diseases. The report includes detailed transcripts of the discussions held with industry experts.

     

    The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), drug portfolio, recent developments and an informed future outlook.

    • GW Pharmaceuticals
    • Corbus Pharmaceuticals
    • Tilray
    • Tetra Bio-Pharma
    • Botanix Pharmaceuticals
    • Kalytera Therapeutics
    • Therapix Biosciences
    • Echo Pharmaceuticals
    • Avicanna
    • GB Sciences

     

    For additional details, please visit 
    https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html or email sales@rootsanalysis.com

     

    You may also be interested in the following titles: 

    1. Neoantigen Targeted Therapies Market, 2019-2030
    2. Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics
    3. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
    4. Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030

     

    Contact:
    Gaurav Chaudhary
    +1 (415) 800 3415

    +44 (122) 391 1091
    Gaurav.Chaudhary@rootsanalysis.com

     

    Elastomeric Closure Components Market for Vials, Cartridges and Syringes, 2019-2030: Focus on Caps, Needle Shields, Plungers, Stoppers, Seals, Tip Caps and Other Closures’ report features a comprehensive study of the current scenario and future potential


    Submitted 2 day(s) ago by Harry sins

     

    To order this detailed 400+ page report, please visit this link

     

    Key Inclusions

    • A detailed assessment of the current market landscape of companies manufacturing elastomeric container closures, featuring information on the type of closure (cap, needle shield, plunger, seal, stopper, and tip cap), type of respective primary container(s) (vial, syringe, and cartridge), elastomeric material(s) used for fabricating the aforementioned closures (such as bromobutyl, chlorobutyl, and others), drug type(s) that are compatible with elastomeric closures, sterilization status of closures (pre-sterilized and unsterilized), affiliated sterilization technique (if the closure(s) is available in the pre-sterilized format), scale of production (small scale, and large scale), type of customization (if available), affiliated dimensions, along with compliance certifications of the product.
    • A comprehensive analysis on the packaging trends of over 230 drug products (including both biologics and small molecule drugs) that were approved over the last five years (beginning 2014), featuring an assessment of the packaging requirements of various container-closure systems based on parameters, such as year of approval of drug, type of molecule, dosage form, route of administration, holding temperature, type of packaging material(s) used for manufacturing primary container and affiliated closure, and leading drug developers (in terms of number of drugs packaged using elastomeric closures).
    • An analysis of various developments / recent trends related to elastomeric packaging materials, offering insights on [A] partnerships and collaborations established within the industry, and [B] recent global conferences related to pharmaceutical packaging industry.
    • Elaborate profiles of key players in this domain (shortlisted on the basis of size of product portfolio), featuring a brief overview of the company (including information on company headquarters, year of establishment, number of employees, and key members of the executive team), financial information (if available), detailed description of proprietary elastomeric closures, recent developments, and an informed future outlook.
    • A case study on the role of robotics in pharmaceutical manufacturing and fill / finish operations, highlighting the advantages of using automation / automated technologies in such processes. It includes profiles of industry players offering such equipment for the aseptic processing of pharmaceutical products.
    • An elaborate discussion on emerging trends (such as focus on personalized therapies, shift towards more flexible packaging, upgrading packaging components to enhance drug product safety, and growing adoption of smart packaging solutions) that are likely to have an impact on the future adoption of elastomeric container-closure components in the pharmaceutical packaging industry. It also features a Harvey ball analysis, highlighting the relative effect of each trend on the overall pharmaceutical packaging industry.
    • An in-depth analysis to estimate the current and future demand for elastomeric closures across key primary packaging containers, including vials, syringes and cartridges, in different regions for the period 2019-2030. Input parameters considered for this analysis include current supply of different primary packaging components and their respective closures and the estimated the proportion of elastomeric closures that are likely to be supplied, which is indicative of the demand.

     

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

     

    • Type of packaging container
      • Vials
      • Syringes
      • Cartridges

     

    • Type of packaging closure
      • Seal
      • Stopper
      • Cap
      • Plunger
      • Barrel
      • Needle Shield

     

    • Sterilization status
      • Pre-sterilized
      • Unsterilized

     

    • Key geographical regions
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

     

    To request sample pages, please visit this link

     

     

    Key Questions Answered

    • What are the popular types of elastomeric materials and coatings being used for the fabrication of closures for parenteral containers (vials, ampoules and syringes)?
    • What are the types of drugs which require elastomeric closures to ensure minimize the risk of extractables and leachables?
    • Who are the leading manufacturers of elastomeric closures across the globe?
    • What is the relative popularity of various types of elastomeric materials used for the packaging of different closure types?
    • How do parameters such as dosage form, route of administration and storage temperature of drugs, influence choice of elastomeric closures?
    • What is the proportion of closures available in pre-sterilized format in the market?
    • What are the popular sterilizing techniques used for pre-sterilization of closures?
    • What are the key drivers of partnership activity in this industry?
    • What are the key challenges associated with the manufacturing of elastomeric components?
    • What are the key considerations for choosing materials for fabricating closures?
    • What are the benefits of pre-sterilized closures? Who are the key players that offer pre-sterilized container-closure kits / systems?
    • Which are latest innovations in the field of elastomeric packaging materials?
    • What is the current and future demand for parenteral containers and their respective closures from 2019 to 2030?
    • What are the key factors that are likely to influence the evolution of the elastomeric closures market?
    • How is the current and future market opportunity likely to be distributed across key market segments and geographies?

     

    You may also be interested in the following titles:

    1. Medical Device Contract Manufacturing Market, 2019-2030
    2. Biologics Fill / Finish Services Market, 2019 – 2030
    3. Pre-Sterilized / Ready-to-Use Primary Packaging: Focus on Cartridges, Syringes and Vials, 2018-2030

     

    Contact Us

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

    Currently, there are over 240 closures, fabricated using a variety of elastomeric materials, available for use in parenteral primary packaging containers; majority of these products are available in the ready-to-use format, claims Roots Analysis


    Submitted 2 day(s) ago by Harry sins

     

    The materials used to fabricate pharmaceutical packaging components are extremely important to preserving the stability, efficacy and safety of drug formulations. In fact, according to the USFDA, in the last two years, there have been over 2,000 drug and device recalls owing to packaging-related concerns. Elastomeric closures, with various types of coatings (such as FluoroTec® and Teflon®), have emerged as a promising option for developing closures for pharmaceutical containers.

     

    To order this 400+ page report, which features 185+ figures and 235+ tables, please visit this link

     

    The USD 9.3 billion (by 2030) financial opportunity within elastomeric closures market has been analyzed across the following segments:

     

    • Type of packaging container
      • Vials
      • Syringes
      • Cartridges

     

    • Type of packaging closure
      • Seal
      • Stopper
      • Cap
      • Plunger
      • Barrel
      • Needle Shield

     

    • Sterilization status
      • Pre-sterilized
      • Unsterilized

     

    • Key geographical regions
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

     

    The Elastomeric Closure Components Market For Vials, Cartridges and Syringes, 2019-2030 report features the following companies, which we identified to be key players in this domain:

    • Aptar Pharma
    • Daikyo Seiko
    • Datwyler Group
    • DWK Life Sciences
    • Hebei First Rubber Medical Technology (a Part of DESHENG Group)
    • Jiangsu Hualan New Pharmaceutical Material
    • Lonstroff (a Part of Sumitomo Rubber Industries)
    • Ompi (a Part of Stevanato Group)
    • West Pharmaceutical Services

     

    Table of Contents

     

    1. Preface

      2. Executive Summary
    2. Introduction

    3. Market Landscape

    4. Company Profiles

    5. Packaging Trend Analysis for Recently Approved Drugs

    6. Recent Developments

    7. Demand Analysis

    8. Market Forecast

    9. Case Study: Robotics in Pharmaceutical Packaging

    10. Emerging Trends in Pharmaceutical Packaging

    11. Executive Insights

     

    1. Appendix 1: Tabulated Data

     

    1. Appendix 2: List of Companies and Organizations

     

    To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/elastomeric-closures-market-focus-on-parenteral-containers-2019-2030/255.html

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com 

     

    The elastomeric closures market is projected to reach USD 9.3 Billion by 2030, growing at an annualized rate of 6.7%, claims Roots Analysis


    Submitted 2 day(s) ago by Harry sins

     

    Roots Analysis has done a detailed study on Elastomeric Closure Components Market For Vials, Cartridges and Syringes, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

     

    To order this 400+ page report, which features 185+ figures and 235+ tables, please visit this link

     

    Key Market Insights

    • The elastomeric container closures market is fragmented, featuring the presence of a large number of established players; a relatively larger proportion of small-sized players are based in developing geographies
    • Currently, there are over 240 closures, fabricated using a variety of elastomeric materials, available for use in parenteral primary packaging containers; majority of these products are available in the ready-to-use format
    • Over time, companies have established preferences regarding fabrication materials for container-closure systems for different drug classes in order to ensure that their products are free from chemical impurities
    • A number of conferences related to pharmaceutical packaging have been organized in the recent past; in addition, stakeholders have also entered into strategic agreements to strengthen their product portfolios
    • In order to cope up with emerging trends in the pharmaceutical packaging market, it is important for container closure manufacturers to improve existing practices to cater to the changing needs of drug developers
    • The global demand for elastomeric closures is presently driven by rising adoption of parenteral containers; in future, pre-sterilized and coated closures are anticipated to drive the demand at a relatively faster pace
    • The overall market is poised to grow steadily; the opportunity is likely to be well-distributed across various types of containers, types of closures and regions

     

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/elastomeric-closures-market-focus-on-parenteral-containers-2019-2030/255.html

     

    Table of Contents

     

    1. PREFACE

    1.1.      Scope of the Report

    1.2.      Research Methodology

    1.3.      Chapter Outlines

     

    1. EXECUTIVE SUMMARY

     

    1. INTRODUCTION

    3.1.      Chapter Overview

    3.2.      Pharmaceutical Packaging

    3.2.1.    Types of Pharmaceutical Packaging

    3.2.2.    Innovation in Pharmaceutical Packaging

    3.2.3.    Traditional Aseptic Pharmaceutical Filling Operations

    3.2.4.    Limitations of Traditional Primary Packaging

     

    3.3.      Role of Containers-Closures Systems in Pharmaceutical Packaging

    3.4.      Types of Closures Used in Pharmaceutical Packaging

    3.4.1.    Closures for Prefilled Syringes / Syringes

    3.4.2.    Closures for Vials

    3.4.3.    Closures for Cartridges

    3.5.      Key Considerations for Choosing Materials for Fabricating Closures

     

    3.6.      Elastomeric Packaging Materials

    3.6.1.    Key Properties of Elastomeric Packaging Materials

    3.6.2.    Popular Types of Elastomeric Packaging Materials

    3.6.3.    Regulatory Guidelines for Elastomeric Closures

    3.6.4.    Manufacturing Process for Elastomeric Closures

    3.6.5.    Quality Assessment Tests for Elastomeric Closures

    3.6.6.    Advantages and Limitations of Elastomeric Packaging Materials

     

    3.7.      Concluding Remarks

     

    1. MARKET LANDSCAPE

    4.1.      Chapter Overview

    4.2.      Elastomeric Closures for Parenteral Containers: List of Products

    4.2.1.    Analysis by Type of Closure

    4.2.1.1. Analysis by Type of Closure and Headquarters of Manufacturer

    4.2.1.2. Analysis by Type of Closure and Size of Player

    4.2.2.    Analysis by Type of Container

    4.2.3.    Analysis by Type of Elastomeric Material

    4.2.4.    Analysis by Drug Class               

    4.2.5.    Analysis by Sterilization Status

    4.2.6.    Analysis by Sterilization Technique

    4.2.7.    Analysis by Type of Coating

     

    4.3.      Elastomeric Closures for Parenteral Containers: List of Manufacturers

    4.3.1.    Analysis by Year of Establishment

    4.3.2.    Analysis by Company Size

    4.3.3.    Analysis by Location of Headquarters

    4.3.4.    Analysis by Target Market

    4.3.5.    Analysis by Scale of Production

    4.3.6.    Leading Manufacturers: Analysis by Number of Products

    4.3.7.    Manufacturer Landscape: Analysis by Company Size and Location of Headquarters

     

    4.4.      Elastomeric Closures for Parenteral Containers: Recent Initiatives of Players

    4.5.      Concluding Remarks

     

    1. COMPANY PROFILES

    5.1.      Chapter Overview

    5.2.      Key Players Based in North America

    5.2.1.    Aptar Pharma (a Part of AptarGroup)

    5.2.1.1. Company Overview

    5.2.1.2. Financial Information

    5.2.1.3. Product Portfolio

    5.2.1.4. Recent Developments and Future Outlook

     

    5.2.2.    DWK Life Sciences

    5.2.2.1. Company Overview

    5.2.2.2. Product Portfolio

    5.2.2.3. Recent Developments and Future Outlook

     

    5.2.3.    West Pharmaceutical Services

    5.2.3.1. Company Overview

    5.2.3.2. Financial Information

    5.2.3.3. Product Portfolio

    5.2.3.4. Recent Developments and Future Outlook

     

    5.3.      Key Players Based in Europe

    5.3.1.    Datwyler Sealing Solutions (a Part of Datwyler Group)

    5.3.1.1. Company Overview

    5.3.1.2. Financial Information

    5.3.1.3. Product Portfolio

    5.3.1.4  Recent Developments and Future Outlook

     

    5.3.2.    Lonstroff (a Part of  Sumitomo Rubber Industries)

    5.3.2.1. Company Overview

    5.3.2.2. Financial Information

    5.3.2.2. Product Portfolio

    5.3.2.3. Recent Developments and Future Outlook

     

    5.3.3.    Ompi (a Part of Stevanato Group)

    5.3.3.1. Company Overview

    5.3.3.2. Product Portfolio

    5.3.3.3. Recent Developments and Future Outlook

     

    5.4.      Key Players Based in Asia-Pacific

    5.4.1     Daikyo Seiko

    5.4.1.1. Company Overview

    5.4.1.2. Product Portfolio

    5.4.1.3. Recent Developments and Future Outlook

     

    5.4.2.    Hebei First Rubber Medical Technology (a Part of DESHENG Group)

    5.4.2.1. Company Overview

    5.4.2.2. Product Portfolio

    5.4.2.3. Recent Developments and Future Outlook

     

    5.4.3.    Jiangsu Hualan New Pharmaceutical Material

    5.4.3.1. Company Overview

    5.4.3.2. Product Portfolio

    5.4.3.3. Recent Developments and Future Outlook

     

    1. PACKAGING TRENDS ANALYSIS FOR RECENTLY APPROVED DRUGS

    6.1.      Chapter Overview

    6.2.      List of Approved Drugs (2014-2018)

    6.2.1.    Analysis by Year of Approval

    6.2.2.    Analysis by Type of Molecule

    6.2.3.    Analysis by Type of Biologic

    6.2.4.    Analysis by Holding Temperature Range

    6.2.5.    Analysis by Type of Container

    6.2.6.    Analysis by Type of Container and Year of Approval

    6.2.7.    Analysis by Type of Container and Type of Molecule

    6.2.8.    Analysis by Type of Container and Dosage Form

    6.2.9.    Analysis by Type of Container and Route of Administration

    6.2.10.  Analysis by Type of Container and Holding Temperature Range

    6.2.11.  Popular Type of Material Used for Containers

    6.2.12.  Analysis by Type of Closure

    6.2.13.  Analysis by Type of Closure and Year of Approval

    6.2.14.  Analysis by Type of Closure and Type of Molecule

    6.2.15.  Analysis by Type of Closure and Dosage Form

    6.2.16.  Analysis by Type of Closure and Route of Administration

    6.2.17.  Analysis by Type of Closure and Holding Temperature Range

    6.2.18.  Popular Type of Material Used for Closures

    6.2.19.  Analysis by Type of Elastomeric Material Used for Closures and Dosage Form

    6.2.20.  Analysis by Type of Elastomeric Material Used for Closures and Route of Administration

    6.2.21.  Analysis by Type of Elastomeric Material Used for Closures and Holding Temperature Range

    6.2.22.  Analysis by Type of Elastomeric Material Used for Closures

    6.2.23.  Most Active Players: Analysis by Number of Drugs Packaged Using Elastomeric Closures

    6.2.24.  Concluding Remarks

     

    1. RECENT DEVELOPMENTS

    7.1.      Chapter Overview

    7.2.      Pharmaceutical Packaging Industry: Partnership Activity

    7.2.1.    Partnership Models

    7.2.2.    List of Partnerships and Collaborations

    7.2.2.1. Analysis by Year of Partnership

    7.2.2.2. Analysis by Type of Partnership

    7.2.2.3. Analysis by Focus Area

    7.2.2.4. Most Active Players: Analysis by Number of Partnerships

     

    7.3.      Elastomeric Container Closures in Pharmaceutical Packaging Industry: Recent Expansions

     

    7.4.      Pharmaceutical Packaging Industry: Recent Conferences

    7.4.1.    List of Recent Conferences

    7.4.1.1. Analysis by Year of Occurrence

    7.4.1.2. Analysis by Geography

    7.4.2.    Elastomeric Container Closures: List of Recent Conferences

    7.4.2.1. Analysis by Focus Area / Agenda

    7.4.3.    Geographical Mapping of Conferences

     

    7.5.      Concluding Remarks

     

    1. DEMAND ANALYSIS

    8.1.      Chapter Overview

    8.2.      Scope and Methodology

    8.3.      Global Demand for Elastomeric Closures, 2019-2030

    8.3.1.    Analysis by Type of Primary Container

    8.3.1.1. Global Demand for Elastomeric Closures for Vials

    8.3.1.2. Global Demand for Elastomeric Closures for Syringes

    8.3.1.3. Global Demand for Elastomeric Closures for Cartridges

    8.3.2.    Analysis by Type of Closure

    8.3.2.1. Global Demand for Elastomeric Seals

    8.3.2.2. Global Demand for Elastomeric Stoppers

    8.3.2.3. Global Demand for Elastomeric Caps

    8.3.2.4. Global Demand for Elastomeric Plungers

    8.3.2.5. Global Demand for Elastomeric Barrels

    8.3.2.6. Global Demand for Elastomeric Needle Shields

     

    8.3.3.    Analysis by Sterilization Status

    8.3.3.1. Global Demand for Pre-Sterilized Elastomeric Closures

    8.3.3.1.1. Global Demand for Pre-Sterilized Elastomeric Seals

    8.3.3.1.2. Global Demand for Pre-Sterilized Elastomeric Stoppers

    8.3.3.1.3. Global Demand for Pre-Sterilized Elastomeric Caps

    8.3.3.1.4. Global Demand for Pre-Sterilized Elastomeric Plungers

    8.3.3.1.5. Global Demand for Pre-Sterilized Elastomeric Barrels

    8.3.3.1.6. Global Demand for Pre-Sterilized Elastomeric Needle Shields

     

    8.3.3.2. Global Demand for Unsterilized Elastomeric Closures

    8.3.3.2.1. Global Demand for Unsterilized Elastomeric Seals

    8.3.3.2.2. Global Demand for Unsterilized Elastomeric Stoppers

    8.3.3.2.3. Global Demand for Unsterilized Elastomeric Caps

    8.3.3.2.4. Global Demand for Unsterilized Elastomeric Plungers

    8.3.3.2.5. Global Demand for Unsterilized Elastomeric Barrels

    8.3.3.2.6. Global Demand for Unsterilized Elastomeric Needle Shields

     

    8.3.4.    Analysis by Geography

    8.3.4.1. Demand for Elastomeric Closures in North America

    8.3.4.1.1. Demand for Elastomeric Seals in North America

    8.3.4.1.2. Demand for Elastomeric Stoppers in North America

    8.3.4.1.3. Demand for Elastomeric Caps in North America

    8.3.4.1.4. Demand for Elastomeric Plungers in North America

    8.3.4.1.5. Demand for Elastomeric Barrels in North America

    8.3.4.1.6. Demand for Elastomeric Needle Shields in North America

     

    8.3.4.2. Demand for Elastomeric Closures in Europe

    8.3.4.2.1. Demand for Elastomeric Seals in Europe

    8.3.4.2.2. Demand for Elastomeric Stoppers in Europe

    8.3.4.2.3. Demand for Elastomeric Caps in Europe

    8.3.4.2.4. Demand for Elastomeric Plungers in Europe

    8.3.4.2.5. Demand for Elastomeric Barrels in Europe

    8.3.4.2.6. Demand for Elastomeric Needle Shields in Europe

     

    8.3.4.3. Demand for Elastomeric Closures in Asia-Pacific

    8.3.4.3.1. Demand for Elastomeric Seals in Asia-Pacific

    8.3.4.3.2. Demand for Elastomeric Stoppers in Asia-Pacific

    8.3.4.3.3. Demand for Elastomeric Caps in Asia-Pacific

    8.3.4.3.4. Demand for Elastomeric Plungers in Asia-Pacific

    8.3.4.3.5. Demand for Elastomeric Barrels in Asia-Pacific

    8.3.4.3.6. Demand for Elastomeric Needle Shields in Asia-Pacific

     

    8.3.4.4. Demand for Elastomeric Closures in Rest of the World

    8.3.4.4.1. Demand for Elastomeric Seals in Rest of the World

    8.3.4.4.2. Demand for Elastomeric Stoppers in Rest of the World

    8.3.4.4.3. Demand for Elastomeric Caps in Rest of the World

    8.3.4.4.4. Demand for Elastomeric Plungers in Rest of the World

    8.3.4.4.5. Demand for Elastomeric Barrels in Rest of the World

    8.3.4.4.6. Demand for Elastomeric Needle Shields in Rest of the World

     

    8.4.      Concluding Remarks

     

    1. MARKET FORECAST

    9.1.      Chapter Overview

    9.2.      Forecast Methodology and Key Assumptions

    9.3.      Global Elastomeric Closures Market, 2019-2030

    9.3.1.    Global Elastomeric Closures Market, 2019-2030: Distribution by Type of Primary Container

    9.3.1.1. Global Elastomeric Closures Market for Vials, 2019-2030

    9.3.1.2. Global Elastomeric Closures Market for Syringes, 2019-2030

    9.3.1.3. Global Elastomeric Closures Market for Cartridges, 2019-2030

     

    9.3.2.    Global Elastomeric Closures Market, 2019-2030: Distribution by Type of Closure

    9.3.2.1. Global Elastomeric Closures Market for Seals, 2019-2030

    9.3.2.2. Global Elastomeric Closures Market for Stoppers, 2019-2030

    9.3.2.3. Global Elastomeric Closures Market for Caps, 2019-2030

    9.3.2.4. Global Elastomeric Closures Market for Plungers, 2019-2030

    9.3.2.5. Global Elastomeric Closures Market for Barrels, 2019-2030

    9.3.2.6. Global Elastomeric Closures Market for Needle Shields, 2019-2030

     

    9.3.3.    Global Elastomeric Closures Market, 2019-2030: Distribution by Sterilization Status

    9.3.3.1. Global Pre-Sterilized Elastomeric Closures Market, 2019-2030

    9.3.3.1.1. Global Pre-Sterilized Elastomeric Closures Market for Seals, 2019-2030

    9.3.3.1.2. Global Pre-Sterilized Elastomeric Closures Market for Stoppers, 2019-2030

    9.3.3.1.3. Global Pre-Sterilized Elastomeric Closures Market for Caps, 2019-2030

    9.3.3.1.4. Global Pre-Sterilized Elastomeric Closures Market for Plungers, 2019-2030

    9.3.3.1.5. Global Pre-Sterilized Elastomeric Closures Market for Barrels, 2019-2030

    9.3.3.1.6. Global Pre-Sterilized Elastomeric Closures Market for Needle Shields, 2019-2030

     

    9.3.3.2. Global Unsterilized Elastomeric Closures Market, 2019-2030

    9.3.3.2.1. Global Unsterilized Elastomeric Closures Market for Seals, 2019-2030

    9.3.3.2.2. Global Unsterilized Elastomeric Closures Market for Stoppers, 2019-2030

    9.3.3.2.3. Global Unsterilized Elastomeric Closures Market for Caps, 2019-2030

    9.3.3.2.4. Global Unsterilized Elastomeric Closures Market for Plungers, 2019-2030

    9.3.3.2.5. Global Unsterilized Elastomeric Closures Market for Barrels, 2019-2030

    9.3.3.2.6. Global Unsterilized Elastomeric Closures Market for Needle Shields, 2019-2030

     

    9.3.4.    Global Elastomeric Closures Market, 2019-2030: Distribution by Geography

    9.3.4.1. Elastomeric Closures Market in North America, 2019-2030

    9.3.4.1.1. Elastomeric Closures Market for Seals in North America, 2019-2030

    9.3.4.1.2. Elastomeric Closures Market for Stoppers in North America, 2019-2030

    9.3.4.1.3. Elastomeric Closures Market for Caps in North America, 2019-2030

    9.3.4.1.4. Elastomeric Closures Market for Plungers in North America, 2019-2030

    9.3.4.1.5. Elastomeric Closures Market for Barrels in North America, 2019-2030

    9.3.4.1.6. Elastomeric Closures Market for Needle Shields in North America, 2019-2030

     

    9.3.4.2. Elastomeric Closures Market in Europe, 2019-2030

    9.3.4.2.1. Elastomeric Closures Market for Seals in Europe, 2019-2030

    9.3.4.2.2. Elastomeric Closures Market for Stoppers in Europe, 2019-2030

    9.3.4.2.3. Elastomeric Closures Market for Caps in Europe, 2019-2030

    9.3.4.2.4. Elastomeric Closures Market for Plungers in Europe, 2019-2030

    9.3.4.2.5. Elastomeric Closures Market for Barrels in Europe, 2019-2030

    9.3.4.2.6. Elastomeric Closures Market for Needle Shields in Europe, 2019-2030

     

    9.3.4.3. Elastomeric Closures Market in Asia-Pacific, 2019-2030

    9.3.4.3.1. Elastomeric Closures Market for Seals in Asia-Pacific, 2019-2030

    9.3.4.3.2. Elastomeric Closures Market for Stoppers in Asia-Pacific, 2019-2030

    9.3.4.3.3. Elastomeric Closures Market for Caps in Asia-Pacific, 2019-2030

    9.3.4.3.4. Elastomeric Closures Market for Plungers in Asia-Pacific, 2019-2030

    9.3.4.3.5. Elastomeric Closures Market for Barrels in Asia-Pacific, 2019-2030

    9.3.4.3.6. Elastomeric Closures Market for Needle Shields in Asia-Pacific, 2019-2030

     

    9.3.4.4. Elastomeric Closures Market in Rest of the World, 2019-2030

    9.3.4.4.1. Elastomeric Closures Market for Seals in Rest of the World, 2019-2030

    9.3.4.4.2. Elastomeric Closures Market for Stoppers in Rest of the World, 2019-2030

    9.3.4.4.3. Elastomeric Closures Market for Caps in Rest of the World, 2019-2030

    9.3.4.4.4. Elastomeric Closures Market for Plungers in Rest of the World, 2019-2030

    9.3.4.4.5. Elastomeric Closures Market for Barrels in Rest of the World, 2019-2030

    9.3.4.4.6. Elastomeric Closures Market for Needle Shields in Rest of the World, 2019-2030

     

    9.4.      Concluding Remarks

     

    1. CASE STUDY: ROBOTICS IN PHARMACEUTICAL PACKAGING

    10.1.     Chapter Overview

    10.2.     Role of Robots in the Pharmaceutical Industry

    10.2.1.  Key Considerations for Selecting a Robotic System

    10.2.2.  Advantages of Robotic Systems

    10.2.3.  Disadvantages of Robotic Systems

    10.3.     Companies Providing Robots for Pharmaceutical Industry

    10.4.     Companies Providing Equipment Integrated with Robotic Systems for Pharmaceutical Packaging

    10.4.1.  Aseptic Technologies

    10.4.1.1. Crystal® L1 Robot Line

    10.4.1.2. Crystal® SL1 Robot Line

     

    10.4.2.  AST

    10.4.2.1. ASEPTiCell® Series

    10.4.2.2. ASEPTiCell® VSM-25

     

    10.4.3.  Bosch Packaging Technology

    10.4.3.1. ATO

     

    10.4.4.  Dara Pharmaceutical Packaging

    10.4.4.1. SYX-E CARTRIDGE + RABS

     

    10.4.5.  Fedegari Group

    10.4.5.1. Fedegari Isolator

     

    10.4.6.  IMA

    10.4.6.1. INJECTA

    10.4.6.2. STERI LIF3

     

    10.4.7.  Steriline

    10.4.7.1. Nest Filling Line RNFM

     

    10.4.8.  Vanrx Pharmasystems

    10.4.8.1. Microcell Vial Filler

    10.4.8.2. SA25 Aseptic Filling Workcell

     

    1. EMERGING TRENDS IN PHARMACEUTICAL PACKAGING

    11.1.     Chapter Overview

    11.2.     Shift Towards Self-Medication using Advanced Drug Delivery Devices

    11.3.     Focus on Developing Improved Packaging Components and Ongoing Efforts to Optimize Manufacturing Costs

    11.4.     Availability of Modular Facilities

    11.5.     Initiatives Focused on Automation of Fill / Finish Operations

    11.6.     Establishment of Business Relationships Focused on Designing Compatible Packaging Materials for Various Drug Products

    11.7.     Increasing Activity in Developing Regions

    11.8.     Growing Adoption of Smart Packaging Solutions

    11.9.     Concluding Remarks

     

    1. EXECUTIVE INSIGHTS

    12.1.     Chapter Overview

    12.2.     Aseptic Technologies

    12.2.1. Company Snapshot

    12.2.2. Interview Transcript: Julien Maréchal, Business Development and Technology Director

     

    12.3.     BioPhorum Operations Group

    12.3.1. Company Snapshot

    13.3.2. Interview Transcript: Malcolm Gilmore, Facilitator

     

    12.4.     Lonstroff

    12.4.1. Company Snapshot

    12.4.2. Interview Transcript: Marco Pederiva, Marketing and Sales Director

     

    12.5.     PYRAMID Laboratories

    12.5.1. Company Snapshot

    12.5.2. Interview Transcript: Konstantin Kazarian, Business Development Project Manager

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

    The elastomeric closures market is projected to reach USD 9.3 Billion by 2030, growing at an annualized rate of 6.7%, claims Roots Analysis


    Submitted 2 day(s) ago by Harry sins

     

    Driven by the growing complexity of modern pharmacological interventions, industry stakeholders have developed container-closures systems using more versatile materials; in this context, elastomers have demonstrated significant potential

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Elastomeric Closure Components Market For Vials, Cartridges and Syringes, 2019-2030.”

     

    The report features a comprehensive study of the current scenario and future potential of the elastomeric, primary packaging closure market. It features an in-depth analysis, highlighting the various types of elastomeric closures including stoppers, needle shields and plungers, available in the market for various types of primary packaging containers, such as cartridges, syringes and vials. In addition to other elements, the study includes:

    • A detailed assessment of the current market landscape of companies manufacturing elastomeric container closures.
    • A comprehensive analysis on the packaging trends of over 230 drug products (including both biologics and small molecule drugs) that were approved over the last five years (beginning 2014).
    • An analysis of various developments / recent trends related to elastomeric packaging materials.
    • Elaborate profiles of key players in this domain (shortlisted on the basis of size of product portfolio).
    • A case study on the role of robotics in pharmaceutical manufacturing and fill / finish operations.
    • An elaborate discussion on emerging trends that are likely to have an impact on the future adoption of elastomeric container-closure components in the pharmaceutical packaging industry.
    • An in-depth analysis to estimate the current and future demand for elastomeric closures across key primary packaging containers, including vials, syringes and cartridges, in different regions for the period 2019-2030.
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

     

    • Type of packaging container
      • Vials
      • Syringes
      • Cartridges

     

    • Type of packaging closure
      • Seal
      • Stopper
      • Cap
      • Plunger
      • Barrel
      • Needle Shield

     

    • Sterilization status
      • Pre-sterilized
      • Unsterilized

     

    • Key geographical regions
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

     

     

    Key companies covered in the report

    • Aptar Pharma
    • Daikyo Seiko
    • Datwyler Group
    • DWK Life Sciences
    • Hebei First Rubber Medical Technology (a Part of DESHENG Group)
    • Jiangsu Hualan New Pharmaceutical Material
    • Lonstroff (a Part of Sumitomo Rubber Industries)
    • Ompi (a Part of Stevanato Group)
    • West Pharmaceutical Services

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/elastomeric-closures-market-focus-on-parenteral-containers-2019-2030/255.html

     

    Other Recent Offerings

    1. Medical Device Contract Manufacturing Market, 2019-2030
    2. Biologics Fill / Finish Services Market, 2019 – 2030
    3. Pre-Sterilized / Ready-to-Use Primary Packaging: Focus on Cartridges, Syringes and Vials, 2018-2030

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

    Xwatch Review | Smart watch Review

    toptechgadgets.shop
    Submitted 2 day(s) ago by harish889

    At Top Tech Gadgets Shop, in our exclusive Xwatch Review we introduce you to a smartwatch that is the digital future of all high end watches.

    There are lots of wearable items in the market, be it earbuds, fitness bands or smart glasses. We are constantly upgrading. Now let me be honest, I just hate Smart Watches because they are so costly.

    But my wife out of nowhere decided to give me a smartwatch “Xwatch” After using it for a month it has changed my perspective.

    Xwatch is a really cool device. You can pair it with your iOS or Android phone via Bluetooth. I can answer a phone call, control my music app, store music, click pictures or videos, check health activities, and even regulate my blood pressure! Know more in our Xwatch Review.

    Smart Sanitizer Pro Review (UV Sanitizer): Sanitize Your All Gadgets

    toptechgadgets.shop
    Submitted 2 day(s) ago by harish889

    We are here with our Smart Sanitizer Pro Review Top Tech Gadgets Shop.

    ‘Are we unsafe in our homes too?’ I asked my doctor as I was really worried about the widespread viruses around us.

    Since we all have been told to stay indoors during this sensitive season, I spent most of the time in my room.

    During the day several people visit your house and unknowingly there are ways through which diseases can enter your house. Shopkeepers, grocery delivery, if there’s some repair work in the house, newspaper guy and etc.

    “You must buy a Smart Sanitizer Pro Said my doctor. He then asked me to order this device because it can kill viruses within 6 minutes! It is a medical Grade UV Light Sanitizer. Know more in our Smart Sanitizer Pro Review

    Smart Sanitizer Pro Is An UV Sanitizer Device that Kills Viruses And Bacteria From Things we put inside It. Read Smart Sanitizer Pro Review before you buy Smart Sanitizer Pro.

    FitTrack Reviews: 50% Off on FitTrack BMI Scale, Buy Now!

    toptechgadgets.shop
    Submitted 2 day(s) ago by harish889

    At Top Tech Gadgets Shop, in our exclusive Fit Track Review we introduce you to a magical scale that will help you to diagnose what’s going wrong in your own body!

    Fittrack Smart Body BMI Scale: Check the FitTrack Review. FitTrack is the Smartest BMI Scale with App Tracking System. FitTrack Body BMI Scale will keeps healthy.

    While you are on your way to get a healthy lifestyle, there are a dozen changes that your body undergoes. You don’t get to see these chemical changes going inside your body.

    FitTrack gives you 17 different measurements ranging from BMI, body weight, muscle mass and so on. This helps you to have a better understanding of your own body. Know more in our Fit Track Review.

    Fit Track Features

     In this Fit Track Review, I must mention some of its main features that make Fit Track Smart scale a super smart device –

     

    1. Fit Track has a biometric scanner - This helps in giving you 17 different body measurements that are very important.

     

    1. Can be used by multiple users - Recognizes and tracks progress for 8 different users. Fit Track allows you to track progress, schedule reminders, and set health goals!

     

    1. Runs on your smartphone - The Fit Track smart scale comes with an app which is iPhone and Android compatible.

     

    1. Battery support - It runs on batteries like any other digital weighing machine. Four AAA batteries are required therefore you don’t need to carry an extra charger or any power cord for it.

     

    1. Lifetime warranty - Fit Track smart scale comes with a lifetime warranty and a 30-day risk-free trial.

     

    1. Water resistant – You can keep it in your bathroom too!

     

    Just download the Free Fit Track App on your smartphone to get started. Step on the Smart scale with your bare feet. Instantly get to see 17 different important health insights about your body within the next few seconds. The Fit Track comes from an American manufacturer and has been officially approved for sale by the FDA. Being approved by the FDA in the USA is a quality feature that proves that the scale is not dangerous.

     

    Vor- und Nachteile des schlanken Keto-Produkts

    slimymedpremium.shop
    Submitted 3 day(s) ago by slimymedpremium

    Zahlreiche Menschen brauchen einen dünnen Körper, nicht nur im Sommer. Trotzdem ist mit diesem Unternehmen viel Arbeit verbunden, weshalb einige Leute Dinge verwenden möchten, die ihnen helfen können, fit zu werden. Eine schlanke Premium-Diät ist eine solche Bereitschaft.

    Besuchen Sie die offizielle Website von slimymed:- http://slimymedpremium.shop/

     

    https://in.pinterest.com/pin/809099889300366130?nic_v2=1a3smm0Bl

    https://twitter.com/HSuggetions/status/1318783414678421504/photo/1

    https://www.instagram.com/p/CGl_mV2h3AH/

    https://www.linkedin.com/pulse/how-does-slimymed-work-used-premium-jyoti-srs-

    https://sites.google.com/view/slimymed-primeum-nhrstoffe/

    http://socialbusinesspedia.com/people/slimymedpremium

    http://rosalind.info/users/slimymedpremium/

    http://sco.lt/7RC49Y

    https://www.reddit.com/user/slimymedpremiumdiet/comments/jf9bd2/wie_funktioniert_slimymed_und_wie_wird_slimymed/

    https://clyp.it/user/2pgo5to4

    https://dribbble.com/shots/14429587-Vor-und-Nachteile-des-schlanken-Keto-Produkts?

    https://www.spreaker.com/user/slimymedpremium

    http://hawkee.com/profile/744191/

    https://clarity.fm/slimymedpremium

    https://clyp.it/user/2pgo5to4

    https://www.indiegogo.com/individuals/24971124

    https://disqus.com/by/slimymedpremium/

    https://hyperspaces.inglobetechnologies.com/helpdesk/index.php?qa=user&qa_1=slimymedpremium

    https://wrapbootstrap.com/user/slimymedpremium

    https://www.codechef.com/users/slimymedreview

    https://www.industryhuddle.com/profile?id=88636

    https://www.wysp.ws/slimymedpremium/

    https://skitterphoto.com/photographers/9901/slimymed-premium

    http://truckcamvideos.com/user/slimymedpremium

    https://peatix.com/user/6818266/view

    http://hiphopinferno.com/user/slimymedpremium

    LiboMAX - ME USA Boost Your Performance, Stamina, And Size | Reviews

    libomax.shop
    Submitted 3 day(s) ago by libomaxmale

    Libromax Male Performance Matrix, a male exhibition supplement, is a double activity recipe that fills in as a testosterone level sponsor. Containing an unpredictable framework of exceptionally nourishing fixings that have been deductively demonstrated to help sexual energy and wellbeing. This enhancement was uncommonly made for all men to build charisma and assist men with enduring longer.

    Visit Official Website: http://libomax.shop/

    https://bit.ly/31qRKjb


    https://www.facebook.com/Libomax-Male-Enhancement-101097051800664/


    https://youtu.be/-Grx4Y8e34U


    https://www.linkedin.com/pulse/libomax-male-enhancement-does-really-work-prak-lee

     

    Vape Shop | Vape Store in UK | Vape Shop in UK - UK Vapor Waves

    ukvaporwaves.com
    Submitted 3 day(s) ago by ukvaporwaves

    UK Vapor Waves offers a wide range of e-cigarette products. Vape shops can offer a greater selection of e-cigarettes than conventional retailers. While vape shops offer mostly reusable e-cigarettes, cig-a-likes are mostly available at convenience stores.

    The ‘Contract Regulatory Affairs Management Market for Medical Devices, 2019-2030’ report features a detailed study on the current landscape of contract service providers focused on regulatory affairs management for medical devices.


    Submitted 4 day(s) ago by Harry sins

     

     

    To order this detailed 550+ page report, please visit this link

     

    Key Inclusions

     

    • A detailed review of the current market landscape of the medical devices regulatory affairs outsourcing market, featuring a list of over 400 CROs engaged in this domain, and detailed analysis based on a number of relevant parameters, such as year of establishment, size of employee base, geographical location, device class (class I, class II, and class III), type and size of clientele (medical device developers, medical device manufacturers, medical device research organizations, and others), types of services offered, ([A] regulatory management services (such as legal representation, notified body selection, project registration and clinical trial application, regulatory writing and publishing, regulatory document submission, product labelling related service, gap-analysis, technical dossier set-up, vigilance & medical device report, risk management-related services), [B] additional services (such as biostatistics, consulting, clinical operations, post-marketing activities, quality assurance, reimbursement, training)), region(s) of operation wherein the company is offering regulatory management services.
    • A detailed discussion on the need for regulatory review / oversight across different stages of the medical devices supply chain, with emphasis on the optimization of the supply chain using upcoming tools / technologies (such as artificial intelligence, big data analytical, blockchain, internet of things and others).
    • An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.
    • Elaborate profiles of popular players that specialize in offering end-to-end regulatory services for medical devices across key geographies (North America, Europe and Asia-Pacific). Each profile features a brief overview of the company, including information on company headquarters, year of establishment, number of employees, and therapeutic area expertise, financial information (if available), detailed description of service portfolio, and an informed future outlook.
    • A benchmark analysis, highlighting the key focus areas of very small-sized, small-sized, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
    • An elaborate discussion on the various outsourcing business models adopted for regulatory affairs management, along with an insightful Harvey ball analysis of key considerations that need to be assessed by industry stakeholders while selecting a CRO partner.
    • An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers that are active in the domain, based on information gathered via secondary research (for top-ten medical device players) and primary research.
    • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing regulatory affairs management services to medical device developers.

     

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

    • Medical Device Class
    • Class I
    • Class II
    • Class III

     

    • Therapeutic Area
    • Cardiovascular Disorders
    • CNS Disorders
    • Metabolic Disorders
    • Oncological Disorders
    • Ophthalmological Disease
    • Orthopedic Disorders
    • Pain Disorders
    • Respiratory Disorders
    • Others

     

    • Type of Regulatory Affairs Service
    • Pharmacies GAP-Analysis
    • Pharmacies Legal Representation
    • Pharmacies Notified Body Selection
    • Product Labelling-related Services
    • Product Registration and Clinical Trial Applications
    • Regulatory Document Submissions
    • Regulatory Writing and Publishing
    • Risk Management-related Services
    • Technical Dossier Set-up
    • Vigilance & Medical Device Report

     

    • Key Geographical Regions
    • North America
    • Europe
    • Asia-Pacific and Rest of the World

     

    To request sample pages, please visit this link

     

    Key Questions Answered

    • Who are the leading CROs offering regulatory affairs-management services for medical devices?
    • What are differences in regulatory guidelines for medical device approval, across various geographies?
    • What are the key performance indicators used by sponsors to evaluate potential service providers?
    • What are the popular outsourcing models used by medical device companies for regulatory affairs-management purposes?
    • What are the key challenges faced by medical device developers / manufacturers in terms of regulations related to medical device approvals?
    • How is the current and future market opportunity likely to be distributed across key market segments?

     

    You may also be interested in the following titles:

    1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030
    2. Medical Device Labels Manufacturing Market, 2019-2030
    3. Medical Device Contract Manufacturing Market, 2019-2030

     

    Contact Us

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     

    Over 400 companies claim to possess the required expertise to offer regulatory affairs management-related services to medical device-focused business entities, claims Roots Analysis


    Submitted 4 day(s) ago by Harry sins

     

     

    More than 130 medical devices were approved by the FDA since January 2018, while several are currently being evaluated across more than 9,500 (active) clinical trials, worldwide. Even though technical innovation has enabled the development of a variety of versatile medical devices, product approval, given stringent regulatory standards, is still a concern.

     

    To order this 550+ page report, which features 245+ figures and 250+ tables, please visit this link

     

    The USD 820 million (by 2030) financial opportunity within the contract regulatory affairs-management services market for medical devices has been analyzed across the following segments:

    • Medical Device Class
    • Class I
    • Class II
    • Class III

     

    • Therapeutic Area
    • Cardiovascular Disorders
    • CNS Disorders
    • Metabolic Disorders
    • Oncological Disorders
    • Ophthalmological Disease
    • Orthopedic Disorders
    • Pain Disorders
    • Respiratory Disorders
    • Others

     

    • Type of Regulatory Affairs Service
    • Pharmacies GAP-Analysis
    • Pharmacies Legal Representation
    • Pharmacies Notified Body Selection
    • Product Labelling-related Services
    • Product Registration and Clinical Trial Applications
    • Regulatory Document Submissions
    • Regulatory Writing and Publishing
    • Risk Management-related Services
    • Technical Dossier Set-up
    • Vigilance & Medical Device Report

     

    • Key Geographical Regions
    • North America
    • Europe
    • Asia-Pacific and Rest of the World

     

    The Contract Regulatory Affairs-Management Market for Medical Devices, 2019-2030 report features the following companies, which we identified to be key players in this domain:

    • CTI Clinical Trial and Consulting Services
    • CROMSOURCE
    • ICON
    • Intertek
    • Medpace
    • MIC Medical
    • North American Science Associates (NAMSA)
    • Parexel
    • PharmaLex
    • Premier Research 
    • Société Générale de Surveillance (SGS)
    • Underwriters Laboratory (UL)

     

    Table of Contents

     

    1. Preface

      2. Executive Summary

    2. Introduction

    3. Role of Regulatory Affairs in Medical Device Supply Chain

    4. Regulatory and Reimbursement Landscape for Medical Devices

    5. Competitive Landscape

    6. Company Profiles

    7. Competitive Benchmarking

    8. Guide to Regulatory Outsourcing Models

    9. Medical Device Regulatory Affairs: Key Performance Indicators

    10. Market Forecast

    11. Conclusion

    12. Survey Insights

    13. Executive Insights

     

    1. Appendix 1: Tabulated Data

     

    1. Appendix 2: List of Companies and Organizations

     

    To purchase a copy, please visit  https://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html  

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     

    The contract regulatory affairs-management services market for medical devices is estimated to be worth USD 820 million by 2030, growing at a CAGR of 6.9%,


    Submitted 4 day(s) ago by Harry sins

     

    Roots Analysis has done a detailed study on Medical Device CROs for Regulatory Affairs Management Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

     

    To order this 550+ page report, which features 245+ figures and 250+ tables, please visit this link

     

    Key Market Insights

    • Over 400 companies claim to possess the required expertise to offer regulatory affairs management-related services to medical device-focused business entities
    • The market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of such firms are located in the developed geographies
    • Service providers are catering to a diverse clientele, enabling sponsors to compliance to the standards of both regional and international regulators
    • Owing to the high competition, companies involved in this domain are steadily expanding their capabilities in order to augment their respective service portfolios and comply to evolving industry benchmarks
    • CROs are actively engaged in expanding their global footprint in order to enable their clients to navigate the technical and regulatory complexities across various geographies
    • The medical device regulatory affairs outsourcing market is anticipated to grow at an annualized rate of 6.8%; the opportunity is likely to be distributed across different therapeutic areas and geographies
    • Based on prevalent and anticipated trends, the revenue share will vary across important market segments, such as different types of services, size of service provider and device class

     

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html

     

    Table of Contents

     

    1. PREFACE
      1.1. Scope of the Report
      1.2. Research Methodology
      1.3. Chapter Outlines

      2. EXECUTIVE SUMMARY

    2. INTRODUCTION
      3.1. Chapter Overview

    3.2. Contract Research Organizations (CROs)

    3.2.1. Evolution of CROs

    3.3. Role of CROs in the Medical Device Industry

    3.4. Types of Medical Device CROs

    3.5. Types of Services Offered by CROs

    3.5.1. Types of Regulatory Affairs-Related Services Offered by CROs

    3.6. Need for Outsourcing Regulatory Affairs-Related Operations for Medical Devices

    3.7. Key Considerations for Selecting a Suitable CRO Partner

    3.8. Advantages of Working with CROs

    3.9. Risks and Challenges Related to Working with CROs

    3.10. Concluding Remarks

     

    1. ROLE OF REGULATORY AFFAIRS IN MEDICAL DEVICE SUPPLY CHAIN

    4.1. Chapter Overview

    4.2. Overview of Medical Device Supply Chain

    4.2.1. Importance of Regulatory Affairs in Medical Device Supply Chain

    4.2.1.1. Concept and Feasibility Assessment Stage

    4.2.1.2. Preclinical Stage

    4.2.1.3. Manufacturing / Production Stage

    4.2.1.4. Marketing Stage

    4.2.1.5. Post-Marketing Stage

    4.3. Factors Affecting the Medical Device Supply Chain

    4.4. Key Performance Indicators for Medical Device Supply Chain Management

    4.5. Optimization of Regulatory Affairs in the Medical Device Supply Chain

    4.5.1. Digitalization of the Medical Device Supply Chain

     

    1. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

    5.1. Chapter Overview

    5.2. General Regulatory and Reimbursement Guidelines for Medical Devices

    5.3. Regulatory and Reimbursement Landscape in North America

    5.3.1. The US Scenario

    5.3.1.1. Regulatory Authority

    5.3.1.2. Review / Approval Process

    5.3.1.3. Reimbursement Landscape

    5.3.1.3.1. Payer Mix

    5.3.1.3.2. Reimbursement Process

    5.3.2.    The Canadian Scenario

    5.3.2.1. Regulatory Authority

    5.3.2.2. Review / Approval Process

    5.3.2.3. Reimbursement Landscape

    5.3.2.3.1. Payer Mix

    5.3.2.3.2. Reimbursement Process

    5.3.3.    The Mexican Scenario

    5.3.3.1. Regulatory Authority

    5.3.3.2. Review / Approval Process

    5.3.3.3. Reimbursement Landscape

    5.3.3.3.1. Payer Mix

     

    5.4.      Regulatory and Reimbursement Landscape in Europe

    5.4.1.    Overall Scenario

    5.4.1.1. Overall Regulatory Authority

    5.4.1.2. Overall Review / Approval Process

    5.4.2.    The UK Scenario

    5.4.2.1. Regulatory Authority

    5.4.2.2. Review / Approval Process

    5.4.2.3. Reimbursement Landscape

    5.4.2.3.1. Payer Mix

    5.4.2.3.2. Reimbursement Process

    5.4.3.    The French Scenario

    5.4.3.1. Regulatory Authority

    5.4.3.2. Review / Approval Process

    5.4.3.3. Reimbursement Landscape

    5.4.3.3.1. Payer Mix

    5.4.3.3.2. Reimbursement Process

    5.4.4.    The German Scenario

    5.4.4.1. Regulatory Authority

    5.4.4.2. Review / Approval Process

    5.4.4.3. Reimbursement Landscape

    5.4.4.3.1. Payer Mix

    5.4.4.3.2. Reimbursement Process

    5.4.5.    The Italian Scenario

    5.4.5.1. Regulatory Authority

    5.4.5.2. Review / Approval Process

    5.4.5.3. Reimbursement Landscape

    5.4.5.3.1. Payer Mix

    5.4.5.3.2. Reimbursement Process

    5.4.6.    The Spanish Scenario

    5.4.6.1. Regulatory Authority

    5.4.6.2. Review / Approval Process

    5.4.6.3. Reimbursement Landscape

    5.4.6.3.1. Payer Mix

    5.4.6.3.2. Reimbursement Process

     

    5.5.      Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World

    5.5.1.    The Australian Scenario

    5.5.1.1. Regulatory Authority

    5.5.1.2. Review / Approval Process

    5.5.1.3. Reimbursement Landscape

    5.5.1.3.1. Payer Mix

    5.5.1.3.2. Reimbursement Process

    5.5.2.    The Brazilian Scenario

    5.5.2.1. Regulatory Authority

    5.5.2.2. Review / Approval Process

    5.5.2.3. Reimbursement Landscape

    5.5.2.3.1. Payer Mix

    5.5.2.3.2. Reimbursement Process

    5.5.3.    The Chinese Scenario

    5.5.3.1. Regulatory Authority

    5.5.3.2. Review / Approval Process

    5.5.3.3. Reimbursement Landscape

    5.5.3.3.1. Payer Mix

    5.5.3.3.2. Reimbursement Process

    5.5.4.    The Indian Scenario

    5.5.4.1. Regulatory Authority

    5.5.4.2. Review / Approval Process

    5.5.4.3. Reimbursement Landscape

    5.5.4.3.1. Payer Mix

    5.5.5.    The Israeli Scenario

    5.5.5.1. Regulatory Authority

    5.5.5.2. Review / Approval Process

    5.5.5.3. Reimbursement Landscape

    5.5.5.3.1. Payer Mix

    5.5.6.    The Japanese Scenario

    5.5.6.1. Regulatory Authority

    5.5.6.2. Review / Approval Process

    5.5.6.3. Reimbursement Landscape

    5.5.6.3.1. Payer Mix

    5.5.6.3.2. Reimbursement Process

    5.5.7.    The New Zealand Scenario

    5.5.7.1. Regulatory Authority

    5.5.7.2. Review / Approval Process

    5.5.7.3. Reimbursement Landscape

    5.5.7.3.1. Payer Mix

    5.5.7.3.2. Reimbursement Process

    5.5.8.    The Singaporean Scenario

    5.5.8.1. Regulatory Authority

    5.5.8.2. Review / Approval Process

    5.5.8.3. Reimbursement Landscape

    5.5.8.3.1. Payer Mix

    5.5.8.3.2. Reimbursement Process

    5.5.9.    The South Korea Scenario

    5.5.9.1. Regulatory Authority

    5.5.9.2. Review / Approval Process

    5.5.9.3. Reimbursement Landscape

    5.5.9.3.1. Payer Mix

    5.5.9.3.2. Reimbursement Process

    5.5.10. The South African Scenario

    5.5.10.1. Regulatory Authority

    5.5.10.2. Review / Approval Process

    5.5.10.3. Reimbursement Landscape

    5.5.11. The Taiwanese Scenario

    5.5.11.1. Regulatory Authority

    5.5.11.2. Review / Approval Process

    5.5.11.3. Reimbursement Landscape

    5.5.11.3.1. Payer Mix

    5.5.11.3.2. Reimbursement Process

    5.5.12. The Thailand Scenario

    5.5.12.1. Regulatory Authority

    5.5.12.2. Review / Approval Process

    5.5.12.3. Reimbursement Landscape

    5.6.      Comparison of Regional Regulatory Environment

    5.7.      Concluding Remarks

     

    1. COMPETITIVE LANDSCAPE

    6.1.      Chapter Overview

    6.2.      CROs Offering Regulatory Affairs-Related Services for Medical Devices: List of Companies

    6.2.1.    Analysis by Year of Establishment

    6.2.2.    Analysis by Size of Employee Base

    6.2.3.    Analysis by Location of Headquarters

    6.2.4.    Analysis by Company Size and Geography

    6.3.      CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Area of Specialization

    6.3.1.    Analysis by Area of Specialization

    6.4.      CROs Offering Medical Device Regulatory Services: Information on Type of Regulatory Affairs-Related Services Offered

    6.4.1.    Analysis by Type of Regulatory Affairs-Related Service Offered

    6.4.2.    Analysis by Year of Establishment, Geography and Type of Regulatory Affairs-Related Services           Offered

    6.5.      CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Type of  Additional Services Offered

    6.5.1.    Analysis by Type of Additional Services Offered

    6.6.      CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Device Class

    6.6.1.    Analysis by Device Class

    6.7.      CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Type and Size of Clientele

    6.7.1.    Analysis by Type and Size of Clientele

    6.8.      CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Medical Device Regulatory Compliance Authorities

    6.8.1.    Analysis by Medical Device Regulatory Compliance Authorities

     

    6.9.      CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Geographical Reach (Region-wise)

    6.9.1.    Analysis by Geographical Reach (Region-Wise)

     

    6.10.     CROs Offering Regulatory Affairs-Related Services for Medical Devices: Information on Geographical Reach (Country-wise)

    6.10.1.  Analysis by Geographical Reach (Country-Wise)

     

    1. COMPANY PROFILES

    7.1. Chapter Overview

     

    7.2. CROs Headquartered in North America

    7.2.1. CTI Clinical Trial and Consulting (CTI)

    7.2.1.1. Company Overview

    7.2.1.2. Service Portfolio

    7.2.1.3. Future Outlook

     

    7.2.2. Medpace

    7.2.2.1. Company Overview

    7.2.2.2 Financial Information

    7.2.2.3. Service Portfolio

    7.2.2.4. Future Outlook

     

    7.2.3. NAMSA

    7.2.3.1. Company Overview

    7.2.3.2. Service Portfolio

    7.2.3.3. Future Outlook

     

    7.2.4. PAREXEL

    7.2.4.1. Company Overview

    7.2.4.2 Financial Information

    7.2.4.3. Service Portfolio

    7.2.4.4. Future Outlook

     

    7.2.5. Premier Research

    7.2.5.1. Company Overview

    7.2.5.2. Service Portfolio

    7.2.5.3. Future Outlook

     

    7.2.6. Underwriters Laboratory (UL)

    7.2.6.1. Company Overview

    7.2.6.2. Service Portfolio

    7.2.6.3. Future Outlook

     

    7.3. CROs Headquartered in Europe

    7.3.1. CROMSOURCE

    7.3.1.1. Company Overview

    7.3.1.2. Service Portfolio

    7.3.1.3 Future Outlook

     

    7.3.2. ICON

    7.3.2.1. Company Overview

    7.3.2.2 Financial Information

    7.3.2.3. Service Portfolio

    7.3.2.4. Future Outlook

     

    7.3.3. Intertek

    7.3.3.1. Company Overview

    7.3.3.2 Financial Information

    7.3.3.3. Service Portfolio

    7.3.3.4. Future Outlook

     

    7.3.4. PharmaLex

    7.3.4.1. Company Overview

    7.3.4.2. Service Portfolio

    7.3.4.3 Future Outlook

    7.3.5. Société Générale de Surveillance (SGS)

    7.3.5.1. Company Overview

    7.3.5.2. Service Portfolio

    7.3.5.3 Future Outlook

     

    7.3.4. SteriPack

    7.3.4.1. Company Overview

    7.3.4.2. Service Portfolio

    7.3.4.3 Future Outlook

     

    7.4. CROs Headquartered in Asia-Pacific and Rest of the World

    7.4.1. MIC Medical

    7.4.1.1. Company Overview

    7.4.1.2. Service Portfolio

    7.4.1.3 Recent Developments

     

    1. COMPETITIVE BENCHMARKING

    8.1. Chapter Overview

    8.2. Benchmark Analysis: Methodology

    8.3. Region-wise Benchmark Analysis

    8.3.1. North America, Peer Group I

    8.3.2. North America, Peer Group II

    8.3.3. North America, Peer Group III

    8.3.4. North America, Peer Group IV

    8.3.5. Europe, Peer Group V

    8.3.6. Europe, Peer Group VI

    8.3.7. Europe, Peer Group VII

    8.3.8. Europe, Peer Group VIII

    8.3.9. Asia Pacific and Rest of the World, Peer Group IX

    8.3.10. Asia Pacific and Rest of the World, Peer Group X

    8.3.11. Asia Pacific and Rest of the World, Peer Group XI

    8.3.12. Asia Pacific and Rest of the World, Peer Group XII

    8.4. Concluding Remarks

     

    1. GUIDE TO REGULATORY OUTSOURCING MODELS

    9.1. Chapter Overview

    9.2. Guiding Models for Regulatory Outsourcing

     

    9.2.1. Functional Service Providers (FSP) Model: Large Medical Device Developers

    9.2.1.1. Vendor Evaluation

     

    9.2.2. End-to-End Model: Small-Sized Medical Device Developers

    9.2.2.1. Vendor Evaluation

     

    9.2.3. Hybrid Model: Mid-Sized Medical Device Developers

    9.2.3.1. Vendor Evaluation

     

    9.3. Concluding Remarks

     

    1. MEDICAL DEVICE REGULATORY AFFAIRS: KEY PERFORMANCE INDICATORS

    10.1. Chapter Overview

    10.2. Definition and Importance of Key Performance Indicators

    10.3. Key Considerations for Selection of Key Performance Indicators

    10.4. Types of Key Performance Indicators

    10.4.1. Financial Indicators

    10.4.1.1. Most Important KPIs

    10.4.1.1.1. Financial Stability

    10.4.1.1.2. Cost of Services Offered

    10.4.1.1.3. Comparative Analysis of Financial Indicators

     

    10.4.1.2. Industry Perspective

    10.4.1.2.1. Sponsor (Big Pharma) Perspective

    10.4.1.2.2. Contract Service Providers’ Perspective

     

    10.4.2. Process / Capability Indicators

    10.4.2.1. Most Important KPIs

    10.4.2.1.1. Proximity to Sponsor

    10.4.2.1.2. Capability to Innovate / Mitigate Risk

    10.4.2.1.3. Strength of Service Portfolio

    10.4.2.1.4. Comparative Analysis of Process / Capability Indicators

    10.4.2.2. Industry Perspective

    10.4.2.2.1. Sponsor (Big Pharma) Perspective

    10.4.2.2.2. Contract Service Providers’ Perspective

     

    10.4.3. Market Reputation Indicators

    10.4.3.1. Most Important KPIs

    10.4.3.1.1. Flexibility / Adaptability

    10.4.3.1.2. Time Management

    10.4.3.1.3. Quality / Reliability

    10.4.3.1.4. Regulatory Compliance / Track Record

    10.4.3.1.5. Comparative Analysis of Market Reputation Indicators

     

    10.4.3.2. Industry Perspective

    10.4.3.2.1. Sponsor (Big Pharma) Perspective

    10.4.3.2.2. Contract Service Providers’ Perspective

     

    10.5. Comparison of Key Performance Indicators

    10.6. Concluding Remarks

     

    1. MARKET FORECAST

    11.1 Chapter Overview

    11.2. Forecast Methodology and Key Assumptions

    11.3. Overall Medical Device Regulatory Affairs Outsourcing Market, 2019-2030

     

    11.4. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Geography, 2019 and 2030

    11.4.1. Medical Device Regulatory Affairs Outsourcing Market in North America, 2019-2030

    11.4.1.1. Medical Device Regulatory Affairs Outsourcing Market in the US, 2019-2030

    11.4.1.2. Medical Device Regulatory Affairs Outsourcing Market in Rest of North America, 2019-2030

     

    11.4.2. Medical Device Regulatory Affairs Outsourcing Market in Europe, 2019-2030

    11.4.2.1. Medical Device Regulatory Affairs Outsourcing Market in Italy, 2019-2030

    11.4.2.2. Medical Device Regulatory Affairs Outsourcing Market in Germany, 2019-2030

    11.4.2.3. Medical Device Regulatory Affairs Outsourcing Market in France, 2019-2030

    11.4.2.4. Medical Device Regulatory Affairs Outsourcing Market in Spain, 2019-2030

    11.4.2.5. Medical Device Regulatory Affairs Outsourcing Market in the UK, 2019-2030

    11.4.2.6. Medical Device Regulatory Affairs Outsourcing Market in Rest of Europe, 2019-2030

     

    11.4.3. Medical Device Regulatory Affairs Outsourcing Market in Asia-Pacific, 2019-2030

    11.4.3.1. Medical Device Regulatory Affairs Outsourcing Market in China, 2019-2030

    11.4.3.2. Medical Device Regulatory Affairs Outsourcing Market in Japan, 2019-2030

    11.4.3.3. Medical Device Regulatory Affairs Outsourcing Market in India, 2019-2030

    11.4.3.4. Medical Device Regulatory Affairs Outsourcing Market in Rest of the Asia-Pacific, 2019-2030

     

    11.4.4. Medical Device Regulatory Affairs Outsourcing Market in Rest of the World, 2019-2030

     

    11.5. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Type of Regulatory Affairs-Related Service, 2019 and 2030

    11.5.1. Medical Device Regulatory Affairs Outsourcing Market for GAP-Analysis, 2019-2030

    11.5.2. Medical Device Regulatory Affairs Outsourcing Market for Legal Representation, 2019-2030

    11.5.3. Medical Device Regulatory Affairs Outsourcing Market for Notified Body Selection, 2019-2030

    11.5.4. Medical Device Regulatory Affairs Outsourcing Market for Product Labeling-Related Services, 2019-2030

    11.5.5. Medical Device Regulatory Affairs Outsourcing Market for Product Registration and Clinical Trial Applications, 2019-2030

    11.5.6. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Writing and Publishing, 2019-2030

    11.5.7. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Document Submissions, 2019-2030

    11.5.8. Medical Device Regulatory Affairs Outsourcing Market for Risk Management Service, 2019-2030

    11.5.9. Medical Device Regulatory Affairs Outsourcing Market for Technical Dossier Set-Up, 2019-2030

    11.5.10. Medical Device Regulatory Affairs Outsourcing Market for Vigilance & Medical Device Report, 2019-2030

    11.6. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Device Class, 2019 and 2030

    11.6.1. Medical Device Regulatory Affairs Outsourcing Market for Class I Devices, 2019-2030

    11.6.2. Medical Device Regulatory Affairs Outsourcing Market for Class II Devices, 2019-2030

    11.6.3. Medical Device Regulatory Affairs Outsourcing Market for Class III Devices, 2019-2030

     

    11.7. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Therapeutic Area, 2019 and 2030

    11.7.1. Medical Device Regulatory Affairs Outsourcing Market for Cardiovascular Disorders, 2019-2030

    11.7.2. Medical Device Regulatory Affairs Outsourcing Market for Central Nervous System (CNS) Disorders, 2019-2030

    11.7.3. Medical Device Regulatory Affairs Outsourcing Market for Metabolic Disorders, 2019-2030

    11.7.4. Medical Device Regulatory Affairs Outsourcing Market for Oncological Disorders, 2019-2030

    11.7.5. Medical Device Regulatory Affairs Outsourcing Market for Orthopedic Disorders, 2019-2030

    11.7.6. Medical Device Regulatory Affairs Outsourcing Market for Ophthalmic Disorders, 2019-2030

    11.7.7. Medical Device Regulatory Affairs Outsourcing Market for Pain Disorders, 2019-2030

    11.7.8. Medical Device Regulatory Affairs Outsourcing Market for Respiratory Disorders, 2019-2030

    11.7.9. Medical Device Regulatory Affairs Outsourcing Market for Other Therapeutic Areas, 2019-2030

     

    11.8. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Type of Regulatory Affairs-Related Service and Geography

    11.8.1. Medical Device Regulatory Affairs Outsourcing Market for GAP-Analysis in North America, 2019-2030

    11.8.2. Medical Device Regulatory Affairs Outsourcing Market for GAP-Analysis in Europe, 2019-2030

    11.8.3. Medical Device Regulatory Affairs Outsourcing Market for GAP-Analysis in Asia-Pacific, 2019-2030

    11.8.4. Medical Device Regulatory Affairs Outsourcing Market for GAP-Analysis in Rest of the World, 2019-2030

    11.8.5. Medical Device Regulatory Affairs Outsourcing Market for Legal Representation in North America, 2019-2030

    11.8.6. Medical Device Regulatory Affairs Outsourcing Market for Legal Representation in Europe, 2019-2030

    11.8.7. Medical Device Regulatory Affairs Outsourcing Market for Legal Representation in Asia-Pacific, 2019-2030

    11.8.8. Medical Device Regulatory Affairs Outsourcing Market for Legal Representation in Rest of the World, 2019-2030

    11.8.9. Medical Device Regulatory Affairs Outsourcing Market for Notified Body Selection in North America, 2019-2030

    11.8.10. Medical Device Regulatory Affairs Outsourcing Market for Notified Body Selection in Europe, 2019-2030

    11.8.11. Medical Device Regulatory Affairs Outsourcing Market for Notified Body Selection in Asia-Pacific, 2019-2030

    11.8.12. Medical Device Regulatory Affairs Outsourcing Market for Notified Body Selection in Rest of the World, 2019-2030

    11.8.13. Medical Device Regulatory Affairs Outsourcing Market for Product Labeling-Related Services in North America, 2019-2030

    11.8.14. Medical Device Regulatory Affairs Outsourcing Market for Product Labeling-Related Services in Europe, 2019-2030

    11.8.15. Medical Device Regulatory Affairs Outsourcing Market for Product Labeling-Related Services in Asia-Pacific, 2019-2030

    11.8.16. Medical Device Regulatory Affairs Outsourcing Market for Product Labeling-Related Services in Rest of the World, 2019-2030

    11.8.17. Medical Device Regulatory Affairs Outsourcing Market for Product Registration and Clinical Trial Applications in North America, 2019-2030

    11.8.18. Medical Device Regulatory Affairs Outsourcing Market for Product Registration and Clinical Trial Applications in Europe, 2019-2030

    11.8.19. Medical Device Regulatory Affairs Outsourcing Market for Product Registration and Clinical Trial Applications in Asia-Pacific, 2019-2030

    11.8.20. Medical Device Regulatory Affairs Outsourcing Market for Product Registration and Clinical Trial Applications in Rest of the World, 2019-2030

    11.8.21. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Writing and Publishing in North America, 2019-2030

    11.8.22. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Writing and Publishing in Europe, 2019-2030

    11.8.23. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Writing and Publishing in Asia-Pacific, 2019-2030

    11.8.24. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Writing and Publishing in Rest of the World, 2019-2030

    11.8.25. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Document Submissions in North America, 2019-2030

    11.8.26. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Document Submissions in Europe, 2019-2030

    11.8.27. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Document Submissions in Asia-Pacific, 2019-2030

    11.8.28. Medical Device Regulatory Affairs Outsourcing Market for Regulatory Document Submissions in Rest of the World, 2019-2030

    11.8.29. Medical Device Regulatory Affairs Outsourcing Market for Risk Management Service in North America, 2019-2030

    11.8.30. Medical Device Regulatory Affairs Outsourcing Market for Risk Management Service in Europe, 2019-2030

    11.8.311. Medical Device Regulatory Affairs Outsourcing Market for Risk Management Service in Asia-Pacific, 2019-2030

    11.8.32. Medical Device Regulatory Affairs Outsourcing Market for Risk Management Service in Rest of the World, 2019-2030

    11.8.33. Medical Device Regulatory Affairs Outsourcing Market for Technical Dossier Set-Up in North America, 2019-2030

    11.8.34. Medical Device Regulatory Affairs Outsourcing Market for Technical Dossier Set-Up in Europe, 2019-2030

    11.8.35. Medical Device Regulatory Affairs Outsourcing Market for Technical Dossier Set-Up in Asia-Pacific, 2019-2030

    11.8.36. Medical Device Regulatory Affairs Outsourcing Market for Technical Dossier Set-Up in Rest of the World, 2019-2030

    11.8.37. Medical Device Regulatory Affairs Outsourcing Market for Vigilance & Medical Device Report in North America, 2019-2030

    11.8.38. Medical Device Regulatory Affairs Outsourcing Market for Vigilance & Medical Device Report in Europe, 2019-2030

    11.8.39. Medical Device Regulatory Affairs Outsourcing Market for Vigilance & Medical Device Report in Asia-Pacific, 2019-2030

    11.8.40. Medical Device Regulatory Affairs Outsourcing Market for Vigilance & Medical Device Report in Rest of the World, 2019-2030

     

    11.9. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Device Class and Geography

    11.9.1. Medical Device Regulatory Affairs Outsourcing Market for Class I Devices in North America, 2019-2030

    11.9.2. Medical Device Regulatory Affairs Outsourcing Market for Class I Devices in Europe, 2019-2030

    11.9.3. Medical Device Regulatory Affairs Outsourcing Market for Class I Devices in Asia-Pacific, 2019-2030

    11.9.4. Medical Device Regulatory Affairs Outsourcing Market for Class I Devices in Rest of the World, 2019-2030

    11.9.5. Medical Device Regulatory Affairs Outsourcing Market for Class II Devices in North America, 2019-2030

    11.9.6. Medical Device Regulatory Affairs Outsourcing Market for Class II Devices in Europe, 2019-2030

    11.9.7. Medical Device Regulatory Affairs Outsourcing Market for Class II Devices in Asia-Pacific, 2019-2030

    11.9.8. Medical Device Regulatory Affairs Outsourcing Market for Class II Devices in Rest of the World, 2019-2030

    11.9.9. Medical Device Regulatory Affairs Outsourcing Market for Class III Devices in North America, 2019-2030

    11.9.10. Medical Device Regulatory Affairs Outsourcing Market for Class III Devices in Europe, 2019-2030

    11.9.11. Medical Device Regulatory Affairs Outsourcing Market for Class III Devices in Asia-Pacific, 2019-2030

    11.9.12. Medical Device Regulatory Affairs Outsourcing Market for Class III Devices in Rest of the World, 2019-2030

    11.10. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Therapeutic Area and Geography

    11.10.1. Medical Device Regulatory Affairs Outsourcing Market for Cardiovascular Disorders in North America, 2019-2030

    11.10.2. Medical Device Regulatory Affairs Outsourcing Market for Cardiovascular Disorders in Europe, 2019-2030

    11.10.3. Medical Device Regulatory Affairs Outsourcing Market for Cardiovascular Disorders in Asia-Pacific, 2019-2030

    11.10.4. Medical Device Regulatory Affairs Outsourcing Market for Cardiovascular Disorders in Rest of the World, 2019-2030

    11.10.5. Medical Device Regulatory Affairs Outsourcing Market for Central Nervous System Disorders in North America, 2019-2030

    11.10.6. Medical Device Regulatory Affairs Outsourcing Market for Central Nervous System Disorders in Europe, 2019-2030

    11.10.7. Medical Device Regulatory Affairs Outsourcing Market for Central Nervous System Disorders in Asia-Pacific, 2019-2030

    11.10.8. Medical Device Regulatory Affairs Outsourcing Market for Central Nervous System Disorders in Rest of the World, 2019-2030

    11.10.9. Medical Device Regulatory Affairs Outsourcing Market for Metabolic Disorders in North America, 2019-2030

    11.10.10. Medical Device Regulatory Affairs Outsourcing Market for Metabolic Disorders in Europe, 2019-2030

    11.10.11. Medical Device Regulatory Affairs Outsourcing Market for Metabolic Disorders in Asia-Pacific, 2019-2030

    11.10.12. Medical Device Regulatory Affairs Outsourcing Market for Metabolic Disorders in Rest of the World, 2019-2030

    11.10.13. Medical Device Regulatory Affairs Outsourcing Market for Oncological Disorders in North America, 2019-2030

    11.10.14. Medical Device Regulatory Affairs Outsourcing Market for Oncological Disorders in Europe, 2019-2030

    11.10.15. Medical Device Regulatory Affairs Outsourcing Market for Oncological Disorders in Asia-Pacific, 2019-2030

    11.10.16. Medical Device Regulatory Affairs Outsourcing Market for Oncological Disorders in Rest of the World, 2019-2030

    11.10.17. Medical Device Regulatory Affairs Outsourcing Market for Ophthalmological Disorders in North America, 2019-2030

    11.10.18. Medical Device Regulatory Affairs Outsourcing Market for Ophthalmological Disorders in Europe, 2019-2030

    11.10.19. Medical Device Regulatory Affairs Outsourcing Market for Ophthalmological Disorders in Asia-Pacific, 2019-2030

    11.10.20. Medical Device Regulatory Affairs Outsourcing Market for Ophthalmological Disorders in Rest of the World, 2019-2030

    11.10.21. Medical Device Regulatory Affairs Outsourcing Market for Orthopedic Disorders in North America, 2019-2030

    11.10.22. Medical Device Regulatory Affairs Outsourcing Market for Orthopedic Disorders in Europe, 2019-2030

    11.10.23. Medical Device Regulatory Affairs Outsourcing Market for Orthopedic Disorders in Asia-Pacific, 2019-2030

    11.10.24. Medical Device Regulatory Affairs Outsourcing Market for Orthopedic Disorders in Rest of the World, 2019-2030

    11.10.25. Medical Device Regulatory Affairs Outsourcing Market for Pain Disorders in North America, 2019-2030

    11.10.26. Medical Device Regulatory Affairs Outsourcing Market for Pain Disorders in Europe, 2019-2030

    11.10.27. Medical Device Regulatory Affairs Outsourcing Market for Pain Disorders in Asia-Pacific, 2019-2030

    11.10.28. Medical Device Regulatory Affairs Outsourcing Market for Pain Disorders in Rest of the World, 2019-2030

    11.10.29. Medical Device Regulatory Affairs Outsourcing Market for Respiratory Disorders in North America, 2019-2030

    11.10.30. Medical Device Regulatory Affairs Outsourcing Market for Respiratory Disorders in Europe, 2019-2030

    11.10.31. Medical Device Regulatory Affairs Outsourcing Market for Respiratory Disorders in Asia-Pacific, 2019-2030

    11.10.32. Medical Device Regulatory Affairs Outsourcing Market for Respiratory Disorders in Rest of the World, 2019-2030

    11.10.33. Medical Device Regulatory Affairs Outsourcing Market for Other Disorders in North America, 2019-2030

    11.10.34. Medical Device Regulatory Affairs Outsourcing Market for Other Disorders in Europe, 2019-2030

    11.10.35. Medical Device Regulatory Affairs Outsourcing Market for Other Disorders in Asia-Pacific, 2019-2030

    11.10.36. Medical Device Regulatory Affairs Outsourcing Market for Other Disorders in Rest of the World, 2019-2030

     

    11.11. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Company Size, 2019-2030

    11.11.1. Medical Device Regulatory Affairs Outsourcing Market for Small-Sized Companies, 2019-2030

    11.11.2. Medical Device Regulatory Affairs Outsourcing Market for Mid-Sized Companies, 2019-2030

    11.11.3. Medical Device Regulatory Affairs Outsourcing Market for Large Companies, 2019-2030

     

    11.12. Concluding Remarks

     

    1. CONCLUSION

    12.1. Chapter Overview

    12.2. Key Takeaways

     

    1. SURVEY INSIGHTS

    13.1. Chapter Overview

    13.2. Company Specifics of Respondents

    13.3. Designation of Respondents

    13.4. Types of Regulatory Affairs-Related Services

    13.5. Analysis by Geographical Reach

    13.6. Type and Size of Clientele

    13.7. Average Number of Projects

    13.8. Proportion of Clients Outsourcing Regulatory Affairs-Related Services

    13.9. Cost of Outsourcing Regulatory Affairs-Related Services

    13.10. Current and Future Market Opportunity

     

    1. EXECUTIVE INSIGHTS

    14.1. Chapter Overview

    14.2. A+ Science

    14.2.1. Company Snapshot

    14.2.2. Interview Transcript: Tania Persson, Business Development Manager

     

    14.3. AtoZ-CRO

    14.3.1. Company Snapshot

    14.3.2. Interview Transcript: Alexa Foltin-Mertgen, Business Development Manager

     

    14.4. CROMSOURCE

    14.4.1. Company Snapshot

    14.4.2. Interview Transcript: Troy Mccall, Chief Operating Officer

     

    14.5. CW Research & Management

    14.5.1. Company Snapshot

    14.5.2. Interview Transcript: Christian Wolflehner, Managing Director, Clinical Trial Specialist

     

    14.6. HungaroTrial

    14.6.1 Company Snapshot

    14.6.2. Interview Transcript: Antal Solyom, Director of Medical Device Unit

    14.7. Metrics Research

     

    14.7.1 Company Snapshot

    14.7.2. Interview Transcript: Dr. Nazish Urooj, Senior Manager, Medical & Clinical Operations

     

    14.8. Vyomus Consulting

    14.8.1 Company Snapshot

    14.8.2. Interview Transcript: Dr. C Omprakash, Technical Director and Partner

     

    1. APPENDIX I: TABULATED DATA

     

    1. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS


    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com



    The contract regulatory affairs-management services market for medical devices is estimated to be worth USD 820 million by 2030, growing at a CAGR of 6.9%, claims Roots Analysis


    Submitted 4 day(s) ago by Harry sins

     

     

    Over the years, outsourcing has become a popular trend with the medical device industry, allowing innovators to leverage the technical and regulatory expertise of contract service providers in order to expedite time to market

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CROs for Regulatory Affairs Management Market, 2019-2030.”

     

    The report features a detailed study on the current landscape of contract service providers focused on regulatory affairs management for medical devices. The study features an in-depth analysis, highlighting the capabilities of the various CROs engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:

    • A detailed review of the current market landscape of the medical devices regulatory affairs outsourcing market, featuring a list of over 400 CROs engaged in this domain.
    • A detailed discussion on the need for regulatory review / oversight across different stages of the medical devices supply chain, with emphasis on the optimization of the supply chain using upcoming tools / technologies.
    • An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America, Europe, Asia-Pacific and rest of the world.
    • Elaborate profiles of popular players that specialize in offering end-to-end regulatory services for medical devices across key geographies.
    • A benchmark analysis, highlighting the key focus areas of very small-sized, small-sized, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups.
    • An elaborate discussion on the various outsourcing business models adopted for regulatory affairs management, along with an insightful Harvey ball analysis of key considerations that need to be assessed by industry stakeholders while selecting a CRO partner.
    • An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers that are active in the domain, based on information gathered via secondary research (for top-ten medical device players) and primary research.
    • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing regulatory affairs management services to medical device developers.
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

     

    • Medical Device Class
    • Class I
    • Class II
    • Class III

     

    • Therapeutic Area
    • Cardiovascular Disorders
    • CNS Disorders
    • Metabolic Disorders
    • Oncological Disorders
    • Ophthalmological Disease
    • Orthopedic Disorders
    • Pain Disorders
    • Respiratory Disorders
    • Others

     

    • Type of Regulatory Affairs Service
    • Pharmacies GAP-Analysis
    • Pharmacies Legal Representation
    • Pharmacies Notified Body Selection
    • Product Labelling-related Services
    • Product Registration and Clinical Trial Applications
    • Regulatory Document Submissions
    • Regulatory Writing and Publishing
    • Risk Management-related Services
    • Technical Dossier Set-up
    • Vigilance & Medical Device Report

     

    • Key Geographical Regions
    • North America
    • Europe
    • Asia-Pacific and Rest of the World

     

    Key companies covered in the report

    • CTI Clinical Trial and Consulting Services
    • CROMSOURCE
    • ICON
    • Intertek
    • Medpace
    • MIC Medical
    • North American Science Associates (NAMSA)
    • Parexel
    • PharmaLex
    • Premier Research 
    • Société Générale de Surveillance (SGS)
    • Underwriters Laboratory (UL)

     

    For more information please click on the following link

    https://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html  

     

    Other Recent Offerings

    1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030
    2. Medical Device Labels Manufacturing Market, 2019-2030
    3. Medical Device Contract Manufacturing Market, 2019-2030

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

    The “Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030” report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator comp


    Submitted 4 day(s) ago by Harry sins

     

    To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link

     

    Key Inclusions

    • A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, purpose of manufacturing (in-house and contract services), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (biologic and small molecule), type of continuous manufacturing related service(s) offered (process development, API manufacturing, intermediate manufacturing, drug product manufacturing, and packaging and fill / finish), type of dosage form (solid and liquid), and installed capacity and batch size (if available).
    • Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market in North America, Europe and Asia-Pacific. Each profile features an overview of the company, along with information related to its service portfolio, continuous manufacturing capabilities and facilities, recent developments and an informed future outlook.
    • An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013, based on several parameters, such as year of an agreement, the type of partnership (research agreements, facility development / establishment agreements, technology enhancement agreements, service alliances, process development agreements, manufacturing agreements and other relevant agreements), scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid). It also provides the regional distribution of the collaborations.
    • An analysis of the expansions related to continuous manufacturing, which have been established since 2013, based on several parameters, such as year of an expansion and the type of expansion (facility / plant expansion, technology installation, technology enhancement and service expansion), geographical location of the facility, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid).
    • An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites). The study examines the distribution of capacity, based on the type of drug molecule (biologic and small molecule), company size (small-sized, mid-sized and large), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location of manufacturing facilities (North America, Europe and Asia-Pacific).
    • A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019, highlighting multiple parameters, such as year of award, type of grant, grant amount, focus area, support period, popular recipient organizations, type of recipient organization, funding institute center, funding mechanism and prominent program officers.
    • An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019. It includes information on key parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of the size of intellectual property portfolio). It also features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach), as well as a patent benchmarking and a detailed valuation analysis.
    • Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
    • A review of the companies offering modular facilities / modular cleanrooms, with information on their geographical location (North America, Europe, Asia-Pacific and rest of the world), year of establishment, company size (small-sized, mid-sized or large) and type of industries served (pharmaceutical, biotechnology or others). It also includes information on the recent projects undertaken / executed by the companies providing modular facilities.
    • A case study of the companies offering technologies / equipment (continuous blenders and mixers, continuous granulators, continuous dryers, continuous compressors, continuous coaters, flow reactors, continuous filtration, distillation and centrifugation equipment, continuous chromatography, PAT technology and other technologies) that can potentially be used in a continuous manufacturing process, providing information on the geographical location of potential stakeholders and the type of technology / equipment provided.
    • A case study on the roadmap for the adoption of continuous manufacturing technique, discussing different strategies that can be followed by the company in order to adopt this technology or transition from batch manufacturing to continuous manufacturing.

     

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

    • Purpose of Manufacturing
    • In-House
    • Contract service
    • Scale of Operation
    • Commercial
    • Preclinical / Clinical
    • Type of Continuous Manufacturing related Service
    • API Manufacturing
    • End Product manufacturing
    • Type of Drug Molecule
    • Biologic
    • Small Molecule
    • Type of dosage form
    • Solid
    • Liquid
    • Key Geographical Regions
    • North America
    • Europe
    • Asia Pacific
    • Transcripts of interviews held with the following senior level representatives of stakeholder companies
    • Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow technologies
    • Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals
    • Nick Thomson, Senior Director Chemical Research and Development, Pfizer
    • Himanshu Gadgil, Director and Chief Scientific Officer, Enzene Biosciences
    • Eric Fang, Chief Scientific Officer, Snapdragon Chemistry)
    • Ian Houson, Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde

     

     

    To request sample pages, please visit this link

     

    Key Questions Answered

    • Who are the key players engaged in continuous manufacturing of small molecules and biologics?
    • What is the installed, global capacity for continuous manufacturing?
    • What are the key growth drivers within this domain?
    • What are the various paths to evolution within this industry?
    • Who are the other key stakeholders (modular facility providers and technology / equipment developers) in this domain?
    • How is the current and future market opportunity likely to be distributed across key market segments?

     

    You may also be interested in the following titles:

    1. Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028
    2. Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030
    3. China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
    4. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030

     

    Contact Us

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

    Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements, claims Roots Analysis


    Submitted 4 day(s) ago by Harry sins

     

    The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks. In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated. In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing.

     

    To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link

     

    The USD 1.9 billion (by 2030) financial opportunity within the continuous manufacturing market has been analyzed across the following segments:

    • Purpose of Manufacturing
    • In-House
    • Contract service

     

    • Scale of Operation
    • Commercial
    • Preclinical / Clinical

     

    • Type of Continuous Manufacturing related Service
    • API Manufacturing
    • End Product manufacturing

     

    • Type of Drug Molecule
    • Biologic
    • Small Molecule

     

    • Type of dosage form
    • Solid
    • Liquid

     

    • Key Geographical Regions
    • North America
    • Europe
    • Asia Pacific

     

    The Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030 report features the following companies, which we identified to be key players in this domain:

    • AbbVie Contract Manufacturing
    • Ajinomoto Bio-Pharma Services
    • Almac
    • Boehringer Ingelheim BioXcellence
    • Cambrex
    • CordonPharma
    • Hovione
    • Kaneka
    • Lonza
    • Patheon
    • SK biotek

     

    Table of Contents

     

    1. Preface

      2. Executive Summary

    2. Introduction

    3. Market Landscape

    4. Companies with Expertise in Continuous Manufacturing in North America: Profiles

    5. Companies with Expertise in Continuous Manufacturing in Europe: Profiles

    6. Companies with Expertise in Continuous Manufacturing in Asia-Pacific: Profiles

    7. Recent Partnerships and Collaborations

    8. Recent Expansions

    9. Capacity Analysis

    10. Academic Grant Analysis

    11. Patent Analysis

    12. Initiatives of Companies with In-House Continuous Manufacturing Capabilities

    13. Case Study: Modular Facilities in pharmaceutical / Biotechnological Industry

     

    1. Case Study: Technology and Equipment Providers

     

    1. Case Study: Roadmap for the Adoption of Continuous Manufacturing Processes

     

    1. Market Forecast and Opportunity Analysis

     

    1. Conclusion

     

    1. Executive Insights

     

    1. Appendix 1: Tabulated Data

     

    1. Appendix 2: List of Companies and Organizations

     

    To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com 

     

    The continuous manufacturing market is projected to grow at an annualized rate of over 15%, till 2030


    Submitted 4 day(s) ago by Harry sins

     

    Roots Analysis has done a detailed study on Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030, covering key aspects of the industry and identifying future growth opportunities.

     

    To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link

     

    Key Market Insights

    • Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoption
    • Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements
    • The market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographies
    • Companies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilities
    • Several patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such efforts
    • Organizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologies
    • Over time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwide
    • Most of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographies
    • Involvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domain
    • As the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects

     

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

     

    Table of Contents

     

    TABLE OF CONTENTS

     

    1. PREFACE

    1.1.      Scope of the Report

    1.2.      Research Methodology

    1.3.      Chapter Outlines

     

    1. EXECUTIVE SUMMARY

     

    1. INTRODUCTION

    3.1.      Chapter Overview

    3.2.      Historical Evolution of Continuous Manufacturing

    3.3.      Continuous Manufacturing in the Pharmaceutical Industry

    3.3.1.    Regulatory Landscape

    3.3.2.    Early Adopters of Continuous Manufacturing

    3.3.3.    Anticipated Shift to Continuous Manufacturing

    3.3.4.    Advantages of Continuous Manufacturing

    3.3.5.    Key Challenges Associated with Continuous Manufacturing

    3.3.6.    Future Perspectives

     

    1. MARKET LANDSCAPE

    4.1.      Chapter Overview

    4.2.      Companies with Expertise in Continuous Manufacturing: Overall Market Landscape

    4.2.1.    Analysis by Year of Establishment

    4.2.2.    Analysis by Company Size

    4.2.3.    Analysis by Purpose of Manufacturing

    4.2.4.    Analysis by Scale of Operation

    4.2.5.    Analysis by Location of Headquarters

    4.2.6.    Analysis by Location of Continuous Manufacturing Facilities

    4.2.7.    Analysis by Type of Drug Molecule

    4.2.8.    Analysis by Type of Continuous Manufacturing Related Service

    4.2.9.    Analysis by Type of Dosage Form

    4.2.10.  Heat Map: Analysis by Company Size and Location of Headquarters

    4.2.11.  Information on Production Capacity

    4.2.12.  Logo Landscape: Analysis by Year of Establishment and Company Size 

    4.2.13.  Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form

    4.2.14.  Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES

    5.1.      Chapter Overview

    5.2.      AbbVie Contract Manufacturing

    5.2.1.    Company Overview

    5.2.2.    Service Portfolio

    5.2.3.    Continuous Manufacturing Capabilities and Facilities

    5.2.4.    Recent Developments and Future Outlook

     

    5.3.      Cambrex

    5.3.1.    Company Overview

    5.3.2.    Service Portfolio

    5.3.3.    Continuous Manufacturing Capabilities and Facilities

    5.3.4.    Recent Developments and Future Outlook

     

    5.4.      Patheon

    5.4.1.    Company Overview

    5.4.2.    Service Portfolio

    5.4.3.    Continuous Manufacturing Capabilities and Facilities

    5.4.4.    Recent Developments and Future Outlook

     

    5.5.      SK biotek

    5.5.1.    Company Overview

    5.5.2.    Service Portfolio

    5.5.3.    Continuous Manufacturing Capabilities and Facilities

    5.5.4.    Recent Developments and Future Outlook

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES

    6.1.      Chapter Overview

    6.2.      Ajinomoto Bio-Pharma Services

    6.2.1.    Company Overview

    6.2.2.    Service Portfolio

    6.2.3.    Continuous Manufacturing Capabilities and Facilities

    6.2.4.    Recent Developments and Future Outlook

     

    6.3.      Almac

    6.3.1.    Company Overview

    6.3.2.    Service Portfolio

    6.3.3.    Continuous Manufacturing Capabilities and Facilities

    6.3.4.    Recent Developments and Future Outlook

     

    6.4.      Boehringer Ingelheim BioXcellence™

    6.4.1.    Company Overview

    6.4.2.    Service Portfolio

    6.4.3.    Continuous Manufacturing Capabilities and Facilities

    6.4.4.    Recent Developments and Future Outlook

     

    6.5.      CordonPharma

    6.5.1.    Company Overview

    6.5.2.    Service Portfolio

    6.5.3.    Continuous Manufacturing Capabilities and Facilities

    6.5.4.    Recent Developments and Future Outlook

     

    6.6.      Hovione

    6.6.1.    Company Overview

    6.6.2.    Service Portfolio

    6.6.3.    Continuous Manufacturing Capabilities and Facilities

    6.6.4.    Recent Developments and Future Outlook

     

    6.7.      Lonza

    6.7.1.    Company Overview

    6.7.2.    Service Portfolio

    6.7.3.    Continuous Manufacturing Capabilities and Facilities

    6.7.4.    Recent Developments and Future Outlook

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES

    7.1.      Chapter Overview

    7.2.      Kaneka

    7.2.1.    Company Overview

    7.2.2.    Service Portfolio

    7.2.3.    Continuous Manufacturing Capabilities and Facilities

    7.2.4.    Recent Developments and Future Outlook     

     

    7.3.      WuXi AppTec

    7.3.1.    Company Overview

    7.3.2.    Service Portfolio

    7.3.3.    Continuous Manufacturing Capabilities and Facilities

    7.3.4.    Recent Developments and Future Outlook                 

     

    1. RECENT PARTNERSHIPS AND COLLABORATIONS

    8.1.      Chapter Overview

    8.2.      Partnership Models

    8.3.      List of Partnerships and Collaborations

    8.3.1.    Analysis by Year of Partnership

    8.3.2.    Analysis by Type of Partnership

    8.3.3.    Analysis by Scale of Operation

    8.3.4.    Analysis by Type of Drug Molecule

    8.3.5.    Analysis by Type of Continuous Manufacturing Related Service

    8.3.6.    Analysis by Type of Dosage Form

    8.3.7.    Most Active Players: Analysis by Number of Partnerships

     

    8.3.8.    Regional Analysis

    8.3.8.1. Intercontinental and Intracontinental Agreements

     

    1. RECENT EXPANSIONS

    9.1.      Chapter Overview

    9.2.      Recent Expansions

    9.2.1.    Analysis by Year of Expansion

    9.2.2.    Analysis by Type of Expansion

    9.2.3.    Analysis by Expanded Scale of Expansion

    9.2.4.    Analysis by Type of Drug Molecule

    9.2.5.    Analysis by Type of Continuous Manufacturing Related Service

    9.2.6.    Analysis by Type of Dosage Form

    9.2.7.    Most Active Players: Analysis by Number of Expansions

     

    9.2.8.    Regional Analysis

    9.2.8.1. Analysis by Location of Expansion Project

     

    1. CAPACITY ANALYSIS

    10.1.     Chapter Overview

    10.2.     Assumptions and Methodology

    10.3.     Global, Continuous Manufacturing Capacity for Small Molecule APIs

    10.3.1.  Analysis by Company Size

    10.3.2. Analysis by Purpose of Manufacturing

    10.3.3.  Analysis by Scale of Operation

    10.3.4.  Analysis by Location of Headquarters

    10.3.4.  Analysis by Location of Continuous Manufacturing Facilities

     

    10.4.     Global, Continuous Manufacturing Capacity for Small Molecule End Products

    10.4.1.  Analysis by Company Size

    10.4.2. Analysis by Purpose of Manufacturing

    10.4.3.  Analysis by Scale of Operation

    10.4.4.  Analysis by Location of Headquarters

    10.4.5.  Analysis by Location of Continuous Manufacturing Facilities

     

    10.5.     Global, Continuous Manufacturing Capacity for Biologic

    10.5.1.  Analysis by Company Size

    10.5.2. Analysis by Purpose of Manufacturing

    10.5.3.  Analysis by Scale of Operation

    10.5.4.  Analysis by Location of Headquarters

    10.5.5.  Analysis by Location of Continuous Manufacturing Facilities

     

    1. ACADEMIC GRANT ANALYSIS

    11.1.     Chapter Overview

    11.2.     Scope and Methodology

    11.3.     Continuous Manufacturing: List of Academic Grants

    11.3.1.  Analysis by Number of Grants

    11.3.2.  Analysis by Activity Code

    11.3.3.  Analysis by Grant Amount

    11.3.4.  Analysis by Focus Area

    11.3.5.  Analysis by Support Period

    11.3.6   Popular Recipient Organizations: Analysis by Number of Grants

    11.3.7   Analysis by Type of Recipient Organization

    11.3.8.  Analysis by Funding Institute Centre

    11.3.9.  Analysis by Funding Mechanism

    11.3.10. Prominent Program Officers: Analysis by Number of Grants

     

    1. PATENT ANALYSIS

    12.1.     Chapter Overview

    12.2.     Scope and Methodology

    12.3.     Continuous Manufacturing: Patent Analysis

    12.3.1.  Analysis by Publication Year

    12.3.2.  Analysis by Geography

    12.3.3.  Analysis by CPC Symbols

    12.3.4.  Emerging Focus Areas

    12.3.5.  Analysis by Type of Applicant

    12.3.6.  Leading Players: Analysis by Number of Patents

    12.3.7.  Continuous Manufacturing: Three-Dimensional Bubble Analysis

    12.3.8.  Continuous Manufacturing: Patent Valuation Analysis

    12.3.8.1. Leading Patents: Information by Number of Citations

     

    1. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES

    13.1.     Chapter Overview

    13.2.     Continuous Manufacturing Initiatives of Leading Companies

    13.2.1.  AbbVie

    13.2.1.1. Partnered Initiatives

    13.2.1.2 In-House Initiatives

     

    13.2.2.  Amgen

    13.2.2.1. Partnered Initiatives

    13.2.2.2. In-House Initiatives

     

    13.2.3.  Bristol-Myers Squibb

    13.2.3.1. Partnered Initiatives

    13.2.3.2. In-House Initiatives

     

    13.2.4.  GlaxoSmithKline

    13.2.4.1. Partnered Initiatives

    13.2.4.2. In-House Initiatives

     

    13.2.5.  Merck

    13.2.5.1. Partnered Initiatives

    13.2.5.2. In-House Initiatives

     

    13.2.6.  Novartis

    13.2.6.1. Partnered Initiatives

    13.2.6.2. In-House Initiatives

     

    13.2.7.  Pfizer

    13.2.7.1. Partnered Initiatives

    13.2.7.2. In-House Initiatives

     

    13.2.8.  Roche

    13.2.8.1. Partnered Initiatives

    13.2.8.2. In-House Initiatives

    13.2.9.  Sanofi

    13.2.9.1. Partnered Initiatives

    13.2.9.2. In-House Initiatives

     

    1. CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY

    14.1.     Chapter Overview

    14.2.     Historical Background

    14.3.     Concept of Modularization

    14.3.1.  Types of Modules

    14.3.2.  Modular Construction Process

     

    14.4.     Modular Construction in the Pharmaceutical Industry

    14.4.1.  Advantages of Modular Construction in the Pharmaceutical Industry

     

    14.5.     Modular Facility Manufacturers

    14.5.1.  Distribution by Industry Served

    14.5.2.  Distribution by Geography

    14.5.3.  Modular Projects Executed / Undertaken

     

    14.6.     Modular Pharmaceutical Cleanrooms

    14.6.1.  Cleanroom Classification and Current Standards

    14.6.2.  Advantages of Modular Cleanrooms

    14.6.3.  Regulations and Standards Concerning Modular Cleanroom Construction

     

    14.7.     Modular Cleanroom Providers

    14.7.1.  Distribution by Industry Served

    14.7.2.  Distribution by Geography

    14.7.3.  Type of Modular Cleanrooms Offered

     

    1. CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS

    15.1.     Chapter Overview

    15.2.     Types of Continuous Manufacturing Technologies

    15.3.     Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics

    15.3.1.  Continuous Blending and Mixing Equipment

    15.3.2.  Continuous Granulating Equipment

    15.3.3.  Continuous Drying Equipment

    15.3.4.  Continuous Compression Equipment

    15.3.5.  Continuous Coating Equipment

    15.3.6.  Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment

    15.3.7.  Continuous Chromatography Equipment

    15.3.8.  Continuous Reactors / Bioreactors

    15.3.9.  Full Line Continuous Platforms

    15.3.10. Process Analytical Technologies

    15.3.11. Other Technologies

    15.4.     Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment

     

    1. CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES

    16.1.     Chapter Overview

    16.2.     Key Strategies for the Adoption of Continuous Manufacturing Processes

    16.2. 1. Phase I: Process Development and Implementation

    16.2. 2. Phase II: Equipment / Technology Development and Installation

    16.2. 3. Phase III: Facility / Plant Development and Establishment

    16.2. 4. Phase IV: Product Development and Manufacturing

     

    1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

    17.1.     Chapter Overview

    17.2.     Forecast Methodology and Key Assumptions

    17.3.     Overall, Continuous Manufacturing Market, 2020-2030

    17.3.1.  Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030

    17.3.2.  Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030

    17.3.3.  Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030

    17.3.4.  Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.3.5.  Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030

    17.3.6.  Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

     

    17.4.     Continuous Manufacturing Market for Small Molecule, 2020-2030

    17.4.1.  Distribution by Purpose of Manufacturing, 2020-2030

    17.4.2.  Distribution by Scale of Operation, 2020-2030

    17.4.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.4.4.  Distribution by Key Geographical Regions, 2020-2030

     

    17.5.     Continuous Manufacturing Market for Biologic, 2020-2030

    17.5.1.  Distribution by Purpose of Manufacturing, 2020-2030

    17.5.2.  Distribution by Scale of Operation, 2020-2030

    17.5.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.5.4.  Distribution by Key Geographical Regions, 2020-2030

     

    1. CONCLUSION

    18.1.     Chapter Overview

    18.2.     Key Takeaways

     

    1. EXECUTIVE INSIGHTS

    19.1.     Chapter Overview

    19.2.     Zaiput Flow Technologies

    19.2.1.  Company Snapshot

    19.2.2.  Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer

     

    19.3.     CONTINUUS Pharmaceuticals

    19.3.1.  Company Snapshot

    19.3.2.  Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer

     

    19.4.     Snapdragon Chemistry

    19.4.1.  Company Snapshot

    19.4.2.  Interview Transcript: Eric Fang, Chief Scientific Officer

     

    19.5.     Enzene Biosciences

    19.5.1.  Company Snapshot

    19.5.2.  Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer

     

    19.6.     Pfizer

    19.6.1.  Company Snapshot

    19.6.2.  Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development

    19.7.     University of Strathclyde

    19.7.1.  Company Snapshot

    19.7.2.  Interview Transcript: Ian Houson, Technical Project Manager

     

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

    The continuous manufacturing market is estimated to be worth around USD 2 billion in 2030, predicts Roots Analysis


    Submitted 4 day(s) ago by Harry sins

     

    Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030.”

     

    The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

    • A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing
    • Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market
    • An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013
    • An analysis of the expansions related to continuous manufacturing, which have been established since 2013
    • An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites).
    • A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019
    • An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019
    • Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
    • A review of the companies offering modular facilities / modular cleanrooms
    • A case study of the companies offering technologies / equipment
    • A case study on the roadmap for the adoption of continuous manufacturing technique
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
    • Purpose of Manufacturing
    • In-House
    • Contract service
    • Scale of Operation
    • Commercial
    • Preclinical / Clinical
    • Type of Continuous Manufacturing related Service
    • API Manufacturing
    • End Product manufacturing
    • Type of Drug Molecule
    • Biologic
    • Small Molecule
    • Type of dosage form
    • Solid
    • Liquid
    • Key Geographical Regions
    • North America
    • Europe
    • Asia Pacific

     

    • Transcripts of interviews held with the following senior level representatives of stakeholder companies
    • Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow technologies
    • Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals
    • Nick Thomson, Senior Director Chemical Research and Development, Pfizer
    • Himanshu Gadgil, Director and Chief Scientific Officer, Enzene Biosciences
    • Eric Fang, Chief Scientific Officer, Snapdragon Chemistry)
    • Ian Houson, Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde

     

    Key companies covered in the report

    • AbbVie Contract Manufacturing
    • Ajinomoto Bio-Pharma Services
    • Almac
    • Boehringer Ingelheim BioXcellence
    • Cambrex
    • CordonPharma
    • Hovione
    • Kaneka
    • Lonza
    • Patheon
    • SK biotek
    • WuXi AppTec

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

     

    Other Offerings

    1. Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028
    2. Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030
    3. China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
    4. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     

    Almohada de apoyo para dormir para mujeres embarazadas cuerpo PW12 100% algodón estampado de conejo en forma de U almohadas de maternidad durante el embarazo|Almohadas corporales

    es.aliexpress.com
    Submitted 4 day(s) ago by storcobacoba

    Almohada de apoyo para dormir para mujeres embarazadas cuerpo PW12 100% algodón estampado de conejo en forma de U almohadas de maternidad durante el embarazo,Consigue increíbles descuentos en artículos de vendedores chinos y de todo el mundo. ¡Disfruta de envíos gratis, ofertas por tiempo limitado, devoluciones sencillas y protección al comprador! Disfruta de las siguientes ventajas: ✓ Envío gratuito a todo el mundo ✓ Oferta disponible durante un tiempo limitado ✓ Devolución sencilla

    Male Edge Results Before And After | Male Extender Review


    Submitted 4 day(s) ago by malexpills

    Now, you can finally explore your full sexual potential with the 21st century’s penis extender - Male Edge.

    If you are on this page, then you must have heard about this penis extender “Male Edge” a device that is used over the penis to somewhat stretch the tissue over several hours daily.

    Curious about a full Male Edge Results before and after review.

    Well, you have come to the correct blog, and we will give an explanation of everything from the reason why many people use the device to its side effects.

    As you get comfier using the extender, and the tissue begins to stretch, you usually enhance the force and traction on the extender and improve the number of hours per day you’re using this device.

    So let’s start with a quick product review...

     

    Male Edge Review

    The Male Edge is the supreme penis extender product. This device comes with the most accessories to make sure you get the best results in increasing your penis size.

    No matter what size you have, whether small or average, in any case, the ultimate penis extenders can help you do better.

    This device is made in Danish Design, Male Edge is made and put together in Denmark and meets the highest standard quality.

    You enjoy the journey and feel much more confident with Male Edge.

    Now take a closer look at its mechanism to know how this device works in our next section.

     

    How Does Male Edge Really Work?

    The Male Edge device works as per the common penile traction method.

    You will ultimately use a product that you put on your penis, which usually stretches the penis over a longer period. You have to use this product every day for better improvements.

    At the time when your penis is stretched, the tissue cells start multiplying and dividing. Resulting in new penile tissue cells to work for stretched parts.

    Which will mean you get a thicker and longer penis.

    The process is similar to lifting weights in the gym for building more muscles.

    Now, if you are worried about its common side effects then take a look at our next section for more details.

     

    Male Edge Side Effects

    In the design process of Male Edge, few patents were tested for the different Male Edge series.

    It is tested and approved by the Danish Ministry of Health with a European CE mark of satisfaction on top of it.

    This product is manufactured in Denmark taking care of the highest possible standards of quality for your assurance so that you will feel more confident and secure.

    Until now there are no side effects reported from its users or in test series. All patients in studies were able to achieve the desired goal in a shorter time.

    Let's take a look at Male Edge Results claimed by the users and manufacturers.

     

    Male Edge Results    

    Male Edge Results are shown on the official manufacturer's website for your reference purpose and knowledge.

    Personally, some users have also reported seeing a 1-inch improvement that they wanted after using this device. Which seems to be good enough for them.

    Although the improvement is not too much, it is permanent, if you don’t want to use this device afterward then just don't.

    For more insight, check out this Male Edge Before and After Results in Erection as per the study-;

     

    Before study analysis in between (8-24) weeks in range (cm)

    • Length before (9,5-15,0)

    After study analysis after 1(8-24) weeks in range (cm)

    • Length After (12,5-18,5)
    • Difference (1,5-5,0)
    • Length was increased 28% around 10-42 range(cm)

    Check out our next section on Male Edge before and after reviews.

     

    Male Edge Before After Reviews

    There is documentation on the effects of the Male Edge on the official website on penis extender treatment from various sources.

    On their official site, you can easily see Male Edge results collected by them after analyzing, just for you.

    Every document is from a real customer giving an insight on Male Edge before after pictures, and the conclusion of the result is shown in a graph focused on development on average or quick penis growth.

    In summary, all the evidence from before and after results say that the Male Edge penis extender is effective.

     

    Conclusion

    Male Edge is an amazing device focusing on penis size extension solutions. The Male Edge Penis extender works based on traction; the results are permanent because of the ultimate quality of the product.

    There are users from studies who have gained more than 2-inches with the use of this device.

    However, the results can be seen on some weekly criteria which are tested and proven clinically.

    The device price is comfy, considering the reputation of the manufacturing brand, if you are spending extra you’ve got nothing to lose.

    Almond Flour Pancakes

    mediastudies.virginia.edu
    Submitted 4 day(s) ago by samovitch

    This is The Best Almond Flour Pancakes check it out : https://www.posts123.com/article/490060

    The Best Almond Flour Pancakes

    mediastudies.virginia.edu
    Submitted 4 day(s) ago by samovitch

    This is The Best Almond Flour Pancakes have a Try 

    The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China


    Submitted 5 day(s) ago by Harry sins

    Key Inclusions

    • A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities.
    • A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.
    • A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
    • Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China. Each profile includes an overview of the company, information related to its pharmaceutical manufacturing service portfolio, details related to its manufacturing facilities, recent developments, and an informed future outlook.
    • A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues), featuring a [A] analysis by investments made, with detailed information on investments related to R&D centers and manufacturing facilities in established and emerging regions of China, [B] Harvey ball framework, presenting a summary of all initiatives
    • A case study of the key recent developments (including partnerships and acquisitions) pertaining to the manufacturing of pharmaceutical drugs, during 2014-2020 (till February), based on several parameters, such as year of partnership, type of partnership and geography.
    • A detailed capacity analysis based on the individual reactor capacities of various industry stakeholders, taking into consideration parameters, such as company size (small-sized, mid-sized, large and very large), and location of the manufacturing facility (Eastern China, Southern China and Northern China).
    • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
    • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.

     

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

     

    • Key Geographical Regions
    • Eastern China
    • Southern China
    • Northern China 

     

    • Type of Product
    • Active Pharmaceutical Ingredients (APIs)
    • Drug Products

     

    • Type of Drug Product
    • Solid
    • Liquid / Semi-Solid
    • Injectable
    • Others

     

    • Scale of Operation
    • Clinical
    • Commercial

     

    • Company Size
    • Small
    • Mid-Sized
    • Large / Very Large

     

     

    To request sample pages, please visit this link

     

    Key Questions Answered

    • Who are the leading China-based pharmaceutical CMOs engaged in the production of APIs, intermediates and FDFs?
    • What are the key manufacturing hubs within China (in terms of number of manufacturing facilities)?
    • What is the current installed capacity for manufacturing of pharmaceuticals, in China?
    • What are the major market trends and driving factors that are likely to impact the growth of the pharmaceutical manufacturing market in China?
    • What is the likely short-term and long-term impact of the COVID-19 pandemic on the pharmaceutical contract manufacturing industry in China?
    • What kind of initiatives are being undertaken by big pharmaceutical players for pharmaceutical manufacturing in China?
    • How is the current and future market opportunity likely to be distributed across key market segments?

     

    You may also be interested in the following titles:

    1. China Biopharmaceutical Contract Manufacturing Market, 2020 – 2030
    2. HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030
    3. Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

     

    Contact Us

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

    Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China, offering services for pharmaceutical API, intermediates and FDF manufacturing, claims Roots Analysis


    Submitted 5 day(s) ago by Harry sins

     

     

    A growing economy, large population base, and innovation-friendly environment are other key parameters that are anticipated to drive the growth of the pharmaceutical contract manufacturing market in China. Further, in order to meet the growing demand for their services, CMOs having manufacturing facilities in China are actively expanding their existing capacities and capabilities in the region.

     

    To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this link

     

    The USD 13 billion (by 2030) financial opportunity within the pharmaceuticals contract manufacturing market in China has been analyzed across the following segments:

    • Key Geographical Regions
    • Eastern China
    • Southern China
    • Northern China 

     

    • Type of Product
    • Active Pharmaceutical Ingredients (APIs)
    • Drug Products

     

    • Type of Drug Product
    • Solid
    • Liquid / Semi-Solid
    • Injectable
    • Others

     

    • Scale of Operation
    • Clinical
    • Commercial

     

    • Company Size
    • Small
    • Mid-Sized
    • Large / Very Large

     

     

    The China Pharmaceutical Contract Manufacturing Services Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

    • 2Y-Chem
    • Aurisco Pharmaceutical
    • ChemPartner
    • Dorrapharma
    • Hubei Biocause Pharmaceutical
    • Infoark
    • Ningbo Menovo Pharmaceutical
    • Shandong Xinhua Pharmaceutical
    • Shanghai Acebright Pharmaceuticals
    • STA Pharmaceutical
    • Zhejiang Huahai Pharmaceutical

     

    Table of Contents

     

    1. Preface

      2. Executive Summary

    2. Introduction

    3. Case Study: Comparison of Small Molecules and Large Molecules

    4. Market Overview

    5. Manufacturing Facilities of Pharmaceutical CMOs in China

    6. Pharmaceutical Manufacturing Regulations in China

    7. Company Profiles

    8. Big Pharma Initiatives in China

    9. Recent Trends

    10. Capacity Analysis

    11. SWOT Analysis

    12. Market Forecast

     

    1. Case Study: Impact of Coronavirus Outbreak

    2. Conclusion

     

    1. Executive Insights

     

    1. Appendix 1: Tabulated Data

     

    1. Appendix 2: List of Companies and Organizations

     

    To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com 

     

     

    The contract manufacturing market for Pharmaceuticals in China is projected to grow at an annualized rate of ~8.9%, till 2030


    Submitted 5 day(s) ago by Harry sins

    Roots Analysis has done a detailed study on China Pharmaceutical Contract Manufacturing Services Market, 2020-2030, covering key aspects of the industry and identifying key future growth opportunities.

     

    To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this link

     

    Key Market Insights

    • Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China, offering services for pharmaceutical API, intermediates and FDF manufacturing
    • CMOs have established manufacturing facilities across different regions of China; Eastern China has emerged as a popular hub, serving as a base of operations for many contract service providers
    • The current, installed manufacturing capacity of pharmaceutical CMOs in China is estimated to be over 46 million liters; interestingly, capacity utilization has been observed to be ~75% over the last few years
    • Big pharma players have also invested significantly in this region for initiatives related to the establishment or expansion of R&D centers and manufacturing facilities focused on pharmaceutical products
    • Innovator companies are expected to continue outsourcing clinical and commercial manufacturing operations to China-based CMOs; the contract services industry in the region is likely to grow at a CAGR of ~8.9%
    • In the long-term, the projected future opportunity is anticipated to be well distributed across various market segments, such as different types of products (APIs and FDFs), region (eastern china, southern china, western china) and others

     

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

     

    Table of Contents

     

    1. PREFACE
      1.1. Scope of the Report
      1.2.                  Research Methodology
      1.3.                  Chapter Outlines

      2.                     EXECUTIVE SUMMARY

    2. INTRODUCTION
      3.1. Chapter Overview
      3.2.                  Need for Outsourcing in the Pharmaceutical Industry
      3.3.                  Overview of the Pharmaceutical Contract Manufacturing
      3.4.                  Evolution of the Pharmaceutical Contract Manufacturing Industry
      3.4.1.               Traditional Contract Manufacturing Organizations (CMOs)

    3.4.2.               Modern CMOs
    3.5.                  Services Offered by CMOs
    3.6.                  Pharmaceutical Contract Manufacturing Scenario in China

    3.7.                  Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs

     

    1. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
      4.1.                  Chapter Overview
      4.2.                  Small Molecule and Large Molecule Drugs / Therapies

    4.2.1.                Comparison of General Characteristics
    4.2.2.                Comparison of Manufacturing Processes
    4.2.3.                Comparison of Key Manufacturing-related Challenges

     

    1. MARKET OVERVIEW
      5.1.                  Chapter Overview
      5.2.                  Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies

    5.2.1.                Analysis by Year of Establishment
    5.2.2.                Analysis by Company Size
    5.2.3.                Analysis by Location of Headquarters

    5.2.4.                Analysis by Type of Product (API and FDF)
    5.2.5.                Analysis by Type of FDF
    5.2.6.                Analysis by Type of Packaging

    5.2.7.                Analysis by Manufacturing Facilities

     

    5.3.                  Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies

    5.3.1.                Analysis by Year of Establishment

    5.3.2.                Analysis by Company Size

    5.3.3.                Analysis by Location of Headquarters

    5.3.4.                Analysis by Type of Product (API and FDF)

    5.3.5.                Analysis by Type of FDF

    5.3.6.                Analysis by Type of Packaging

    5.3.7                 Analysis by Manufacturing Facilities

     

    1. MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA
      6.1.                  Chapter Overview
      6.2.                  Chinese Pharmaceutical CMOs: List of Manufacturing Facilities

      6.2.1.                Analysis by CMO Manufacturing Facilities in Eastern China
      6.2.2.                Analysis by CMO Manufacturing Facilities in Southern China
      6.2.3.                Analysis by CMO Manufacturing Facilities in Northern China

    2. PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA

    7.1.                   Chapter Overview

    7.1.1.                Health Authorities in China

    7.1.2.                Overview of Regulatory Guidelines in China

     

    1. COMPANY PROFILES

    8.1.                   Chapter Overview

    8.2.                  2Y-Chem

    8.2.1.                Company Overview

    8.2.2.                Service Portfolio

    8.2.3.                China-based Manufacturing Facilities and Capabilities

    8.2.4.                Recent Developments and Future Outlook

     

    8.3.                  Aurisco Pharmaceutical

    8.3.1.                Company Overview

    8.3.2.                Service Portfolio

    8.3.3.                China-based Manufacturing Facilities and Capabilities

    8.3.4.                Recent Developments and Future Outlook

     

    8.4.                  ChemPartner

    8.4.1.                Company Overview

    8.4.2.                Service Portfolio

    8.4.3.                China-based Manufacturing Facilities and Capabilities

    8.4.4.                Recent Developments and Future Outlook

     

    8.5.                  Dorrapharma

    8.5.1.                Company Overview

    8.5.2.                Service Portfolio

    8.5.3.                China-based Manufacturing Facilities and Capabilities

    8.5.4.                Recent Developments and Future Outlook

     

    8.6.                  Hubei Biocause Pharmaceutical

    8.6.1.                Company Overview

    8.6.2.                Service Portfolio

    8.6.3.                China-based Manufacturing Facilities and Capabilities

    8.6.4.                Recent Developments and Future Outlook

     

    8.7.                  Infoark

    8.7.1.                Company Overview

    8.7.2.                Service Portfolio

    8.7.3.                China-based Manufacturing Facilities and Capabilities

    8.7.4.                Recent Developments and Future Outlook

     

    8.8.                  Ningbo Menovo Pharmaceutical

    8.8.1.                Company Overview

    8.8.2.                Service Portfolio

    8.8.3.                China-based Manufacturing Facilities and Capabilities

    8.8.4.                Recent Developments and Future Outlook

     

    8.9.                  Shandong Xinhua Pharmaceutical

    8.9.1.                Company Overview

    8.9.2.                Service Portfolio

    8.9.3.                China-based Manufacturing Facilities and Capabilities

    8.9.4.                Recent Developments and Future Outlook

     

    8.10.                 Shanghai Acebright Pharmaceuticals 

    8.10.1.             Company Overview

    8.10.2.             Service Portfolio

    8.10.3.             China-based Manufacturing Facilities and Capabilities

    8.10.4.             Recent Developments and Future Outlook

               

    8.11.                 STA Pharmaceutical

    8.11.1.             Company Overview

    8.11.2.             Service Portfolio

    8.11.3.             China-based Manufacturing Facilities and Capabilities

    8.11.4.             Recent Developments and Future Outlook

     

    8.12.                 Zhejiang Huahai Pharmaceutical

    8.12.1.             Company Overview

    8.12.2.             Service Portfolio

    8.12.3.             China-based Manufacturing Facilities and Capabilities

    8.12.4.             Recent Developments and Future Outlook

     

    1. BIG PHARMA INITIATIVES IN CHINA

    9.1.                   Chapter Overview

    9.2.                   Big Pharma Players: List of Initiatives

    9.2.1.                Analysis by Number of Initiatives

    9.2.2.                Analysis by Year of Initiative

    9.2.3.                Analysis by Company and Year of Initiative

    9.2.4.                Analysis by Type of Initiative

     

    9.3.                   Benchmark Analysis of Big Pharma Players

    9.3.1.                Harvey Ball Analysis: Summary of Investments Made

    9.3.2.                Geographical Analysis by Investments Made (Facility Specific)

     

    1. RECENT TRENDS

    10.1.                 Chapter Overview

    10.2.                 CMOs with Manufacturing Facilities in China: List of Partnerships

    10.3.                 Analysis by Year and Type of Partnership

    10.4.                 Logo Landscape of Key Partners

    10.5.                 Geographical Analysis

               

    1. CAPACITY ANALYSIS

    11.1.                 Chapter Overview

    11.2.                 Key Assumptions and Methodology

    11.3.                 CMOs with Manufacturing Facilities in China: Installed Capacity

    11.3.1.              Analysis by Company Size

    11.3.2.             Analysis by Location of Chinese Manufacturing Facilities

    11.3.2.1.           Capacity Analysis: Eastern China

    11.3.2.2.           Capacity Analysis: Southcentral China

    11.3.2.3.           Capacity Analysis: Northern China

     

    1. SWOT ANALYSIS

    12.1.                 Chapter Overview

    12.2.                 Comparison of SWOT Factors

    12.3.                 Concluding Remarks

     

    1. MARKET FORECAST

    13.1.                 Chapter Overview

    13.2.                 Forecast Methodology and Key Assumptions

    13.3.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030

    13.4.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

    13.4.1.              Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030

    13.4.2.              Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030

    13.4.3.              Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030

    13.5.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Product

    13.5.1.              API Contract Manufacturing Services Market in China, 2020-2030

    13.5.1.1.           API Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

    13.5.1.1.1.        API Contract Manufacturing Services Market in Eastern China, 2020-2030

    13.5.1.1.2.        API Contract Manufacturing Services Market in Southern China, 2020-2030

    13.5.1.1.3.        API Contract Manufacturing Services Market in Northern China, 2020-2030

    13.5.2.              Drug Product Contract Manufacturing Services Market in China, 2020-2030

    13.5.2.1.           Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

    13.5.2.1.1.        Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030

    13.5.2.1.2.        Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030

    13.5.2.1.3.        Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030

               

    13.5.2.2.           Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Drug Product

    13.5.2.2.1.        Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Solid Drug Product

    13.5.2.2.2.        Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Liquid and Semi Solid Drug Product

    13.5.2.2.3.        Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Injectable Drug Product

    13.5.2.2.4.        Drug product Contract Manufacturing Services Market in China, 2020-2030: Share of Other Drug Products

    13.6.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Scale of Operation

    13.6.1.              Clinical Scale Contract Manufacturing Services Market in China, 2020-2030

    13.6.2.              Commercial Scale Contract Manufacturing Services Market in China, 2020-2030    

    13.7.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Size of Manufacturers

    13.7.1.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies

    13.7.2.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies

    13.7.3.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies

     

     

     

    1. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK

    14.1.                 Chapter Overview

     

    14.2.                 Current Opinions and Recuperative Initiatives of Key Players

    14.2.1.              Wuxi AppTec

    14.2.2.              Porton Pharma Solutions

    14.2.3.              Lonza

    14.3.                 Impact on Future Market Opportunity for Pharmaceutical CMOs in China

     

     

    1. CONCLUSION

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

    The contract manufacturing market for Pharmaceuticals in China is estimated to be worth USD 13 billion in 2030, predicts Roots Analysis


    Submitted 5 day(s) ago by Harry sins

    Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primar

    Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.”

     

    The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features:

    • A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs). 
    • A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.
    • A brief discussion of various regulatory guidelines in China and various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
    • Detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China.
    • A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).
    • An analysis of the partnerships and acquisitions that have been established in this domain, in the recent past.
    • A detailed capacity analysis based on the installed reactor capacities of the manufacturing facilities in China.
    • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
    • Key Geographical Regions
    • Eastern China
    • Southern China
    • Northern China 

     

    • Type of Product
    • Active Pharmaceutical Ingredients (APIs)
    • Drug Products

     

    • Type of Drug Product
    • Solid
    • Liquid / Semi-Solid
    • Injectable
    • Others

     

    • Scale of Operation
    • Clinical
    • Commercial

     

    • Company Size
    • Small
    • Mid-Sized
    • Large / Very Large

     

     

    Key players covered in the report

    • 2Y-Chem
    • Aurisco Pharmaceutical
    • ChemPartner
    • Dorrapharma
    • Hubei Biocause Pharmaceutical
    • Infoark
    • Ningbo Menovo Pharmaceutical
    • Shandong Xinhua Pharmaceutical
    • Shanghai Acebright Pharmaceuticals
    • STA Pharmaceutical
    • Zhejiang Huahai Pharmaceutical

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

     

    Other Recent Offerings

    1. China Biopharmaceutical Contract Manufacturing Market, 2020 – 2030
    2. HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030
    3. Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     

    ily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.”

     

    The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features:

    • A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs). 
    • A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.
    • A brief discussion of various regulatory guidelines in China and various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
    • Detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China.
    • A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).
    • An analysis of the partnerships and acquisitions that have been established in this domain, in the recent past.
    • A detailed capacity analysis based on the installed reactor capacities of the manufacturing facilities in China.
    • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
    • Key Geographical Regions
    • Eastern China
    • Southern China
    • Northern China 

     

    • Type of Product
    • Active Pharmaceutical Ingredients (APIs)
    • Drug Products

     

    • Type of Drug Product
    • Solid
    • Liquid / Semi-Solid
    • Injectable
    • Others

     

    • Scale of Operation
    • Clinical
    • Commercial

     

    • Company Size
    • Small
    • Mid-Sized
    • Large / Very Large

     

     

    Key players covered in the report

    • 2Y-Chem
    • Aurisco Pharmaceutical
    • ChemPartner
    • Dorrapharma
    • Hubei Biocause Pharmaceutical
    • Infoark
    • Ningbo Menovo Pharmaceutical
    • Shandong Xinhua Pharmaceutical
    • Shanghai Acebright Pharmaceuticals
    • STA Pharmaceutical
    • Zhejiang Huahai Pharmaceutical

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

     

    Other Recent Offerings

    1. China Biopharmaceutical Contract Manufacturing Market, 2020 – 2030
    2. HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030
    3. Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     

    The “China Biopharmaceutical Contract Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China.


    Submitted 5 day(s) ago by Harry sins

    To order this detailed 250+ page report, please visit this link

     

    Key Inclusions

    • A detailed review of the overall landscape of companies offering contract manufacturing services for biopharmaceuticals in China, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities, as well as location of these facilities, type of business segment, type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, stability studies, quality assurance and control, scale-up, downstream processing, regulatory support, data analytics and reporting, and others), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression system(s) used (mammalian, microbial and others), type of bioreactor(s) used (single-use bioreactors and stainless steel bioreactors) and its mode of operation (batch, fed-batch and perfusion), type of packaging, and affiliations to regulatory accreditations and certifications (if any).
    • An analysis of the various partnerships pertaining to biopharmaceutical manufacturing in China, which have been established since 2016, based on several parameters, such as the year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area of the deal, target indication, most active players (in terms of number of partnerships signed), and geography.
    • An analysis of the various expansion initiatives undertaken by contract manufacturers in China, in order to augment their capabilities, over the period 2016-2020 (till February), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.
    • A clinical trial analysis of completed and active studies related to biopharmaceuticals that have been / are being / are likely to be conducted in China, based on trial registration year, trial phase, trial recruitment status, type of sponsor / collaborator, geography and number of patients enrolled.
    • An estimate of the overall, installed capacity for manufacturing biopharmaceuticals, based on data reported by industry stakeholders in the public domain; it highlights the distribution of available biopharmaceutical production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), key geographical regions (China, Hong-Kong, Taiwan) and expression system used.
    • A review of recent initiatives undertaken by big pharma players in China for the manufacturing of biopharmaceuticals, highlighting trends across various parameters, such as number of initiatives, year of initiative, and benchmark analysis of big pharma players.
    • A qualitative analysis, highlighting the various factors that need to be taken into consideration by drug / therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
    • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biopharmaceutical products. Each profile features an overview of the company, its financial performance (if available), information on its service portfolio, details related to manufacturing capabilities and facilities, recent developments (partnerships and expansions), and an informed future outlook.
    • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
    • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.

     

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

    • Type of Product
    • API
    • FDF

     

    • Type of Expression System Used
    • Mammalian
    • Microbial
    • Others

     

    • Scale of Operation
    • Preclinical / Clinical
    • Commercial

     

    • Size of Manufacturers
    • Small
    • Mid-sized
    • Large / Very Large

     

    • Type of Biologic
    • Antibody 
    • Vaccine
    • Others

     

    To request sample pages, please visit this link

     

    Key Questions Answered

    • Who are the leading biopharmaceutical contract manufacturers in China?
    • What is the annual clinical demand for biopharmaceuticals in China?
    • What is the current installed capacity for manufacturing biopharmaceuticals in China?
    • What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
    • What were the various expansion initiatives carried out by Chinese biopharmaceutical CMOs?
    • What were the different biopharmaceutical focused initiatives undertaken by big pharma players in the recent past, in China?
    • How is the current and future market opportunity likely to be distributed across key market segments?

     

    You may also be interested in the following titles:

    1. China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
    2. Live Biotherapeutics Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030
    3. Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030

     

    Contact Us

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

    Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products, claims Roots Analysis


    Submitted 5 day(s) ago by Harry sins

     

    Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs. Further, in order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives.  

     

    To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link

     

    The USD 2.6 billion (by 2030) financial opportunity within the China biopharmaceutical contract manufacturing market has been analyzed across the following segments:

    • Type of Product 
    • API
    • FDF

     

    • Type of Expression System Used
    • Mammalian
    • Microbial
    • Others

     

    • Scale of Operation
    • Preclinical / Clinical
    • Commercial

     

    • Size of Manufacturer
    • Small
    • Mid-sized
    • Large / Very Large

     

    • Type of Biologic 
    • Antibody 
    • Vaccine
    • Others

     

    The China Biopharmaceutical Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

    • ChemPartner Biologics
    • JHL Biotech
    • JOINN Biologics
    • MabPlex
    • Mycenax Biotech
    • WuXi AppTec

     

    Table of Contents

     

    1. Preface

      2. Executive Summary

    2. Introduction

    3. Case Study: Comparison of Small Molecules and Large Molecules

    4. Competitive Landscape

    5. Company Profiles

    6. Partnerships

    7. Recent Expansions

    8. Clinical Trial Analysis

    9. Regional Capability Analysis

    10. Capacity Analysis

    11. Big Pharma Biopharmaceutical Manufacturing Initiatives in China

    12. Make Versus Buy Decision Making Framework

    13. Market Sizing and Opportunity Analysis

     

    1. COVID-19 Impact on China Biopharmaceutical CMO Market

     

    1. SWOT Analysis

     

    1. Future of the China Biopharmaceutical CMO Market

     

    1. Interview Transcripts

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

     

    To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com  

    The Chines biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~13%, till 2030


    Submitted 5 day(s) ago by Harry sins

    Roots Analysis has done a detailed study on China Biopharmaceutical Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

     

    To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link

     

    Key Market Insights

    • Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products
    • Several players provide one-stop solutions and are capable of operating at various scales; the landscape includes a mix of both established players and new entrants
    • In order to cater to the evolving needs of clients / sponsors, CMOs have established facilities across different regions of China; Eastern China, with the maximum number of sites, has emerged as a manufacturing hub
    • With over 80 deals inked in past five years, there has been a surge in the partnership activity within this domain; majority of these collaborations were signed for the development and manufacturing of antibody-based products
    • Big pharma players have also made significant investments in this region, including establishing new facilities, expanding existing R&D centers and growing manufacturing facilities, focused on biotherapeutics
    • We expect global biopharmaceutical developers to continue to outsource their manufacturing operations to China in the long term; we anticipate the CMO industry in the region to grow at an annualized rate of ~13%, till 2030

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

     

    Table of Contents

     

    1. PREFACE
      1.1. Scope of the Report
      1.2.      Research Methodology
      1.3.      Chapter Outlines

      2.         EXECUTIVE SUMMARY

    2. INTRODUCTION
      3.1. Chapter Overview

     

    • Overview of Biopharmaceuticals

     

    3.3.      Manufacturing of Biopharmaceuticals

    3.3.1.    Types of Expression Systems Used

    3.3.1.1. Bacterial Expression Systems

    3.3.1.2. Yeast Expression Systems

    3.3.1.3. Insect Expression Systems

    3.3.1.4. Plant Expression Systems

    3.3.1.5. Mammalian Expression Systems

    3.3.1.6. Fungal Expression Systems

     

    3.3.2.    Processing Steps

    3.3.2.1. Upstream Processing

    3.3.2.2. Downstream Processing

     

    3.4.      Overview of Contract Manufacturing

    3.4.1.    Contract Manufacturing Scenario in China

    3.5.      Need for Outsourcing in the Biopharmaceutical Industry

    3.5.1.    Biopharmaceutical Outsourcing in China: Regulatory Scenario

     

    3.6.      Commonly Outsourced Operations in the Biopharmaceutical Industry

     

    3.7.      Basic Guidelines for Selecting a CMO Partner

    3.8.      Advantages of Outsourcing Manufacturing Services

    3.8.1.    Benefits of Engaging Chinese Contract Service Providers

     

    3.9.      Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing

    3.9.1.    Challenges Associated with Engaging Chinese Contract Service Providers

    3.10.     Future Perspective

     

    1. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES

    4.1.      Chapter Overview

     

    4.2.      Small Molecule and Large Molecule Drugs / Therapies

    4.2.1.    Comparison of Key Characteristics

    4.2.2.    Comparison of Manufacturing Processes

    4.2.3.    Comparison of Key Manufacturing-Related Challenges

               

    1. COMPETITIVE LANDSCAPE

    5.1.      Chapter Overview

     

    5.2.      Chinese Biopharmaceutical Contract Manufacturers: Overall Market Landscape

    5.2.1.    Analysis by Year of Establishment

    5.2.2.    Analysis by Company Size

    5.2.3.    Analysis by Scale of Operation

    5.2.4.    Analysis by Location of Headquarters

    5.2.5.    Analysis by Location of Manufacturing Facilities

    5.2.6.    Analysis by Type of Product

    5.2.7.    Analysis by Types of Services Offered

    5.2.8.    Analysis by Type of Biologic

    5.2.9.    Analysis by Expression System Used

    5.2.10.  Analysis by Type of Bioreactor Used

    5.2.11.  Analysis by Mode of Operation of Bioreactor

    5.2.12.  Analysis by Packaging Form Used

    5.2.13.  Analysis by Regulatory Accreditations / Certifications

               

    1. COMPANY PROFILES

    6.1       Chapter Overview

     

    6.2       ChemPartner Biologics

    6.2.1.    Company Overview

    6.2.2.    Service Portfolio

    6.2.3.    Manufacturing Facilities and Capabilities

    6.2.4.    Recent Developments and Future Outlook

     

    6.3.      JHL Biotech

    6.3.1.    Company Overview

    6.3.2.    Service Portfolio

    6.3.3.    Manufacturing Facilities and Capabilities

    6.3.4.    Recent Developments and Future Outlook

     

    6.4.      JOINN Biologics

    6.4.1.    Company Overview

    6.4.2.    Service Portfolio

    6.4.3.    Manufacturing Facilities and Capabilities

    6.4.4.    Recent Developments and Future Outlook

     

    6.5       MabPlex

    6.5.1.    Company Overview

    6.5.2.    Service Portfolio

    6.5.3.    Manufacturing Facilities and Capabilities

    6.5.4.    Recent Developments and Future Outlook

     

    6.6.      Mycenax Biotech

    6.6.1.    Company Overview

    6.6.2.    Service Portfolio

    6.6.3.    Manufacturing Facilities and Capabilities

    6.6.4.    Recent Developments and Future Outlook

     

    6.7.      WuXi AppTec

    6.7.1.    Company Overview

    6.7.2.    Financial Information

    6.7.3.    Service Portfolio

    6.7.4.    Manufacturing Facilities and Capabilities

    6.7.5.    Recent Developments and Future Outlook

     

    1. PARTNERSHIPS

    7.1       Chapter Overview

     

    7.2.      Partnership Models

     

    7.3.      Chinese Biopharmaceutical Contract Manufacturers: Recent Partnerships

    7.3.1.    Analysis by Year of Partnership

    7.3.2.    Analysis by Type of Partnership

    7.3.3.    Analysis by Scale of Operation

    7.3.4.    Analysis by Type of Biologic

    7.3.5.    Analysis by Focus Area

    7.3.6.    Analysis by Therapeutic Area

    7.3.7.    Most Active Players: Analysis by Number of Partnerships

    7.3.8.    Geographical Analysis

    7.3.9.    Geographical Distribution by Number of Partnerships

    7.3.10.  Intercontinental and Intracontinental Agreements

     

    1. RECENT EXPANSIONS

    8.1.      Chapter Overview

     

    8.2.      Chinese Biopharmaceutical Contract Manufacturers: Recent Expansions

    8.2.1.    Analysis by Year of Expansion

    8.2.2.    Analysis by Type of Expansion

    8.2.3.    Analysis by Scale of Operation

    8.2.4.    Analysis by Type of Biologic

    8.2.5.    Analysis by Location of Expansion Project

    8.2.6.    Analysis by Capacity of Expanded Facility

    8.2.7.    Most Active Players: Analysis by Number of Expansions

    8.2.8.    Analysis by Region

     

    1. CLINICAL TRIAL ANALYSIS

    9.1.      Chapter Overview

     

    9.2.      Scope and Methodology

     

    9.3       Clinical Trial Analysis: Biologic Drugs

    9.3.1.    Analysis by Trial Registration Year

    9.3.2.    Analysis by Trial Phase

    9.3.3.    Analysis by Trial Status

    9.3.4.    Geographical Analysis by Number of Clinical Trials

    9.3.5.    Geographical Analysis by Enrolled Patient Population

    9.3.6.    Analysis of Enrolled Patient Population by Trial Registration Year

    9.3.7.    Analysis of Enrolled Patient Population by Trial Phase

    9.3.8.    Analysis by Type of Sponsor / Collaborator

    9.3.9.    Most Active Players: Analysis by Number of Registered Trials

    9.3.10.  Analysis by Clinical Trial Center

    1. REGIONAL CAPABILITY ANALYSIS

    10.1.     Chapter Overview

    10.2.     Assumptions and Key Parameters

    10.3.     Overall Landscape of Chinese Biopharmaceutical Contract Manufacturers

    10.4.     Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Northern China

    10.5.     Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Eastern China

    10.6.     Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Central China

    10.7.     Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Southern China

     

    1. CAPACITY ANALYSIS

    11.1.     Chapter Overview

     

    11.2.     Assumptions and Methodology

     

    11.3.     Chinese Biopharmaceutical Contract Manufactures: Installed Capacity

    11.3.1.  Analysis by Company Size

    11.3.2.  Analysis by Scale of Operation

    11.3.3.  Analysis by Expression System Used

    11.3.4.  Analysis by Location of Manufacturing Facility

    11.3.5.  Analysis by Company Size and Location of Manufacturing Facility

    11.3.6.  Analysis by Company Size and Location of Manufacturing Facility

     

    11.4.     Concluding Remarks

     

    1. BIG PHARMA BIOPHARMACEUTICAL MANUFACTURING INITIATIVES IN CHINA

    12.1.     Chapter Overview

     

    12.2.     List of Biopharmaceutical R&D and Manufacturing Initiatives of Big Pharma Players in China

    12.2.1.  Analysis by Number of Initiatives

    12.2.2.  Analysis by Year of Initiative

    12.2.3.  Analysis by Company and Year of Initiative

     

    12.2.4.  Analysis by Type of Initiative

    12.2.5.  Analysis by Type of Biologic

     

    12.3.     Competitive Benchmarking of Big Pharmaceutical Players

    12.3.1.  Harvey Ball Analysis: Big Pharma Investment Summary

    12.3.2.  Geographical Analysis by Investment Made

     

    1. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

    13.1.     Chapter Overview

    13.2.     Assumptions and Key Parameters

    13.3.     Chines Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making

    13.4.     Conclusion                              

     

    1. MARKET SIZING AND OPPORTUNITY ANALYSIS

    14.1.     Chapter Overview

     

    14.2.     Key Assumptions and Forecast Methodology

    14.3.     Biopharmaceutical Contract Manufacturing Market in China, 2020-2030

    14.3.1.  Biopharmaceutical Contract Manufacturing Market in China for APIs, 2020-2030

    14.3.2.  Biopharmaceutical Contract Manufacturing Market in China for FDFs, 2020-2030

     

    14.4.     Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Expression System Used

    14.4.1.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Mammalian Systems

    14.4.2.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Microbial Systems                    

    14.4.3.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Other Expression Systems

     

    14.5.     Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Scale of Operation

    14.5.1.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Preclinical / Clinical Scale Operations

    14.5.2.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Commercial Operations

               

    14.6.     Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Size of Manufacturers

    14.6.1.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Small Companies

    14.6.2.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Mid-sized Companies

    14.6.3.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Large and Very Large Companies

     

    14.7.     Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Type of Biologic

    14.7.1.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Antibodies

    14.7.2.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Vaccines

    14.7.3.  Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Other Biologics

     

    1. COVID-19 Impact on China Biopharmaceutical CMO Market

    15.1.     Chapter Overview

    15.2.     Evaluation of Impact of COVID-19 Outbreak

     

    15.2.1.   Initiatives and Opinions of Key Players

    15.2.1.1. WuXi AppTec

     

    15.2.1.2. Boehringer Ingelheim

    15.2.1.3. GE Healthcare

    15.2.1.4. Lonza

    15.2.1.5. AmbioPharm

     

    15.2.2. Impact of China Biopharmaceutical Contract Manufacturing Market

    15.3.     Key Strategies to Adopt: A Bird’s Eye View

    15.3.1.  Immediate Steps

    15.3.2.  Short / Long-Term Steps

     

    1. SWOT ANALYSIS

    16.1.     Chapter Overview

    16.2.     Strengths

    16.3.     Weaknesses

    16.4.     Opportunities

    16.5.     Threats

    16.6.     Comparison of SWOT Factors

    16.7.     Concluding Remarks

     

    1. FUTURE OF THE CHINA BIOPHARMACEUTICAL CMO MARKET

    17.1.     Chapter Overview

    17.2.     Outsourcing Activities Anticipated to Increase in Future

    17.3.     Shift from One-time Contracts to Strategic Partnerships

    17.4.     Adoption of Innovative Technologies

    17.4.1.  Single Use Bioreactors

    17.4.2.  Novel Bioprocessing Techniques

    17.4.3.  Bioprocess Automation

     

    17.5.     Growing Popularity of the Quality by Design Principle in Bioprocessing

    17.6.     Increasing Focus on Niche Therapeutic Areas

    17.7.     Biosimilars Market to Contribute to Contract Service Revenues

    17.8.     Capability and Facility Expansions to Establish One Stop Shop Expertise

    17.9.     Increase in Financial In-flow and Outsourcing Budgets

    17.10.   Challenges Faced by Sponsors and Service Providers

    17.10.1. Concerns Associated with Single Use Systems

    17.10.2. Issues Related to Capacity Fluctuations

     

    17.11.   Concluding Remarks

    1. INTERVIEW / SURVEY TRANSCRIPT(S)
    2. APPENDIX 1: TABULATED DATA
    3. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

    The Chinese biopharmaceutical contract manufacturing market is estimated to be worth USD 2.6 billion in 2030, predicts Roots Analysis


    Submitted 5 day(s) ago by Harry sins

     

    The growing biopharma industry in China has resulted in the creation of lucrative business opportunities for contract service providers; region-specific advantages have also attracted several foreign sponsors entities over the last few years

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “China Biopharmaceutical Contract Manufacturing Market, 2020-2030.”

     

    The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

    • A detailed assessment of the current market landscape of companies offering contract manufacturing services for biopharmaceuticals in China.
    • An analysis of the partnerships that have been established in this domain, in the recent past.
    • An analysis of the expansion initiatives undertaken by contract manufacturers in China, in order to augment their capabilities, in the recent past.
    • A detailed analysis of more than 1500 clinical trials related to biopharmaceuticals that have been / are being / are likely to be conducted in China.
    • An estimate of the overall, installed capacity for manufacturing biopharmaceuticals, based on data reported by industry stakeholders in the public domain.
    • An analysis of the initiatives of big biopharma players engaged in this domain.
    • A qualitative analysis, highlighting the various factors that need to be taken into consideration by drug / therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
    • Detailed profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biopharmaceutical products.
    • A case study comparing the key characteristics of large molecule and small molecule drugs.
    • A discussion on industry affiliated trends, key drivers, and challenges, under a SWOT framework, which are likely to impact the evolution of this field.
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
    • Type of Product
    • API
    • FDF
    • Type of Expression System Used
    • Mammalian
    • Microbial
    • Others
    • Scale of Operation
    • Preclinical / Clinical
    • Commercial
    • Size of Manufacturer
    • Small
    • Mid-sized
    • Large / Very Large
    • Type of Biologic
    • Antibody
    • Vaccine
    • Others

     

    Key companies covered in the report

    • ChemPartner Biologics
    • JHL Biotech
    • JOINN Biologics
    • MabPlex
    • Mycenax Biotech
    • WuXi AppTec

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

     

    Other Recent Offerings

    1. China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
    2. Live Biotherapeutics Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030
    3. Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     

    Are there any symptoms of burning-through the pills of Keto BHB RX?

    health
    Submitted 5 day(s) ago by klrahulfans

    Are there any symptoms of burning-through the pills of Keto BHB RX Review?

    No, this dietary item is totally sheltered to utilize and won't have any results on your body. You are not needed to fear it on the grounds that Keto BHB RX is clinically tried and will furnish you with positive results. You simply need to adhere to all the directions related with it so you are having long haul results.

    Related Sites:-

     

    https://ketopillsstore.com/product/keto-bhb-rx/

     

     

    https://en.wikipedia.org/wiki/Sarah_Silverman

     

     

    http://wintersupplement.com/citroburn-review/

     

     

    https://utah.instructure.com/eportfolios/41256/Home/Keto_BHB_RX__The_Best_Weight_Loss_Diet_Pills

     

     

    https://www.surveymonkey.com/r/XS58RRM

     

     

    https://note.com/ketobhbrxreview/n/n08b7742d3887

     

     

    https://www.completefoods.co/diy/recipes/keto-bhb-rx-review-free-trial-offer

     

     

    https://k12.instructure.com/eportfolios/5457/Home/Keto_BHB_RX_Review__Does_Keto_BHB_RX_Really_Work

     

     

    https://canvas.elsevier.com/eportfolios/24720/Home/Keto_BHB_RX_Shark_Tank_Diet_Pills_Reviews__How_Does_It_Work

     

     

    https://mndepted.instructure.com/eportfolios/8685/Home/Keto_BHB_RX_Review__Updated_2020PriceBenefits__Where_To_Buy

     

     

    https://www.reddit.com/user/cashreress/comments/jcpsry/keto_bhb_rx_review_2020/

     

     

    https://patch.com/new-york/new-york-city/classifieds/for-sale/176165/the-lost-book-of-herbal-remedies-review-special-offer-70-off

     

     

    https://sites.google.com/site/ketobhbrxpillsreview/

     

     

    https://publons.com/researcher/3968424/keto-bhb-rx/

     

     

    https://www.surveymonkey.com/r/XS6G3FW

     

     

    https://teespring.com/keto-bhb-rx-review-shark-tank?pid=46&cid=2739

     

     

    https://dribbble.com/shots/14403045-Keto-BHB-RX-Pills-Review-Price-to-Buy-Benefits

     

     

    https://gocrowdera.com/keto-bhb-rx-review

     

     

    https://www.completefoods.co/diy/recipes/keto-bhb-rx-review-2

     

     

    https://gumroad.com/ketoreviewpills/p/is-keto-bhb-rx-review-how-does-it-really-work

     

     

    https://patch.com/new-york/new-york-city/classifieds/for-sale/177241/keto-bhb-rx-review-special-offer-70-off-today

     

     

    https://ketobhbrxpills.over-blog.com/2020/10/keto-bhb-rx-review-45-off-official-website-price-to-by-now.html

     

     

    https://klrahulfans.wixsite.com/keto-bhb-rx-review

     

    https://www.webwiki.com/http://wintersupplement.com/

     

    https://twitter.com/BhbReview/status/1317337706804903936

    Bedrock Health Keto | Official Website

    m.facebook.com
    Submitted 7 day(s) ago by bedrockketo

    https://muckrack.com/bedrockhealthketo/bio


    https://works.bepress.com/bedrock-health-keto/1/


    https://sites.google.com/site/getbedrockhealthketo/


    https://bedrock-health-keto.over-blog.com/dragons-den.html


    https://www.wattpad.com/968092817-bedrock-health-keto-effective-or-scam-reviews-and


    https://www.completefoods.co/diy/recipes/bedrock-health-keto-beware-should-buy-or-not


    https://www.toevolution.com/blog/view/950970/no1-ketogenic-diet-bedrock-health-keto


    https://publons.com/researcher/3968522/bedrock-health-keto/


    https://teespring.com/en-GB/bedrockhealthketoreviews


    http://bedrock-health-keto.moonfruit.com/


    https://www.facebook.com/Bedrock-Health-Keto-103947301500678/


    https://sites.google.com/site/bedrockhealthketoreviews/


    https://bedrock-health-keto.wixsite.com/sharktank


    https://bedrock-health-keto-80.webself.net/


    https://kaalama.org/read-blog/3032


    https://www.mitrlok.com/read-blog/3473_bedrock-health-keto-100-effective.html


    https://www.stunxt.com/blogs/2354/No-1-Ketogenic-Diet-Bedrock-Health-Keto


    https://social.smartzworld.com/read-blog/4980_bedrock-health-keto-buy-1-get-1-bottle.html


    https://wandasn.com/read-blog/932_no-1-bedrock-health-keto-99-discount.html


    https://zwatshitangani.co.za/read-blog/3425_bedrock-health-keto-official-trial.html


    https://lifesspace.com/read-blog/1465_bedrock-health-keto-ketogenic-diet.html


    https://acrochat.com/read-blog/3405_bedrock-health-keto-100-natural-diet.html


    https://envolvedfoundation.org/platform/blogs/1586/Bedrock-Health-Keto-Get-Free-Bottle


    https://gole.life/blogs/2942/Bedrock-Health-Keto-Lose-Upto-99-Fat


    https://www.sportjim.com/blogs/5871/Bedrock-Health-Keto-Upto-95-Off-Today


    http://www.wassernet.com/blogs/3820/Bedrock-Health-Keto-100-Natural-Diet


    http://www.majalisa.com/blogs/3970/NO-1-Bedrock-Health-Keto-99-Discount


    https://wilkasocial.com/read-blog/3172_bedrock-health-keto-buy-1-get-1-bottle.html


    http://dev.infotechnologist.biz/motor/blogs/1061/NO-1-Bedrock-Health-Keto-99-Discount


    http://socialsea.com/blogs/1564/Bedrock-Health-Keto-Buy-1-Get-1-Bottle


    https://talknchat.net/read-blog/804_bedrock-health-keto-100-natural-diet.html


    http://droidt99.com/read-blog/9069_bedrock-health-keto-upto-95-off-today.html


    https://yarabook.com/read-blog/146839_bedrock-health-keto-lose-upto-99-fat.html

     

    Kyto Fit - Burn Stubborn Fat With KytoFit Keto! Special Offer!

    kytofit.info
    Submitted 7 day(s) ago by kytofitusa

    Kyto Fit Keto Diet Pills can help you with showing up at all of your weight decrease destinations! You're involved, we get it. Besides, generally, weight decrease accepts a lower need corresponding to everything going on in your life. Regardless, think about how conceivable it is that you could devour fat and get fit as a fiddle without unquestionably changing your every day plan. Chances are, you don't have the occasion to press in practice gatherings and strong cooking into your viably stuffed schedule. As of now, you don't have to worry over that. Since, this fat devouring pill can get you results while you do your customary thing! Furthermore, that suggests you can finally stop wasting time weight decrease results! Snap underneath to get a low Kyto Fit Keto Cost and endeavor this for yourself now!

    Visit Official Website: http://kytofit.info/

    IVF Cost In Delhi Gaudium IVF & Gynae Fertility Centre Vinsfertility - YouTube

    www.youtube.com
    Submitted 7 day(s) ago by vinsfertility

    Despite the fact that the IVF Cost isn't fixed and many individuals have spent around three to five lakh on the treatment of the unnaturally conceived child. IVF cost in Delhi differs according to the kind of treatment you are getting and the drugs involved in it. Drugs rely on infertility issues, in this manner, it influences the IVF achievement rate also.
     
    Visit the site https://bit.ly/353YvbL
     

    Canzana CBD Hemp Oil’s Biography | Muck Rack

    muckrack.com
    Submitted 8 day(s) ago by cbdhempoil

    Canzana CBD Hemp Oil is natural hemp oil which can cure many regular body problems. It can cure stress and anxiety. This oil can increase mental focus and sharpen memory. It can help improve the quality of sleep. This hemp oil can cure pimples and acne on the skin. People with joint pain and arthritis can get long term relief by using this natural oil. Apart from that, this oil can make the joints more elastic.


    https://kaalama.org/read-blog/2988


    https://muckrack.com/canzanacbdhempoil/bio


    https://sites.google.com/site/canzanacbdoilwheretobuy/


    https://sites.google.com/site/canzanacbdhempoilcapsules/


    https://www.justgiving.com/crowdfunding/canzanacbdhempoil


    https://teespring.com/en-GB/canzanacbdhempoil-uk-trial


    https://canzana-cbd-hemp-oil-uk-80.webself.net/


    https://publons.com/researcher/3966242/canzana-cbd-hemp-oil/


    https://www.toevolution.com/blog/view/948315/no1-canzana-cbd-hemp-oil-uk-united-kingdom


    http://www.wassernet.com/blogs/3791/NO-1-Canzana-CBD-Hemp-Oil-99-Discount


    http://socialsea.com/blogs/1543/Official-Canzana-CBD-Hemp-Oil-Natural


    http://dev.infotechnologist.biz/motor/blogs/1035/Buy-1-Get-1-Canzana-CBD-Hemp-Oil-Bottle


    https://envolvedfoundation.org/platform/blogs/1576/Canzana-CBD-Hemp-Oil-Upto-99-Off-Today


    https://www.bareit.us/read-blog/2378_canzana-cbd-hemp-oil-capsules-trial-offer.html


    https://talknchat.net/read-blog/747_no-1-canzana-cbd-hemp-oil-united-kingdom.html


    http://droidt99.com/read-blog/8935_canzana-cbd-hemp-oil-100-effective-way.html


    https://yarabook.com/read-blog/146228_canzana-cbd-hemp-oil-official-trial-offer.html


    https://www.sportjim.com/blogs/5859/Canzana-CBD-Hemp-Oil-Capsules-Trial-Offer


    https://gole.life/blogs/2916/NO-1-Canzana-CBD-Hemp-Oil-99-Discount


    http://www.majalisa.com/blogs/3925/Canzana-CBD-Hemp-Oil-Upto-99-Off-Today


    https://wandasn.com/read-blog/929_buy-1-get-1-canzana-cbd-hemp-oil-bottle.html


    https://zwatshitangani.co.za/read-blog/3400_official-canzana-cbd-hemp-oil-natural.html


    https://wilkasocial.com/read-blog/3130_canzana-cbd-hemp-oil-100-effective-way.html


    https://www.stunxt.com/blogs/2329/Canzana-CBD-Hemp-Oil-Capsules-Trial-Offer


    https://www.mitrlok.com/read-blog/3407_canzana-cbd-hemp-oil-official-trial-offer.html


    https://lifesspace.com/read-blog/1425_no-1-canzana-cbd-hemp-oil-99-discount.html


    https://acrochat.com/read-blog/3381_canzana-cbd-hemp-oil-100-effective-way.html


    https://social.smartzworld.com/read-blog/4941_canzana-cbd-hemp-oil-upto-99-off-today.html

     

    Top 3 Best IVF Centres in Madurai With High Success Rate 2019 - Vinsfertility.com

    www.vinsfertility.com
    Submitted 8 day(s) ago by vinsfertility

    ✓IVF Centres in Madurai ✓Best Fertility Centres in Madurai, ✓Test Tube Baby Centres in Madurai, Get Phone Numbers, Address, Reviews, Photos, Maps for Top IVF Centres in Madurai on Vinsfertility.com

    Submit your article?

    Submit your articles for more traffic to your website!

    Submit article
    © 2019 topfind88.com. Imprint, All rights reserved.